US20090017069A1 - SARS Vaccine Compositions and Methods of Making and Using Them - Google Patents
SARS Vaccine Compositions and Methods of Making and Using Them Download PDFInfo
- Publication number
- US20090017069A1 US20090017069A1 US12/106,021 US10602108A US2009017069A1 US 20090017069 A1 US20090017069 A1 US 20090017069A1 US 10602108 A US10602108 A US 10602108A US 2009017069 A1 US2009017069 A1 US 2009017069A1
- Authority
- US
- United States
- Prior art keywords
- coronavirus
- sars
- viral
- ether
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 187
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 229940124680 SARS vaccine Drugs 0.000 title description 7
- 230000003612 virological effect Effects 0.000 claims abstract description 226
- 239000002245 particle Substances 0.000 claims abstract description 198
- 239000002904 solvent Substances 0.000 claims abstract description 157
- 150000002632 lipids Chemical class 0.000 claims abstract description 129
- 208000015181 infectious disease Diseases 0.000 claims abstract description 85
- 229960005486 vaccine Drugs 0.000 claims abstract description 83
- 230000002829 reductive effect Effects 0.000 claims abstract description 38
- 210000004369 blood Anatomy 0.000 claims abstract description 27
- 239000008280 blood Substances 0.000 claims abstract description 27
- 239000003937 drug carrier Substances 0.000 claims abstract description 14
- 230000002163 immunogen Effects 0.000 claims abstract description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 151
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 100
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 90
- 239000012530 fluid Substances 0.000 claims description 83
- 230000015961 delipidation Effects 0.000 claims description 74
- 241000711573 Coronaviridae Species 0.000 claims description 63
- 241001465754 Metazoa Species 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 229920004890 Triton X-100 Polymers 0.000 claims description 33
- 239000004094 surface-active agent Substances 0.000 claims description 32
- 210000004779 membrane envelope Anatomy 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 28
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical group FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 claims description 24
- 229960002078 sevoflurane Drugs 0.000 claims description 21
- 229920001774 Perfluoroether Polymers 0.000 claims description 18
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 13
- 230000024932 T cell mediated immunity Effects 0.000 claims description 6
- 125000001033 ether group Chemical group 0.000 claims description 4
- 230000005875 antibody response Effects 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract description 188
- 241000700605 Viruses Species 0.000 abstract description 156
- 230000002458 infectious effect Effects 0.000 abstract description 60
- 239000013060 biological fluid Substances 0.000 abstract description 33
- 230000004224 protection Effects 0.000 abstract description 11
- 229960001438 immunostimulant agent Drugs 0.000 abstract description 5
- 239000003022 immunostimulating agent Substances 0.000 abstract description 5
- 230000003308 immunostimulating effect Effects 0.000 abstract description 5
- 229940021747 therapeutic vaccine Drugs 0.000 abstract description 4
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- 229960004854 viral vaccine Drugs 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 71
- 239000000427 antigen Substances 0.000 description 63
- 108091007433 antigens Proteins 0.000 description 63
- 102000036639 antigens Human genes 0.000 description 63
- 230000028993 immune response Effects 0.000 description 58
- 210000002381 plasma Anatomy 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 40
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 37
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 36
- 238000002474 experimental method Methods 0.000 description 33
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 29
- 239000013504 Triton X-100 Substances 0.000 description 28
- 238000002156 mixing Methods 0.000 description 25
- 241000711466 Murine hepatitis virus Species 0.000 description 23
- 241000315672 SARS coronavirus Species 0.000 description 23
- 150000002170 ethers Chemical class 0.000 description 22
- 238000011282 treatment Methods 0.000 description 21
- 150000001298 alcohols Chemical class 0.000 description 20
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 230000021633 leukocyte mediated immunity Effects 0.000 description 20
- 238000006386 neutralization reaction Methods 0.000 description 19
- 239000003960 organic solvent Substances 0.000 description 19
- 235000012000 cholesterol Nutrition 0.000 description 18
- 244000052769 pathogen Species 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 238000001262 western blot Methods 0.000 description 18
- 238000000605 extraction Methods 0.000 description 17
- 210000000987 immune system Anatomy 0.000 description 17
- 239000003995 emulsifying agent Substances 0.000 description 16
- 238000002255 vaccination Methods 0.000 description 16
- 208000036142 Viral infection Diseases 0.000 description 15
- 239000008346 aqueous phase Substances 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- 230000009385 viral infection Effects 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000001717 pathogenic effect Effects 0.000 description 14
- 239000003610 charcoal Substances 0.000 description 13
- 241000725303 Human immunodeficiency virus Species 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 12
- 101001024647 Severe acute respiratory syndrome coronavirus Nucleoprotein Proteins 0.000 description 11
- 229930195733 hydrocarbon Natural products 0.000 description 11
- 230000001524 infective effect Effects 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 108010067390 Viral Proteins Proteins 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- 230000002939 deleterious effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 150000002430 hydrocarbons Chemical class 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 210000002845 virion Anatomy 0.000 description 10
- 238000011510 Elispot assay Methods 0.000 description 9
- 101710198474 Spike protein Proteins 0.000 description 9
- 208000006454 hepatitis Diseases 0.000 description 9
- 231100000283 hepatitis Toxicity 0.000 description 9
- -1 normal sera Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 230000002779 inactivation Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 241000714177 Murine leukemia virus Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229940037642 autologous vaccine Drugs 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010017384 Blood Proteins Proteins 0.000 description 6
- 102000004506 Blood Proteins Human genes 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 229940096437 Protein S Drugs 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000028996 humoral immune response Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 230000000644 propagated effect Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 206010061598 Immunodeficiency Diseases 0.000 description 5
- 208000029462 Immunodeficiency disease Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000036755 cellular response Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 238000000635 electron micrograph Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000007813 immunodeficiency Effects 0.000 description 5
- 230000009851 immunogenic response Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 210000003567 ascitic fluid Anatomy 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 230000001926 lymphatic effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000005373 pervaporation Methods 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000712891 Arenavirus Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000008620 Cholesterol Assay Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000711950 Filoviridae Species 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 241000701372 Iridovirus Species 0.000 description 3
- 208000005228 Pericardial Effusion Diseases 0.000 description 3
- 241000711902 Pneumovirus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 229940031567 attenuated vaccine Drugs 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000012930 cell culture fluid Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 210000001733 follicular fluid Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 229940124590 live attenuated vaccine Drugs 0.000 description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 210000004912 pericardial fluid Anatomy 0.000 description 3
- 210000004910 pleural fluid Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 244000052613 viral pathogen Species 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical class CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001455610 Ephemerovirus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000711828 Lyssavirus Species 0.000 description 2
- 241000700560 Molluscum contagiosum virus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical class CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000713112 Orthobunyavirus Species 0.000 description 2
- 241000150452 Orthohantavirus Species 0.000 description 2
- 241000150218 Orthonairovirus Species 0.000 description 2
- 241000700629 Orthopoxvirus Species 0.000 description 2
- 241000712894 Orthotospovirus Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241000700639 Parapoxvirus Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 241000710778 Pestivirus Species 0.000 description 2
- 241000713137 Phlebovirus Species 0.000 description 2
- 241001112090 Pseudovirus Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000713675 Spumavirus Species 0.000 description 2
- 241000711517 Torovirus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000701067 Varicellovirus Species 0.000 description 2
- 241000711970 Vesiculovirus Species 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000012578 cell culture reagent Substances 0.000 description 2
- 238000011437 continuous method Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical class CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 241001147422 tick-borne encephalitis virus group Species 0.000 description 2
- POSZUTFLHGNLHX-KSBRXOFISA-N tris maleate Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)\C=C/C(O)=O POSZUTFLHGNLHX-KSBRXOFISA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241001533466 Asfivirus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000701397 Avihepadnavirus Species 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 238000003735 Beta-Glo Assay System Methods 0.000 description 1
- 241000701021 Betaherpesvirinae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 241001493160 California encephalitis virus Species 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000712467 Cytorhabdovirus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000974840 Ellipes Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- 241000701046 Gammaherpesvirinae Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 241001135958 Human type D retrovirus Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500343 Influenzavirus C Species 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000700563 Leporipoxvirus Species 0.000 description 1
- 241000701043 Lymphocryptovirus Species 0.000 description 1
- 241000701387 Lymphocystivirus Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000700559 Molluscipoxvirus Species 0.000 description 1
- 241000700627 Monkeypox virus Species 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000701029 Murid betaherpesvirus 1 Species 0.000 description 1
- 241000701034 Muromegalovirus Species 0.000 description 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 1
- 241000700562 Myxoma virus Species 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 241000712466 Nucleorhabdovirus Species 0.000 description 1
- 241000700635 Orf virus Species 0.000 description 1
- 241000700732 Orthohepadnavirus Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000701382 Ranavirus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000701037 Rhadinovirus Species 0.000 description 1
- 241000122129 Roseolovirus Species 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- 241001135555 Sandfly fever Sicilian virus Species 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 241000404000 Tanapox virus Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 240000001068 Thogoto virus Species 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000700574 Yatapoxvirus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001455 anti-clotting effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940043232 butyl acetate Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 201000005332 contagious pustular dermatitis Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical class CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940023867 prime-boost vaccine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- XZTJQQLJJCXOLP-UHFFFAOYSA-M sodium;decyl sulfate Chemical compound [Na+].CCCCCCCCCCOS([O-])(=O)=O XZTJQQLJJCXOLP-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010246 ultrastructural analysis Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10161—Methods of inactivation or attenuation
- C12N2730/10162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
- C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to a delipidation method employing a solvent system useful for extracting lipids from a virus, thereby creating a modified viral particle.
- the virus is severe acute respiratory syndrome (SARS) caused by Coronaviruses.
- the solvent system of the present invention is optimally designed such that upon delipidation of the virus, the viral particle remains substantially intact.
- the resultant modified viral particle has exposed antigens (or epitopes), which foster and promote cellular responses and antibody production when introduced into a human or an animal.
- the resulting modified viral particle of the present invention initiates a positive immunogenic response in the species into which it is re-introduced.
- the present invention can be applied to delipidating viruses from a specific patient for future reintroduction into the patient, to delipidating stock viruses, or non-patient specific viruses, for use as a vaccine, or to delipidating and combining both non-patient specific viruses and patient specific viruses to create a therapeutic cocktail.
- viruses of varied etiology, affect billions of animals and humans each year and inflict an enormous economic burden on society.
- Many viruses contain lipid as a major component of the membrane that surrounds them. Viruses affect animals and humans causing extreme suffering, morbidity, and mortality. These viruses travel throughout the body in biological fluids such as blood, peritoneal fluid, lymphatic fluid, pleural fluid, pericardial fluid, cerebrospinal fluid, and in various fluids of the reproductive system. Fluid contact at any site promotes transmission of disease.
- Other viruses reside primarily in different organ systems and in specific tissues, proliferate and then enter the circulatory system to gain access to other tissues and organs at remote sites. If the body does not exhibit a positive immune response against these pathogens, they infect many cell types within the body, inhibiting these cells from performing their normal functions.
- the human immune system is composed of various cell types that collectively protect the body from different viruses.
- the immune system provides multiple means for targeting and eliminating foreign elements, including humoral and cellular immune responses, participating primarily in antigen recognition and elimination.
- An immune response to foreign elements requires the presence of B-lymphocytes (B cells) or T-lymphocytes (T cells) in combination with antigen-presenting cells (APC), which are usually macrophage or dendrite cells.
- B cells B cells
- T-lymphocytes T cells
- APC antigen-presenting cells
- the APCs are specialized immune cells that capture antigens. Once inside an APC, antigens are broken down into smaller fragments called epitopes—the unique markers carried by the antigen surface. These epitopes are subsequently displayed on the surface of the APCs and are responsible for triggering an antibody response in defense of the infection.
- APC displaying antigens in the form of unique epitope markers
- B cells are activated, proliferating and producing antibodies. These antibodies specifically bind to the antigens present on the virus. After the antibody attaches, the APC engulfs the entire antigen and kills it. This type of antibody immune response is primarily involved in the prevention of viral infection.
- T cells are activated on recognizing the antigen displayed on the APC.
- CTL cytotoxic T cells
- CD8 + T killer cells that proliferate and kill target cells that specifically present antigens.
- the second involves helper T cells (HTL) or CD4 + T cells that regulate the production of antibodies and the activity of CD8 + cells.
- the CD4 + T cells provide growth factors to CD8 + T cells that allow them to proliferate and function efficiently.
- Viruses contain an outer envelope made up of lipids and fats derived from the host cell membrane during the budding process. Viruses are comprised of virions, non-cellular infectious agents consisting of a single type of nucleic acid (either RNA or DNA), surrounded by a protein coat. The outer protein covering of viruses is called a capsid, made up of repeating subunits called capsomeres.
- viruses are non-metabolic, they only reproduce within living host cells.
- the virus codes the proteins of the viral envelope while the host cell codes the lipids and carbohydrates. Therefore, the lipid and carbohydrate content within a given viral envelope is dependent on the particular host.
- the enveloped viral particles therefore partially adopt the identity of the host cell, via lipid and carbohydrate content, and are able to conceal antigens associated with them, which would normally have initiated an immune response. Instead, the viral particle confuses the host immune system by presenting it with an antigenic complex that contains components of host tissues, and is perceived by the host immune system as partly “self” and partly “foreign”. The immune system is forced to produce the “compromise”, ineffective antibodies which do not destroy the viral particles, allowing them to proliferate and slowly cause severe damage to the body, while destroying host cells.
- AIDS acquired immune deficiency syndrome
- HAV human immunodeficiency virus
- Related viruses affect animal species, for example, simians and felines (SIV and FIV, respectively).
- SARS severe acute respiratory syndrome
- anti-viral drug therapies are directed toward preventing or inhibiting viral replication and appear to focus on the initial attachment of the virus to the T4 lymphocyte or macrophage, the transcription of viral RNA to viral DNA and the assembly of new virus during replication.
- the high mutation rate of the virus is a major difficulty with existing treatments because the various strains become resistant to anti-viral drug therapy.
- anti-viral drug therapy treatment may cause the evolution of resistant strains of the virus.
- Other drawbacks to drug therapies are the undesirable side effects and patient compliance requirements.
- many individuals are afflicted with multiple viral infections such as a combination of HIV and hepatitis. Such individuals require even more aggressive and expensive drug regimens to counteract disease progression, which in turn cause greater side effects and a greater likelihood of multiple drug resistance.
- Vaccines have been singularly responsible for conferring immune response against several human pathogens. They are designed to stimulate the immune system to protect against various viral infections.
- a vaccine is produced from an antigen, isolated or produced from the disease-causing microorganism, which can elicit an immune response.
- the B cells in the blood stream perceive the antigens contained by the vaccine as foreign or ‘non-self” and respond by producing antibodies, which bind to the antigens and inactivate them. Memory cells are thereby produced and remain ready to mount a quick protective immune response against subsequent infection with the same disease-causing agent.
- the immune system will recognize the protein and instigate an effective defense against infection.
- the current methods of vaccination do have drawbacks, making them less than optimally desirable for immunizing individuals against particular pathogens, such as coronavirus and HIV.
- the existing vaccine strategies aim to expose the body to the antigens associated with infective pathogens so that the body builds an immune response against these pathogens.
- coronavirus, hepatitis B and HIV pathogens are able to survive and proliferate in the human body despite the immune response.
- One explanation offered in the prior art is that the antigens of these microorganisms change constantly so the antibodies produced in response to a particular antigen are no longer effective when the antigen mutates.
- antigenic variation has been addressed via the attempted use of combination drugs or antigens, no prior art vaccine has succeeded adequately in addressing infections such as SARS.
- Described in the prior art are methods of treating viral particles with organic solvents and high temperatures thus dissolving the lipid envelopes and subsequently inactivating the virus.
- blood is withdrawn from the patient and separated into two phases—the first phase including red cells and platelets and the second phase containing plasma, white cells, and cell-free virus (virion).
- the second phase is treated with an organic solvent, thereby killing the infected cells and virions, and subsequently reintroduced into the patient.
- the high organic solvent concentrations cause cell death and damage to the antigens. Essentially, this method results in a “chemical kill” of the cell.
- Glutaraldehyde is one such solvent whereby cell inactivation is achieved as known by those of ordinary skill in the art by fixation with a dilute solution of glutaraldehyde at about 1:250. Although treating the virus with glutaraldehyde effectively delipidates the virus, it also destroys the core. Destruction of the core is not desirable for producing a modified viral particle useful for inducing an immune response in a recipient.
- Chloroform is another such solvent. Chloroform, however, denatures many plasma proteins and is not suitable for use with biological fluids, which will be reintroduced into the animal or human. These plasma proteins deleteriously affected by chloroform serve important biological functions including coagulation, hormonal response, and immune response. These functions are essential to life and thus damage to these proteins may have an adverse effect on a patient's health, possibly leading to death.
- a target protein or antigen associated with the infective pathogen is administered to the individual. This includes presenting the protein as part of a non-infective (inactivated) or less infective (attenuated) agent or as a discrete protein composition.
- a target protein or antigen associated with the infective pathogen is administered to the individual. This includes presenting the protein as part of a non-infective (inactivated) or less infective (attenuated) agent or as a discrete protein composition.
- Known to one of ordinary skill in the art are the following different types of vaccines: live attenuated vaccines, whole inactivated vaccines, DNA vaccines, combination vaccines, recombinant vaccines, live recombinant vector vaccines, virus like particles and synthetic peptide vaccines.
- live attenuated vaccines the viruses are rendered less pathogenic to the host, either by specific genetic manipulation of the virus genome or by passage in some type of tissue culture system. In order to achieve genetic manipulation, an inessential gene is deleted or one or more essential genes in the virus are partially damaged. Upon genetic manipulation, the viral particles become less virulent yet retain antigenic features.
- Live attenuated vaccines can also be used as “vaccine vectors” for other genes, wherein they act as carriers of genes from a second virus (or other pathogen) against which protection is required. Attenuated vaccines (less infective and not inactivated), however, pose several problems. First, it is difficult to ascertain when the attenuated vaccine is no longer pathogenic. The risk of viral infection from the vaccine is too great to properly test for effective attenuation. In addition, attenuated vaccines carry the risk of reverting into a virulent form of the pathogen.
- Whole inactivated vaccines are known in the art for immunizing against infection by introducing killed or inactivated viruses to introduce pathogen proteins to an individual's immune system.
- the administration of killed or inactivated pathogens, via heat or chemical means, into an individual introduces the pathogens to the individual's immune system in a non-infective form thereby initiating an immune response defense.
- Wholly inactivated vaccines provide protection by directly generating cellular and humoral immune responses against the pathogenic immunogens. There is little threat of infection, because the viral pathogen is killed or otherwise inactivated.
- Subunit vaccines are yet another form of vaccination well known to one of ordinary skill in the art. These consist of one or more isolated proteins derived from the pathogen. These proteins act as target antigens against which an immune response is exhibited. The proteins selected for the subunit vaccine are displayed by the pathogen so that upon infection of an individual by the pathogen, the individual's immune system recognizes the pathogen and instigates an immune response. Subunit vaccines are not whole infective agents and are therefore incapable of becoming infective.
- DNA vaccine is another type known in the art and uses actual genetic material of pathogens.
- synthetic peptide vaccines are made up of parts of synthetic peptides. These synthetic peptides comprise portions of viral proteins chosen specifically to achieve an anti-viral immune response. Also mentioned in the prior art are combination vaccines that, when used in conjunction with one another, generate a broad spectrum of immune responses.
- What is needed is a therapeutic method and system for providing patients with patient-specific viral antigens capable of initiating a protective immune response. Accordingly, what is needed is a simple, effective method that does not appreciably denature or extract proteins from the biological sample being treated. What is also needed is an effective delipidation process via which a viral particle is modified, rather than destroyed, thereby both reducing and/or eliminating infectivity of the viral particle and invoking a patient specific, autologous immune response to further reduce viral infection and prevent further infection.
- What is also needed is an effective means to immunize individuals against viral pathogen infection that is unique to the individual due to viral mutations.
- the means would elicit a broad protective immune response with minimized risk of infecting the individual.
- the present invention solves the problems described above by providing a simple, effective and efficient method for treating and preventing viral infection.
- the present invention provides a simple, effective and efficient method for treating and preventing SARS viral infection.
- the method of the present invention affects the lipid envelope of a virus by utilizing an efficient solvent system, which does not denature or destroy the virus.
- the present invention employs an optimal solvent and energy system to create, via delipidation, a non-synthetic, host-derived or non host-derived modified viral particle that has its lipid envelope at least partially removed, generating a positive immunologic response when administered to a patient, thereby providing that patient with some degree of protection against the virus. It is believed that these modified viral particles have at least one antigen exposed that was not exposed prior to the delipidation process.
- the present invention is also effective in producing an autologous, patient-specific therapeutic vaccine against the virus, by treating a biological fluid containing the virus such that the virus is present in a modified form, with reduced infectivity, and such that an immune response is initiated upon reintroduction of the fluid with reduced lipid content into the patient.
- This autologous method ensures that patient specific antigens, for example patient specific viral antigens, are introduced into the same patient from which they were obtained to induce an immune response. This is an important feature since a patient's physiology may modify the antigens present in an infectious organism such as a virus.
- a biological fluid for example, blood
- the plasma is separated from the blood and treated to reduce the lipid content of the virus in the plasma using an optimal solvent system.
- a lipid-containing virus, treated in this manner in order to reduce its infectivity and create a modified viral particle with reduced lipid content is administered to a patient, such as an animal or a human, optionally together with a pharmaceutically acceptable carrier, in order to initiate an immune response in the animal or human and create antibodies that bind the exposed epitopes of the modified viral particle.
- Adjuvants may also be administered with the modified viral particle in the pharmaceutically acceptable carrier or separately.
- the present method is also employed to produce non-autologous vaccines, wherein biological fluids with lipid containing viruses from at least one animal or human are treated to produce a modified viral particle for administration into a different (non-autologous) animal or human.
- the present invention is also effective in producing an non-autologous, vaccine against the virus, by treating a biological fluid such as plasma obtained from an animal or a human with the present method to reduce lipid levels in the fluid and in the virus within the fluid.
- a biological fluid such as plasma obtained from an animal or a human
- Such treated fluid with reduced lipid levels and containing modified virus with reduced lipid levels may be introduced into another animal or human which was not the source of the treated biological fluid.
- This non-autologous method is employed to vaccinate a recipient animal or human against one or more infectious organisms such as viruses.
- Biological fluids may be used from animals or humans infected with one or more infectious organisms such as viruses, and treated with the present methods to produce a vaccine for administration to a recipient animal or human.
- various stock supplies of virus may be added to a biological fluid before treating the fluid with the method of the present invention to create a vaccine.
- the present invention encompasses vaccines made with the delipidation method of the present invention that include more than one strain of the same infectious organism, for example more than one clade of the coronavirus that causes SARS.
- Such vaccines provide an immune response to more than one strain of the same infectious organism.
- Any number of different infectious strains or clades of the same virus may be chosen and treated with the delipidation method of the present invention to form numerous vaccines.
- various stock supplies of different strains or clades of virus may be added to a biological fluid before treating the fluid with the method of the present invention to create a vaccine capable of generating an immune response.
- Stocks of one or more viral preparation may be employed to make a non-autologous vaccine directed to one or more viruses. In this manner combination vaccines are produced which provide protection against multiple strains or clades of a virus or against multiple viruses.
- the present invention encompasses vaccines made with the delipidation method of the present invention that include more than one infectious organism, such as more than one virus.
- Such combination vaccines provide an immune response to more than one infectious organism, for example, SARS, HIV and hepatitis. Any number of different infectious organisms may be chosen and treated with the delipidation method of the present invention to form numerous combination vaccines.
- the present invention provides a modified viral particle comprising at least a partially delipidated viral particle, wherein the partially delipidated viral particle initiates an immune response in a patient and incites protection against an infectious organism in the patient.
- the present invention provides a method for creating a modified viral particle comprising the steps of: receiving a plurality of viral particles, each having a viral envelope, in a fluid; exposing the viral particles to a delipidation process; and, partially delipidating the viral particles wherein the delipidation process at least partially removes the viral envelopes to create the modified viral particle and wherein the modified viral particle is capable of provoking a positive immune response in a patient.
- the present invention also provides an antigen delivery vehicle and a method for creating an antigen delivery vehicle comprising the steps of: receiving a plurality of viral particles, each having a viral envelope, in a fluid; exposing the viral particles to a delipidation process; and, partially delipidating the viral particles to create modified viral particles that act as antigen delivery vehicles, wherein the delipidation process at least partially removes the viral envelopes to expose at least one antigen and wherein the at least one antigen is capable of provoking a positive immune response in a patient.
- the modified viral particles of the present invention comprise at least a partially delipidated viral particle, wherein the partially delipidated viral particle is produced by exposing a non-delipidated viral particle to a delipidation process and wherein the partially delipidated viral particle comprises at least one exposed patient specific antigen that was not exposed in the non-delipidated viral particle.
- the present invention also provides a vaccine composition, comprising at least a partially delipidated viral particle having patient-specific viral antigens and optionally a pharmaceutically acceptable carrier, wherein the partially delipidated viral particle is capable of provoking a positive immune response when the composition is administered to a patient.
- the present invention also provides a method for making a vaccine comprising: contacting a lipid-containing viral particle in a fluid with a first organic solvent capable of extracting lipid from the lipid-containing viral particle; mixing the fluid and the first organic solvent for a time sufficient to extract lipid from the lipid-containing viral particle; permitting organic and aqueous phases to separate; and collecting the aqueous phase containing a modified viral particle with reduced lipid content wherein the modified viral particle is capable of provoking a positive immune response when administered to a patient.
- the vaccine protects against SARS caused by coronavirus.
- the present invention also provides a method to protect a patient against an infectious viral particle comprising administering to the patient an effective amount of a composition comprising a modified viral particle, wherein the modification comprises at least partial removal of a lipid envelope of the infectious viral particle, and optionally a pharmaceutically acceptable carrier, wherein the amount is effective to provide a protective effect against infection by the infectious viral particle in the animal or the human.
- the infectious viral particle is coronavirus.
- the present invention also provides a method for provoking a positive immune response in a patient having a plurality of lipid-containing viral particles, comprising the steps of: obtaining a fluid containing the lipid-containing viral particles from the patient; contacting the fluid containing the lipid-containing viral particles with a first organic solvent capable of extracting lipid from the lipid-containing viral particles; mixing the fluid and the first organic solvent: permitting organic and aqueous phases to separate; collecting the aqueous phase containing modified viral particles with reduced lipid content; and introducing the aqueous phase containing the modified viral particles with reduced lipid content into the animal or the human wherein the modified viral particles with reduced lipid content provoke a positive immune response in the animal or the human.
- the positive immune response is to the coronavirus which causes SARS.
- the present invention also provides a method for treating a viral infection in a patient comprising: removing blood containing a plurality of lipid-containing infectious viral particles from the patient; obtaining plasma from the blood, the plasma containing the lipid-containing infectious viral particles; contacting the plasma containing the lipid-containing infectious viral particles with a first organic solvent capable of extracting lipid from the lipid-containing infectious viral particles to produce modified viral particles having reduced lipid content; mixing the plasma and the first organic solvent; permitting organic and aqueous phases to separate; collecting the aqueous phase containing the modified viral particles; removing residual solvent from the aqueous phase; and, introducing the aqueous phase containing the modified viral particles into the patient wherein the modified viral particles have at least one exposed patient-specific antigen that was not exposed in the plurality of lipid-containing infectious viral particles.
- Introduction of these modified viral particles into the patient produces an immune response to treat or lessen the severity of the viral infection.
- the viral infection that is treated is SARS caused by coronavirus.
- the present invention also provides a method for treating a viral infection in a patient comprising: obtaining a fluid comprising plurality of lipid-containing infectious viral particles from a plurality of patients; optionally combining the lipid-containing infectious viral particles with a suitable biologically acceptable carrier; contacting the fluid containing lipid-containing infectious viral particles with a first organic solvent capable of extracting lipid from the lipid-containing infectious viral particles to produce modified viral particles having reduced lipid content; mixing the carrier and the first organic solvent; permitting organic and aqueous phases to separate; collecting the aqueous phase containing the modified viral particles; and introducing the aqueous phase containing the modified viral particles into a different patient wherein the modified viral particles have at least one exposed antigen that was not exposed in the plurality of lipid-containing infectious viral particles.
- the lipid-containing infectious viral particles represent one or more viral strains or one or more types of virus and are not patient specific. Introduction of these modified viral particles into the patient produces an immune response to treat or lessen the severity of the viral infection.
- the viral infection that is treated is SARS caused by coronavirus.
- the characteristics of the modified viral particle are exhibited in experimental data, showing mice having a positive immunogenic response when vaccinated as compared with a wholly inactivated vaccine.
- data exhibiting protein recovery indicate retention of the structural integrity of the viral particle, removing only its lipid-containing envelope.
- Fluids which may be treated with the method of the present invention include but are not limited to the following: plasma; serum; lymphatic fluid; cerebrospinal fluid; peritoneal fluid; pleural fluid; pericardial fluid; various fluids of the reproductive system including but not limited to semen, ejaculatory fluids, follicular fluid and amniotic fluid; cell culture reagents such as normal sera, fetal calf serum or serum derived from any other animal or human; and immunological reagents such as various preparations of antibodies and cytokines.
- the method of the present invention may be used to treat viruses containing lipid in the viral envelope.
- a preferred virus treated with the method of the present invention is the coronavirus that causes SARS, and subtypes and clades thereof.
- Other viruses that can be treated with the method of the present invention include the various immunodeficiency viruses including but not limited to human (HIV) and subtypes and clades such as HIV-1 and HIV-2, simian (SIV), feline (FIV), as well as any other form of immunodeficiency virus.
- Other preferred viruses to be treated with the method of the present invention include but are not limited to hepatitis in its various forms.
- Another preferred virus treated with the method of the present invention is the bovine pestivirus. It is to be understood that the present invention is not limited to the viruses provided in the list above. Additional specific viruses are described in the detailed description of this application. All viruses containing lipid, especially in their viral envelope, are included within the scope of the present invention.
- Yet another object of the present invention is to provide a method for treating lipid containing virus in order to create modified viral particles with reduced lipid content, with substantially unaffected protein levels when compared to unmodified viral particles, and with at least one exposed antigen associated with the viral particles that was substantially unexposed in unmodified viral particles.
- Another object of the present invention is to provide a method for treating a biological fluid in order to reduce or eliminate the infectivity of infectious viral organisms contained therein.
- Yet another object of the present invention is to provide a method for creating, in a biological fluid, a plurality of modified lipid containing viral particles having a distribution of reduced lipid content, with a substantial percentage of viral particles having substantially unaffected protein levels when compared to unmodified viral particles.
- Another object of the present invention is to completely or partially delipidate viral particles, wherein the viral particles comprise coronavirus, immunodeficiency virus, hepatitis in its various forms, or any other lipid-containing virus, thereby creating a modified viral particle.
- Yet another object of the present invention is to treat infectious organisms with the method of the present invention in order to reduce their infectivity and provide a vaccine comprising a modified viral particle with reduced lipid content which may be administered to an animal or a human, optionally with a pharmaceutically acceptable carrier and optionally an immunostimulant compound, to prevent or minimize clinical manifestation of disease in a patient following exposure to the virus.
- Still another object of the present invention is to treat infectious organisms with the method of the present invention in order to reduce their infectivity and provide a vaccine comprising a modified viral particle with reduced lipid content which may be administered to an animal or a human optionally with a pharmaceutically acceptable carrier and optionally an immunostimulant compound, to initiate a positive immunogenic response in the animal or human.
- Another object is to provide a method of modifying viral particles to prepare a preventative vaccine for SARS.
- Another object of the present invention is to provide an anti-viral vaccine that induces cellular responses in cells of the immune system, wherein the cellular responses include but are not limited to proliferation of cells and production of immune system molecules such as interferon gamma.
- FIG. 1 is a Western blot showing MHV antigenicity following the delipidation procedure with various solvent conditions, as indicated.
- FIG. 2 shows Western Blots of SARS Spike and SARS nucleocapsid (NC) proteins post delipidation with various solvent conditions, as indicated.
- FIG. 3 representative electron micrographs of ⁇ -irradiated SARS.
- FIG. 4 illustrates the total IgG antibody titers against SARS CoV Spike and NC post delipidation with various solvent conditions, as indicated.
- FIG. 5 illustrates the SARS neutralization titers in sera from mice vaccinated with SARS delipidated with various solvent conditions, as indicated.
- FIG. 6 illustrates the Spike Ab titers, comparing the titers in mice vaccinated with delipidated SARS to those in mice vaccinated with inactivated SARS.
- FIG. 7 illustrates the NC Ab titers comparing the titers in mice vaccinated with delipidated SARS to those in mice vaccinated with inactivated SARS.
- FIG. 8 illustrates the neutralization titers comparing the titers in mice vaccinated with delipidated SARS to mice vaccinated with inactivated SARS.
- FIG. 9 shows the SARS peptide pools generated and used for the ELISPOT assay
- FIG. 10 demonstrates IFN- ⁇ ELISPOT responses to SARS CoV NC and Spike peptide pools (Responses from a representative mouse/group).
- fluid any fluid containing an infectious organism, including but not limited to, a biological fluid obtained from an organism such as an animal or human.
- infectious organisms treated with the method of the present invention are viruses, particularly coronavirus.
- biological fluids obtained from an organism include but are not limited to blood, plasma, serum, cerebrospinal fluid, lymphatic fluid, peritoneal fluid, follicular fluid, amniotic fluid, pleural fluid, pericardial fluid, reproductive fluids and any other fluid contained within the organism.
- Other fluids may include laboratory samples containing infectious organisms suspended in any chosen fluid.
- Other fluids include cell culture reagents, many of which include biological compounds such as fluids obtained from living organisms, including but not limited to “normal serum” obtained from various animals and used as growth medium in cell and tissue culture applications.
- first solvent or “first organic solvent” “or first extraction solvent” are meant a solvent, comprising one or more solvents, used to facilitate extraction of lipid from a fluid or from a lipid-containing biological organism in the fluid. This solvent will enter the fluid and remain in the fluid until being removed.
- Suitable first extraction solvents include solvents that extract or dissolve lipid, including but not limited to alcohols, hydrocarbons, amines, ethers, fluoroethers (including but not limited to fluoromethyl hexafluoroisopropyl ether (Sevoflurane)), surfactants, detergents, and combinations thereof.
- First extraction solvents may be combinations such as the following: 1) an alcohol and an ether; 2) an alcohol and a fluoroether; 3) an alcohol and a surfactant, 4) an ether and a surfactant; or 5) an alcohol, an ether and a surfactant.
- First extraction solvents include, but are not limited to n-butanol, di-isopropyl ether (DIPE), fluoroether such as sevoflurane, surfactants such as Triton X-100 or Tween 20, diethyl ether, and combinations thereof.
- DIPE di-isopropyl ether
- fluoroether such as sevoflurane
- surfactants such as Triton X-100 or Tween 20, diethyl ether, and combinations thereof.
- second extraction solvent is defined as one or more solvents that may be employed to facilitate the removal of a portion of the first extraction solvent.
- Suitable second extraction solvents include any solvent that facilitates removal of the first extraction solvent from the fluid.
- Second extraction solvents include any solvent that facilitates removal of the first extraction solvent including but not limited to ethers, alcohols, hydrocarbons, amines, and combinations thereof.
- Preferred second extraction solvents include diethyl ether and di-isopropyl ether, which facilitate the removal of alcohols, such as n-butanol, from the fluid.
- de-emulsifying agent is a second extraction solvent that assists in the removal of the first solvent which may be present in an emulsion in an aqueous layer.
- delipidation refers to the process of removing at least a portion of a total concentration of lipids in a fluid or in a lipid-containing organism. Lipid-containing organisms may be found within fluids which may or may not contain additional lipids.
- pharmaceutically acceptable carrier or “pharmaceutically acceptable vehicle” are used herein to mean any liquid including but not limited to water or saline, a gel, salve, solvent, diluent, fluid ointment base, liposome, micelle, giant micelle, and the like, which is suitable for use in contact with living animal or human tissue without causing adverse physiological responses, and which does not interact with the other components of the composition in a deleterious manner.
- patient refers to animals and humans.
- patient specific antigen refers to an antigen that is capable of inducing a patient specific immune response when introduced into that patient.
- patient specific antigens may be viral antigens.
- a patient specific antigen includes any antigen, for example a viral antigen, that has been modified or influenced within the patient.
- a modified viral particle particularly a coronavirus particle.
- modified viral particles have lower levels of cholesterol and are immunogenic.
- the present methods expose epitopes that are not usually presented to the immune system by untreated virus. A structural change occurs in the modified viral particles, and proteins on, in, or near the surface of the virus are modified such that a conformational change occurs. Some of these proteins may also separate from the modified viral particle.
- the modified viral particle has a lower lipid content in the envelope, displays modified proteins, reduced infectivity and is immunogenic.
- Several embodiments of the delipidation methods provided herein do not lead to destruction of the viral envelope of the modified, partially delipidated immunogenic viral particles. A significant proportion of the viral envelopes are present following the partial delipidation. Thus, some embodiments of the partial delipidation methods provided herein result in partially delipidated particles comprising viral envelopes, including envelope proteins.
- Methods of the present invention solve numerous problems encountered with prior art methods.
- the method of the present invention exposes additional antigens.
- the host immune system recognizes the viral particle as foreign.
- the method of the present invention what is created is a modified viral particle in which the antigenic core remains intact, thereby using the epitopes of the actual viral particle to initiate a positive immunogenic response in the patient into which it is reintroduced.
- the method of the present invention reduces the deleterious effect on the other plasma proteins, measured by protein recovery, such that the plasma can be reintroduced into the patient.
- a patient-specific antigen that induces protection against the viral particle in the species in which it is introduced.
- the method of the present invention creates an effective means to immunize individuals against viral pathogen infection and elicit a broad, biologically active protective immune response without risk of infecting the individual.
- New vaccines may be developed from certain lipid containing viruses by removing the lipid envelope and exposing antigens hidden beneath the envelope, in turn generating a positive immune response.
- These “autologous vaccines” can be created by the partial removal of the lipid envelope using suitable solvent systems (one which would not damage the antigens contained in the particle) exposing antigens and/or forcing a structural modification in the viral protein structures, which when introduced into the body, would provoke an effective immune response.
- Non-autologous vaccines are also created in the present invention which are administered to patients that are different from the source of the virus to be delipidated.
- Combination vaccines directed against multiple viruses are also within the scope of the present invention.
- Such combination vaccines may be made from various biological fluids, from stock supplies of multiple viruses (e.g., HIV, hepatitis and SARS virus) and/or from multiple strains or clades of a virus (e.g., SARS virus or HIV-1 and HIV-2).
- Modified, partially delipidated viral particles obtained with some embodiments of the methods disclosed herein represent, in some aspects, new therapeutic vaccine compositions for therapeutic immunization and induction of an immune response in animals or humans.
- modified, partially delipidated viral particles obtained with the methods disclosed herein are useful for therapeutic immunization and induction of an immune response in animals or humans infected by a coronavirus.
- administration of the modified, partially delipidated viral particles and compositions comprising such particles provides a new method of treatment, alleviation, or attenuation of coronavirus infections, conditions or clinical symptoms associated with these infections such as those coronaviruses leading to the condition known as SARS.
- Partially delipidated coronavirus viral particles obtained according to some of aspects of the present invention possess at least some structural characteristics that distinguish them from the conventional delipidated viruses. Such characteristics include, but are not limited to, the content of viral proteins, including viral envelope proteins or host viral membrane associated proteins, the cholesterol content of the partially delipidated viral particles, or the ratio of cholesterol content to viral protein.
- a partially delipidated coronavirus viral particle according to some embodiments of the present invention has a lower cholesterol content than the cholesterol content of the non-delipidated coronavirus viral particle.
- the lower cholesterol content of the partially delipidated coronavirus viral particle can be at least 20% to 30% lower than the cholesterol content of the non-delipidated coronavirus viral particle.
- the cholesterol content in the modified, partially delipidated coronavirus viral particle is reduced, for example, no more than 80%, 60%, 55%, or 50% as compared to the unmodified viral particle.
- the protein content in the modified, partially delipidated coronavirus viral particle is reduced, for example, no more than 5%, 10%, 15%, 20%, 30%, 40%, 50% or 55% as compared to the unmodified coronavirus viral particle.
- the modified, partially delipidated coronavirus viral particle has a ratio of ⁇ g of cholesterol relative to ⁇ g of total protein of at least 0.06.
- Viruses are the preferred infectious organism treated with the method of the present invention.
- Viral infectious organisms which may be delipidated by the present invention to form modified viral particles include, but are not limited to the lipid-containing viruses of the following genuses: Alphavirus (alphaviruses), Rubivurus (rubella virus), Flavivirus (Flaviviruses), Pestivirus (mucosal disease viruses), (unnamed, hepatitis C virus), Coronavirus, (Coronaviruses) severe acute respiratory syndrome (SARS), Torovirus, (toroviruses), Arteivirus, (arteriviruses), Paramyxovirus, (Paramyxoviruses), Rubulavirus (rubulavriuses), Morbillivirus (morbillivuruses), Pneumovirinae (the pneumoviruses), Pneumovirus (pneumoviruses), Vesiculovirus (vesiculoviruses), Lyssavirus (ly
- viruses include the following human and animal pathogens: Ross River virus, fever virus, dengue viruses, Murray Valley encephalitis virus, tick-borne encephalitis viruses (including European and far eastern tick-borne encephalitis viruses, California encephalitis virus, St. Louis encephalitis virus, sand fly fever virus, human coronaviruses 229-E and OC43 and others causing the common cold, upper respiratory tract infection, probably pneumonia and possibly gastroenteritis), human parainfluenza viruses 1 and 3, mumps virus, human parainfluenza viruses 2, 4a and 4b, measles virus, human respiratory syncytial virus, rabies virus, Marburg virus, Ebola virus, influenza A viruses and influenza B viruses, Arenavirus: lymphocytic choriomeningitis (LCM) virus; Lassa virus, human immunodeficiency viruses 1 and 2, or any other immunodeficiency virus, hepatitis B virus, hepatitis C virus, hepatitis G virus, Subfamily: human
- a solvent system together with applied energy for example a mechanical mixing system, is used to substantially delipidate the viral particle.
- the delipidation process is dependent upon the total amount of solvent and energy input into a system.
- Various solvent levels and mixing methods, as described below, may be used depending upon the overall framework of the process.
- the solvent or combinations of solvents to be employed in the process of partially or completely delipidating lipid-containing organisms may be any solvent or combination of solvents effective in solubilizing lipids in the viral envelope while retaining the structural integrity of the modified viral particle, which can be measured, in one embodiment, via protein recovery.
- a delipidation process falling within the scope of the present invention uses an optimal combination of energy input and solvent to delipidate the viral particle, while still keeping it intact.
- Suitable solvents comprise hydrocarbons, ethers, fluoroethers, alcohols, phenols, esters, halohydrocarbons, halocarbons, amines, detergents, surfactants, and mixtures thereof.
- Aromatic, aliphatic, or alicyclic hydrocarbons may also be used.
- Suitable solvents include amines and mixtures of amines.
- One solvent system is DIPE, either concentrated or diluted in water or a buffer such as a physiologically acceptable buffer.
- One solvent combination comprises alcohols and ethers.
- Another solvent comprises ether or combinations of ethers and a surfactant, such as Triton X-100.
- Another solvent comprises ether or combinations of ethers, either in the form of symmetrical ethers, asymmetrical ethers or halogenated ethers such as fluoroethers.
- Suitable first extraction solvents include solvents that extract or dissolve lipid, including but not limited to alcohols, hydrocarbons, amines, ethers, fluoroethers (including but not limited to fluoromethyl hexafluoroisopropyl ether (sevoflurane)), surfactants, detergents, and combinations thereof.
- First extraction solvents may be combinations such as the following: 1) an alcohol and an ether; 2) an alcohol and a fluoroether; 3) an alcohol and a surfactant, 4) an ether and a surfactant; or 5) an alcohol, an ether and a surfactant.
- First extraction solvents include, but are not limited to n-butanol, di-isopropyl ether (DIPE), fluoroether such as sevoflurane, surfactants such as Triton X-100 or Tween 20, diethyl ether, and combinations thereof.
- DIPE di-isopropyl ether
- fluoroether such as sevoflurane
- surfactants such as Triton X-100 or Tween 20, diethyl ether, and combinations thereof.
- the optimal solvent systems are those that accomplish two objectives: first, at least partially delipidating the infectious organism or viral particle and second, employing a set of conditions such that there are few or no deleterious effects on the other plasma proteins.
- the solvent system should maintain the integrity of the viral particle such that it can be used to initiate an immune response in the patient. It should therefore be noted that certain solvents, solvent combinations, and solvent concentrations may be too harsh to use in the present invention because they result in a chemical kill.
- the solvent or combination of solvents has a relatively low boiling point to facilitate removal through a vacuum and possibly heat without destroying the antigenic core of the viral particle. It is also preferred that the solvent or combination of solvents be employed at a low temperature because heat has deleterious effects on the proteins contained in biological fluids such as plasma. It is also preferred that the solvent or combination of solvents at least partially delipidate the viral particle.
- Liquid hydrocarbons dissolve compounds of low polarity such as the lipids found in the viral envelopes of the infectious organisms. Particularly effective in disrupting the lipid membrane of a viral particle are hydrocarbons which are substantially water immiscible and liquid at about 37° C.
- Suitable hydrocarbons include, but are not limited to the following: C 5 to C 20 aliphatic hydrocarbons such as petroleum ether, hexane, heptane, octane; haloaliphatic hydrocarbons such as chloroform, 1,1,2-trichloro-1,2,2-trifluoroethane, 1,1,1-trichloroethane, trichloroethylene, tetrachloroethylene, dichloromethane and carbon tetrachloride; thioaliphatic hydrocarbons each of which may be linear, branched or cyclic, saturated or unsaturated; aromatic hydrocarbons such as benzene; ketones; alkylarenes such as toluene; haloarenes; haloalkylarenes; and thioarenes.
- Other suitable solvents may also include saturated or unsaturated heterocyclic compounds such as pyridine and aliphatic, thio- or halo-derivatives thereof.
- Suitable esters for use in the present invention include, but are not limited to, ethyl acetate, propylacetate, butylacetate and ethylpropionate.
- Suitable detergents/surfactants that may be used include but are not limited to the following: sulfates, sulfonates, phosphates (including phospholipids), carboxylates, and sulfosuccinates.
- anionic amphiphilic materials useful with the present invention include but are not limited to the following: sodium dodecyl sulfate (SDS), sodium decyl sulfate, bis-(2-ethylhexyl) sodium sulfosuccinate (AOT), cholesterol sulfate and sodium laurate.
- SDS sodium dodecyl sulfate
- AOT bis-(2-ethylhexyl) sodium sulfosuccinate
- cholesterol sulfate sodium laurate.
- Solvents may be removed from delipidated viral mixtures through the use of additional solvents.
- demulsifying agents such as ethers may be used to remove a first solvent such as an alcohol from an emulsion. Removal of solvents may also be accomplished through other methods, which do not employ additional solvents, including but not limited to the use of charcoal.
- Charcoal may be used in a slurry or alternatively, in a column to which a mixture is applied. Charcoal is a preferred method of removing solvents. Pervaporation may also be employed to remove one or more solvents from delipidated viral mixtures.
- Suitable amines for use in removal of lipid from lipid-containing organisms in the present invention are those which are substantially immiscible in water.
- Typical amines are aliphatic amines—those having a carbon chain of at least 6 carbon atoms.
- a non-limiting example of such an amine is C 6 H 13 NH 2 .
- Ether is a preferred solvent for use in the method of the present invention.
- Particularly preferred are the C 4 -C 8 containing-ethers, including but not limited to ethyl ether, diethyl ether, and propyl ethers (including but not limited to di-isopropyl ether (DIPE)).
- Asymmetrical ethers may also be employed.
- Halogenated symmetrical and asymmetrical ethers may also be employed.
- Fluoroethers including but not limited to fluoromethyl hexafluoroisopropyl ether may also be employed.
- Halogenated symmetrical and asymmetrical ethers such as fluoroethers may be employed alone or in combination with other solvents in different ratios such as (sevoflurane:DIPE ratios of 0.01 parts sevoflurane to 99.99 parts DIPE to 60 parts sevoflurane to 40 parts DIPE, with a specific ratio range of about 10 parts sevoflurane to 90 parts DIPE to 5 parts sevoflurane to 95 parts DIPE, with a specific ratio range of about 10 parts sevoflurane to 90 parts DIPE to 50 parts sevoflurane to 50 parts DIPE, with a specific ratio range of about 20 parts sevoflurane to 80 parts DIPE to 45 parts sevoflurane to 55 parts DIPE, with a specific range of about 25 parts sevoflurane to 75 parts DIPE.
- solvents such as (sevoflurane:DIPE ratios of 0.01 parts sevoflurane to 99.99 parts DIPE to 60 parts sevoflurane to 40 parts DIPE, with a specific
- Low concentrations of solvents such as ethers
- a low concentration range of solvents, such as ethers includes but is not limited to 0.5% to 30%, 0.01% to 10%, 0.01% to 5%, 0.1% to 5%, 0.01% to 2%, or 0.1% to 2%, or any number within these ranges.
- Specific concentrations of solvents, such as ethers, that may be employed include, but are not limited to the following: 0.1%, 0.625%, 1.0% 1.25%, 2%, 2.5%, 3.0%, 3.5%, 5.0% and 10% or higher. It has been observed that dilute solutions of solvents, such as ethers, are effective.
- Such solutions may be aqueous solutions or solutions in aqueous buffers, such as phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- Other physiological buffers may be used, including but not limited to bicarbonate, citrate, Tris, Tris/EDTA, and Trizma.
- Preferred ethers are di-isopropyl ether (DIPE) and diethyl ether (DEE). Low concentrations of ethers may also be used in combination with alcohols, for example, n-butanol.
- appropriate alcohols are those which are not appreciably miscible with plasma or other biological fluids.
- Such alcohols include, but are not limited to, straight chain and branched chain alcohols, including pentanols, hexanols, heptanols, octanols and those alcohols containing higher numbers of carbons.
- Alcohols for use in combination with another solvent include C 4 -C 8 containing alcohols. Accordingly, alcohols that fall within the scope of the present invention are butanols, pentanols, hexanols, heptanols and octanols, and iso forms thereof, in particular, C 4 alcohols or butanols (1-butanol and 2-butanol). The specific alcohol choice is dependent on the second solvent employed.
- Ethers and alcohols can be used in combination as a first solvent for treating the fluid containing the lipid-containing virus, or viral particle. Any combination of alcohol and ether may be used provided the combination is effective to at least partially remove lipid from the infectious organism, without having deleterious effects on the plasma proteins. In one embodiment, lipid is removed from the viral envelope of the infectious organism.
- ratios of alcohol to ether in this solvent range from about 0.01 parts alcohol to 99.99 parts ether to 60 parts alcohol to 40 parts ether, with a specific ratio range of about 10 parts alcohol to 90 parts ether to 5 parts alcohol to 95 parts ether, with a specific ratio range of about 10 parts alcohol to 90 parts ether to 50 parts alcohol to 50 parts ether, with a specific ratio range of about 20 parts alcohol to 80 parts ether to 45 parts alcohol to 55 parts ether, with a specific range of about 25 parts alcohol to 75 parts ether.
- One combination of alcohol and ether is the combination of butanol and di-isopropyl ether (DIPE).
- DIPE di-isopropyl ether
- ratios of butanol to DIPE in this solvent are about 0.01 parts butanol to 99.99 parts DIPE to 60 parts butanol to 40 parts DIPE, with a specific ratio range of about 10 parts butanol to 90 parts DIPE to 5 parts butanol to 95 parts DIPE, with a specific ratio range of about 10 parts butanol to 90 parts DIPE to 50 parts butanol to 50 parts DIPE, with a specific ratio range of about 20 parts butanol to 80 parts DIPE to 45 parts butanol to 55 parts DIPE, with a specific range of about 25 parts butanol to 75 parts DIPE.
- Another combination of alcohol and ether is the combination of butanol with diethyl ether (DEE).
- DEE diethyl ether
- ratios of butanol to DEE are about 0.01 parts butanol to 99.99 parts DEE to 60 parts butanol to 40 parts DEE, with a specific ratio range of about 10 parts butanol to 90 parts DEE to 5 parts butanol to 95 parts DEE with a specific ratio range of about 10 parts butanol to 90 parts DEE to 50 parts butanol to 50 parts DEE, with a specific ratio range of about 20 parts butanol to 80 parts DEE to 45 parts butanol to 55 parts DEE, with a specific range of about 40 parts butanol to 60 parts DEE.
- This combination of about 40% butanol and about 60% DEE (vol:vol) has been shown to have no significant effect on a variety of biochemical and hematological blood parameters, as shown for example in U.S. Pat. No. 4,895,5
- Nonionic surfactants such anionic and nonionic surfactants may also be employed alone or together with other solvents.
- Nonionic surfactants are known to one of ordinary skill in the art and may include without limitation surfactants known as Triton, for example Triton X100 (polyoxyethylene octyl phenyl ether), Tweens such as Tween 20 (PEG(20)sorbitan monolaurate), or Pluronic (block copolymers based on ethylene oxide and propylene oxide).
- surfactants When employed alone, or together with other solvents such as ethers or lower order alcohols, for example DIPE or n-butanol or combinations thereof, surfactants may be used in concentrations of from 0.001% to 1%, 0.07% to 0.8%, 0.05% to 0.5%, or 0.03% to 0.3%.
- various biological fluids may be treated with the method of the present invention in order to reduce the levels of infectivity of the lipid-containing organism in the biological fluid and to create modified viral particles.
- plasma obtained from an animal or human is treated with the method of the present invention in order to reduce the concentration and/or infectivity of lipid-containing infectious organisms, such as coronavirus viral particles, within the plasma and to create modified coronavirus viral particles.
- plasma may be obtained from an animal or human patient by withdrawing blood from the patient using well-known methods and treating the blood in order to separate the cellular components of the blood (red and white cells) from the plasma.
- Such methods for treating the blood are known to one of ordinary skill in the art and include but are not limited to centrifugation and filtration.
- centrifugation and filtration One of ordinary skill in the art understands the proper centrifugation conditions for separating such lipid-containing organisms from the red and white cells.
- Use of the present invention permits treatment of lipid-containing organisms, for example those found within plasma, without having deleterious effects on other plasma proteins and maintaining the integrity of the viral core.
- Viruses in the plasma are affected by the treatment of the plasma with the method of the present invention.
- the lipid-containing viral organism may be separated from the red and white cells using techniques known to one of ordinary skill in the art.
- Biological fluids include stocks of viral preparations including various strains of viruses as well as different types of viruses. Treatment of such biological fluids with the method of the present invention produces modified viral particles that may be administered to a patient as a non-autologous vaccine. Such non-autologous vaccines provide protection in the patient against more than strain of a virus and/or against more than one type of virus.
- Treatment of lipid-containing organisms may occur in biological fluids other than blood and plasma.
- peritoneal fluid may be treated with the present invention to affect the levels and infectivity of lipid-containing organisms without deleterious effects on protein components. The treated fluid may subsequently be reintroduced into the animal or human from which it was obtained. Treatment of non-blood types of fluids affects the lipid-containing organisms in the fluid, such as the virus.
- a biological fluid such as plasma
- the plasma is contacted with a first organic solvent, as described above, capable of solubilizing lipid in the lipid-containing infectious organism.
- the first organic solvent is combined with the plasma in a ratio wherein the first solvent is present in an amount effective to substantially solubilize the lipid in the infectious organism, for example, dissolve the lipid envelope that surrounds the virus.
- Exemplary ratios of first solvent to plasma are described in the following ranges: 0.5-4.0:0.5-4.0; 0.8-3.0:0.8-3.0; and 1-2:0.8-1.5.
- ratios may be applied, depending on the nature of the biological fluid.
- first organic solvent 0.5-4.0:0.5-4.0; 0.8-3.0:0.8-3.0; and 1-2:0.8-1.5.
- the first solvent and fluid are mixed, using methods including but not limited to one of the following suitable mixing methods: gentle stirring; vigorous stirring; vortexing; swirling; homogenization; and, end-over-end rotation.
- the amount of time required for adequate mixing of the first solvent with the fluid is related to the mixing method employed. Fluids are mixed for a period of time sufficient to permit intimate contact between the organic and aqueous phases, and for the first solvent to at least partially or completely solubilize the lipid contained in the infectious organism. Typically, mixing will occur for a period of about 10 seconds to about 24 hours, possibly about 10 seconds to about 2 hours, possibly approximately 10 seconds to approximately 10 or 20 minutes, or possibly about 30 seconds to about 1 hour, depending on the mixing method employed.
- Non-limiting examples of mixing durations associated with different methods include 1) gentle stirring and end-over-end rotation for a period of about 10 seconds to about 24 hours, 2) vigorous stirring and vortexing for a period of about 10 seconds to about 30 minutes, 3) swirling for a period of about 10 seconds to about 2 hours, or 4) homogenization for a period of about 10 seconds to about 10 minutes.
- the solvent is separated from the fluid being treated.
- the organic and aqueous phases may be separated by any suitable manner known to one of ordinary skill in the art. Since the first solvent is typically immiscible in the aqueous fluid, the two layers are permitted to separate and the undesired layer is removed.
- the undesired layer is the solvent layer containing dissolved lipids and its identification, as known to one of ordinary skill in the art, depends on whether the solvent is more or less dense than the aqueous phase. An advantage of separation in this manner is that dissolved lipids in the solvent layer may be removed.
- separation may be achieved through means, including but not limited to the following: removing the undesired layer via pipetting; centrifugation followed by removal of the layer to be separated; creating a path or hole in the bottom of the tube containing the layers and permitting the lower layer to pass through; utilization of a container with valves or ports located at specific lengths along the long axis of the container to facilitate access to and removal of specific layers; and any other means known to one of ordinary skill in the art.
- Another method of separating the layers, especially when the solvent layer is volatile is through distillation under reduced pressure or evaporation at room temperature, optionally combined with mild heating. In one embodiment employing centrifugation, relatively low g forces are employed, such as 900 ⁇ g for about 5 to 15 minutes to separate the phases.
- a preferred method of removing solvent is through the use of charcoal, preferably activated charcoal.
- This charcoal is optionally contained in a column.
- the charcoal may be used in slurry form.
- Various biocompatible forms of charcoal may be used in these columns. Pervaporation methods and use of charcoal to remove solvents are preferred methods for removing solvent.
- a preferred method of removing a first solvent or a demulsifying agent is through the use of adsorbants, such as charcoal.
- the charcoal is preferably activated charcoal. This charcoal is optionally contained in a column, as described above.
- Still another method of removing solvent is the use of hollow fiber contactors. Pervaporation methods and charcoal adsorbant methods of removing solvents are preferred.
- a de-emulsifying agent is employed to facilitate removal of the trapped first solvent.
- the de-emulsifying agent may be any agent effective to facilitate removal of the first solvent.
- a preferred de-emulsifying agent is ether and a more preferred de-emulsifying agent is diethyl ether.
- the de-emulsifying agent may be added to the fluid or in the alternative the fluid may be dispersed in the de-emulsifying agent.
- alkanes in a ratio of about 0.5 to 4.0 to about 1 part of emulsion (vol:vol) may be employed as a de-emulsifying agent, followed by washing to remove the residual alkane from the remaining delipidated organism used for preparing the vaccine.
- Preferred alkanes include, but are not limited to, pentane, hexane and higher order straight and branched chain alkanes.
- the de-emulsifying agent such as ether
- the de-emulsifying agent may be removed through means known to one of skill in the art, including such means as described in the previous paragraph.
- One convenient method to remove the de-emulsifying agent, such as ether, from the system is to permit the ether to evaporate from the system in a running fume hood or other suitable device for collecting and removing the de-emulsifying agent from the environment.
- de-emulsifying agents may be removed through application of higher temperatures, for example from about 24 to 37° C. with or without pressures of about 10 to 20 mbar.
- Another method to remove the de-emulsifying agent involves separation by centrifugation, followed by removal of organic solvent through aspiration, further followed by evaporation under reduced pressure (for example 50 mbar) or further supply of an inert gas, such as nitrogen, over the meniscus to aid in evaporation.
- reduced pressure for example 50 mbar
- an inert gas such as nitrogen
- the method of the present invention may be employed in either a continuous or discontinuous manner. That is, in a continuous manner, a fluid may be fed to a system employing a first solvent which is then mixed with the fluid, separated, and optionally further removed through application of a de-emulsifying agent.
- the continuous method also facilitates subsequent return of the fluid containing delipidated infectious organism to a desired location.
- locations may be containers for receipt and/or storage of such treated fluid, and may also include the vascular system of a human or animal or some other body compartment of a human or animal, such as the pleural, pericardial, peritoneal, and abdominopelvic spaces.
- a biological fluid for example, blood
- a biological fluid is removed from an animal or a human through means known to one of ordinary skill in the art, such as a catheter.
- Appropriate anti-clotting factors as known to one of ordinary skill in the art are employed, such as heparin, ethylenediaminetetraacetic acid (EDTA) or citrate.
- EDTA ethylenediaminetetraacetic acid
- This blood is then separated into its cellular and plasma components through the use of a centrifuge.
- the plasma is then contacted with the first solvent and mixed with the first solvent to effectuate lipid removal from the infectious organism contained within the plasma.
- charcoal, pervaporation or a de-emulsifying agent is optionally employed to remove entrapped first solvent.
- the plasma is then optionally combined with the cells previously separated from the blood to form a new blood sample containing at least partially delipidated viral particles, also called modified viral particles herein.
- the infectivity of the infectious organism is greatly reduced or eliminated.
- the fluid with reduced lipid levels and containing virus with reduced lipid levels may be reintroduced into either the vascular system or some other system of the human or animal.
- the effect of such treatment of plasma removed from the human or animal and return of the sample containing the partially or completely delipidated infectious organism, or modified viral particle, to the human or animal causes a net decrease in the infectivity of the infectious organism contained within the vascular system of the human or animal.
- the modified viral particle also serves to initiate an autologous immune response in the patient when administered to the patient.
- the method of the present invention is employed to treat body fluids in a continuous manner—while the human or animal is connected to an extracorporeal device for such treatment.
- the discontinuous or batch mode the human or animal is not connected to an extracorporeal device for processing bodily fluids with the method of the present invention.
- the present invention employs a fluid previously obtained from a human or animal, which may include, but is not limited to plasma, lymphatic fluid, or follicular fluid.
- the fluid may be contained within a blood bank or in the alternative, drawn from a human or animal prior to application of the method.
- the fluid may be a reproductive fluid or any fluid used in the process of artificial insemination or in vitro fertilization.
- the fluid may also be one not directly obtained from a human or animal but rather any fluid containing a potentially infectious organism, such as cell culture fluid.
- Stocks of various strains or clades of a virus and also stocks of multiple viruses may be used in the present method to produce vaccines.
- this fluid is treated with the method of the present invention to produce a new fluid with reduced lipid levels which contains at least partially or completely delipidated infectious organisms, or modified viral particles.
- One embodiment of this mode of the present invention is to treat plasma samples previously obtained from other animals or humans and stored in a blood bank for subsequent transfusion. This is a non-autologous method of providing vaccine protection. These samples may be treated with the method of the present invention to treat or prevent one or more infectious disease, such as SARS, HIV, hepatitis, and/or cytomegalovirus, from the biological sample.
- infectious disease such as SARS, HIV, hepatitis, and/or cytomegalovirus
- Delipidation of an infectious organism can be achieved by various means.
- a batch method can be used for fresh or stored biological fluids, for example, fresh frozen plasma.
- a variety of the described organic solvents or mixtures thereof can be used for viral inactivation.
- Extraction time depends on the solvent or mixture thereof and the mixing procedure employed.
- the fluid for example, delipidated plasma containing the modified viral particles may be administered to the patient.
- the fluid contains modified viral particles with reduced infectivity, act as a vaccine and provide protection in the patient against the virus or provide a treatment in an infected patient by generating an immune response and decreasing the severity of the disease.
- modified viral particles induce an immune response in the recipient to exposed epitopes on the modified viral particles.
- the modified viral particles may be combined with a pharmaceutically acceptable carrier, and optionally an adjuvant, and administered as a vaccine composition to a human or an animal to induce an immune response in the recipient.
- the modified viral particle which is at least partially or substantially delipidated and has immunogenic properties, is optionally combined with a pharmaceutically acceptable carrier to make a composition comprising a vaccine.
- the modified viral particle is retained in the biological fluid, such as plasma, with reduced lipid levels and is administered to a patient as a vaccine.
- This vaccine composition is optionally combined with an adjuvant or an immunostimulant and administered to an animal or a human. Both autologous and non-autologous vaccines, including combination vaccines, are within the scope of the present invention. It is to be understood that vaccine compositions may contain more than one type of modified viral particle or component thereof, in order to provide protection against more than one strain of a virus or more than one viral disease after vaccination.
- the vaccine can comprise a plurality of modified viral particles having patient-specific antigens and modified viral particles having non-patient specific antigens or stock viral particles that have undergone the delipidation process of the present invention.
- the remaining modified viral particles of the organism are retained in the delipidated biological fluid, and when reintroduced into the animal or human, are presumably ingested by phagocytes and generate an immune response.
- a delipidated infectious organism for example one in the form of a modified viral particle with exposed antigenic determinants
- a pharmaceutically acceptable carrier for example one in the form of a modified viral particle with exposed antigenic determinants
- an adjuvant or an immunostimulant as known to one of ordinary skill in the art.
- the vaccine formulations may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques known to one of ordinary skill in the art. Such techniques include uniformly and intimately bringing into association the active ingredient and the liquid carriers (pharmaceutical carrier(s) or excipient(s)).
- Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers—for example, sealed ampules and vials—and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use.
- the vaccine may be stored at temperatures of from about 4° C. to ⁇ 100° C.
- the vaccine may also be stored in a lyophilized state at different temperatures including room temperature.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets commonly used by one of ordinary skill in the art.
- the vaccine may be sterilized through conventional means known to one of ordinary skill in the art. Such means include, but are not limited to filtration, radiation and heat.
- the vaccine of the present invention may also be combined with bacteriostatic agents, such as thimerosal, to inhibit bacterial growth.
- Preferred unit dosage formulations are those containing a dose or unit, or an appropriate fraction thereof, of the administered ingredient. It should be understood that in addition to the ingredients, particularly mentioned above, the formulations of the present invention may include other agents commonly used by one of ordinary skill in the art.
- the vaccine may be administered through different routes, such as oral, including buccal and sublingual, rectal, parenteral, aerosol, nasal, intramuscular, subcutaneous, intradermal, intravenous, intraperitoneal, and topical.
- the vaccine may also be administered in the vicinity of lymphatic tissue, for example through administration to the lymph nodes such as axillary, inguinal or cervical lymph nodes.
- the vaccine of the present invention may be administered in different forms, including but not limited to solutions, emulsions and suspensions, microspheres, particles, microparticles, nanoparticles, and liposomes. It is expected that from about 1 to 5 dosages may be required per immunization regimen.
- One of ordinary skill in the medical or veterinary arts of administering vaccines will be familiar with the amount of vaccine to be administered in an initial injection and in booster injections, if required, taking into consideration, for example, the age and size of a patient.
- Initial injections may range from about less than 1 ng to 1 gram based on total viral protein. A non-limiting range may be 1 ml to 10 ml.
- the volume of administration may vary depending on the administration route.
- the vaccines of the present invention may be administered before, during or after an infection.
- the vaccine of the present invention may be administered to either humans or animals.
- the viral load (one or more viruses) of a human or an animal may be reduced by delipidation treatment of the plasma.
- the same individual may receive a vaccine directed to the one or more viruses, thereby stimulating the immune system to combat against the virus that remains in the individual.
- the time for administration of the vaccine before initial infection is known to one of ordinary skill in the art.
- the vaccine may also be administered after initial infection to ameliorate disease progression or to treat the disease.
- adjuvants may be administered in conjunction with the modified viral particles in the vaccine composition.
- adjuvants include, but are not limited to the following: polymers, co-polymers such as polyoxyethylene-polyoxypropylene co-polymers, including block co-polymers; polymer P1005; monotide ISA72; Freund's complete adjuvant (for animals); Freund's incomplete adjuvant; sorbitan monooleate; squalene; CRL-8300 adjuvant; alum; QS 21, muramyl dipeptide; trehalose; bacterial extracts, including mycobacterial extracts; detoxified endotoxins; membrane lipids; water-in-oil mixtures, water-in-oil-in-water mixtures or combinations thereof.
- suspending fluids or carriers known to one of ordinary skill in the art may be employed to suspend the vaccine composition.
- Such fluids include without limitation: sterile water, saline, buffer, or complex fluids derived from growth medium or other biological fluids.
- Preservatives, stabilizers and antibiotics known to one of ordinary skill in the art may be employed in the vaccine composition.
- Solvent treatment technology was used to develop a modified coronavirus viral particle to use as a prophylactic vaccine against the SARS virus.
- solvent-treated virus that was subsequently subjected to chemical inactivation was tested for the ability to raise neutralizing antibodies and produce a cellular immune response in mice.
- the coronavirus that produces SARS is also referred to as SARS.
- the SARS stocks used in the experiments were propagated at the Lovelace Respiratory Research Institute (LRRI), Albuquerque, N. Mex., in the laboratory of Dr. Kevin Harrod, Director of the Infectious Disease Program.
- the initial SARS seed stock was provided by the Centers for Disease Control (CDC).
- CDC Centers for Disease Control
- Supernatants from SARS infected VERO cells were then sent to Dr. Erdman at the CDC for inactivation by gamma irradiation.
- MHV Mouse Hepatitis Virus
- DIPE diisopropyl ether
- N SARS nucleocapsid
- DIPE/Butanol n-BuOH
- DIPE/Triton X-100 3%/0.05%) end-over-end mixing for 20 min at room temperature resulted in 60% cholesterol removal and 85% NC recovery.
- inactivated SARS was used to test the utililty of delipidation in enhancing immunogenicity of SARS vaccine.
- To determine the immunogenicity of the delipidated SARS in vivo a series of in vivo mouse experiments were performed.
- mice were vaccinated subcutaneously (sc) with 50 ug of inactivated purified delipidated SARS in incomplete Freund's Adjuvant in a 50 ul volume in one footpad.
- SARS was propagated at Lovelace Respiratory Research Institute (LRRI) by Dr. Kevin Harrod, and virions were purified by Lipid Sciences, Inc.).
- LRRI Lovelace Respiratory Research Institute
- mice were sacrificed, and serum was harvested.
- Serum aliquots were analyzed by Dr. Michael W. Cho at Case Western Reserve University, where SARS neutralization titers were established.
- Dr. Cho's laboratory has established a novel and very reliable neutralization assay for SARS using pseudotyped murine leukemia virus (MuLV) with the Spike protein of SARS-coronavirus (CoV) (or vesicular stomatitis virus-G protein (VSV-G) as a negative control) as previously described (Han et al., 2004 Virology. 326:140-149).
- SARS NC and Spike antibody titers were performed at Lipid Sciences, Inc. using recombinant SARS NC and Spike purchased from Virolabs, Inc (NJ).
- mice vaccinated with SARS delipidated with the DIPE/Triton X-100 method exhibited slightly higher neutralization of >50% compared to the other two groups which averaged about 40%.
- Antibody titers for SARS Spike Protein were similar in all three groups, while the SARS NC titers were higher in mice vaccinated with SARS delipidated with 3% DIPE. Therefore, the “optimal” delipidation was chosen to be the DIPE/Triton X-100 method.
- the experiment tested the cell-mediated immune responses generated by vaccination with delipidated, inactivated SARS at a concentration of 10.0 ug.
- the experiment was designed with four mice per group in the following four groups:
- mice in groups 1, 2, and 3 were primed with the same SARS supernatant obtained from LRRI, as per Experiment #2.
- Mice were injected two weeks post priming, and sacrificed one week after the booster injection since cell mediated immune responses in mice peak at about one week after the booster injection.
- Cell-mediated immune responses were measured using murine interferon-gamma (IFN- ⁇ ) ELISPOT Assay, per manufacturer's protocol (MABTech). Cells were incubated with pools of peptides covering the entire SARS CoV NC and Spike proteins.
- IFN- ⁇ murine interferon-gamma
- ELISPOT Assay Czerkinsky C, et al., (1983) “A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells”. J Immunol Methods 65 (1-2): 109-21.).
- mice neutralizing antibodies were measured with a neutralization assay for SARS using pseudotyped murine leukemia virus (MuLV) expressing the Spike protein of SARS-CoV (or VSV-G as a negative control) as previously described (Han et al., 2004 Virology. 326:140-149).
- Cell mediated immune responses were measured using ELISPOT Assays for IFN- ⁇ .
- ELISPOT Assays have been used extensively for measuring cell mediated immune responses in several different disease models.
- MHV-A59 the MHV permissive cell line 17CL.1, and A04 (a polyclonal goat anti-MHV antibody), were kindly provided by Dr. Kathryn Holmes, University of Colorado Health Sciences.
- TME tris-maleate buffer
- Virus was pelleted by spinning at 32,000 rpm for 4 hr at 4° C. in a 80 Ti rotor (Beckman Coulter, Fullerton, Calif.). Aliquots (0.4 ml) were collected from the bottom of the tube, and quantitated using the Biorad Total Protein Assay (Biorad, Hercules, Calif.).
- SARS CoV-Utah strain was obtained from the Centers for Disease Control (CDC).
- SARS permissive cell line VERO-E6 stock was obtained from ATCC Inc.
- SARS was propagated in VERO-E6 cells in the laboratory of Dr. Kevin Harrod, Lovelace Respiratory Research Institute (LRRI), Albuquerque, N. Mex., and purified using a modified MHV purification protocol, in which SARS supernatant was not PEG precipitated.
- SARS supernatant was directly layered on top of a 20%-55% sucrose gradient layer, and pelleted at 32,000 rpm for 4 hr at 4° C. in a 80 Ti rotor (Beckman Coulter, Fullerton, Calif.).
- SARS-CoV-Ag ELISA kit (MedQuick Testing, SimiValley, Calif.) targeting SARS NC protein, was used according to the manufacturer's instructions.
- Cholesterol in the viral fractions was analyzed by the Amplex Red Total Cholesterol Assay according to manufacturer's protocol (Molecular Probes, Eugene, Oreg.).
- the primary antibody AO4 (goat anti-MHV Ab) was used at 1:2000 dilution.
- the secondary antibody was a rabbit anti-goat horseradish peroxidase (HRP) (Sigma, St. Louis, Mo.) used at 1:5000 dilution.
- HRP colorimetric substrate diaminobenzidine
- DAB Enhanced Liquid Substrate System for Membrane ELISA, Sigma, St. Louis, Mo.
- the primary antibody solution was a cocktail of mouse monoclonal antibodies against SARS Spike and NC (Imgenex, San Diego, Calif.). Positive controls for Spike and NC (Virolabs, Chantilly, Va.) were run at 3.5 ug each.
- the secondary antibody a goat anti-mouse-HRP polyclonal antibody (Sigma, St. Louis, Mo.) was used at a dilution of 1:5000.
- the membrane was developed on a Kodak MS Film (Eastman Kodak, Rochester, N.Y.).
- DIPE Diisopropylether
- EOE end-over-end
- Solvent was removed by passing the mixture through an activated charcoal column. 4. BuOH and sevoflurane (Abbott Labs, Abbott Park, Ill.) at a 75:25 mixture and at a 1:2 virus:solvent ratio (vol:vol), vortexed high speed for 15 sec, with gravity separation at RT. The aqueous layer was removed. Solvent was removed by passing the mixture through an activated charcoal column. 5. A final concentration of 3% DIPE and 0.05% Triton X-100, EOE mixing for 20 min at RT. Solvent was removed by passing the mixture through an activated charcoal column. 6. A final concentration of 3% DIPE, EOE mixing for 20 min at RT. Solvent was removed by passing the mixture through an activated charcoal column. 7. A final concentration of 0.05% Triton X-100 (Sigma, St. Louis, Mo.), EOE mixing for 20 min at RT. Solvent was removed by passing the mixture through an activated charcoal column.
- Electron micrographs (EMs) of ⁇ -irradiated SARS were made by Dr. Dean Erdman and Dr. Charles Humphrey at the CDC. SARS supernatants containing about 1 ⁇ 10 6 PFU/ml were gamma irradiated with 5 ⁇ 10 6 rads, and certified inactivated by Dr. Dean Erdman.
- Table 1 summarizes the data obtained from the seven delipidations performed on MHV, a surrogate for SARS. Protein recoveries post-delipidation were >70%, except for n-BuOH:Sevoflurane delipidated virus, where the recovery was 48%.
- Table 2 summarizes the data obtained from the three chosen delipidation methods performed on SARS.
- the protein recoveries as measured by the SARS ELISA detecting SARS NC were all ⁇ 80%.
- the cholesterol removal was similar to those observed in MHV, as seen in Table 1.
- FIG. 1 illustrates a Western Blot performed on delipidated MHV as discussed in Table 1.
- the polyclonal anti-MHV antibody A04 was kindly provided by Dr. Kathryn Holmes. All lanes show positive reactivity with the anti-MHV Ab.
- the Western Blot for samples delipidated by method #1, and #3 of the delipidation matrix in Table 1 also showed the same patterns of staining as the DIPE: triton delipidated SARS (data not shown).
- FIG. 2 shows Western Blots of SARS Spike and SARS NC proteins post delipidation.
- Lanes 1-3 correspond to samples 1-3 in the SARS delipidation methods listed in Table 2 above.
- Lane 4 is purified SARS Spike and NC proteins from Virolabs. Spike reactivity is seen in 3% DIPE delipidated SARS, while very strong reactivity to NC was observed in all three delipidation protocols.
- the primary antibodies used in SARS Western blots were monoclonal antibodies.
- FIG. 3 shows representative electron micrographs of ⁇ -irradiated SARS
- the EMs of virus pre- and post-irradiation were not significantly different.
- the picture on the right a magnification of 23000 ⁇ , has a typical SARS CoV appearance.
- the Spike proteins are clearly seen on the membrane, and the morphology is consistent with those of SARS CoV.
- the particles obtained by three delipidation processes were tested with respect to generating an immune response.
- the experiment was designed with three mice per group testing the following three groups:
- mice were vaccinated sc with 50 ⁇ g of inactivated delipidated SARS in 50 ⁇ l in one footpad. At three weeks post vaccination, mice were sacrificed, and serum was harvested.
- Serum aliquots were sent to the laboratory of Dr. Michael W. Cho (Case Western Reserve University), where SARS neutralization titers were evaluated using a neutralization assay for SARS using pseudotyped murine leukemia virus (MuLV) with the Spike protein of SARS-CoV (or VSV-G as a negative control) as previously described (Han et al., 2004 Virology. 326:140-149).
- SARS NC and Spike antibody titers were performed at Lipid Sciences, Inc. using recombinant SARS NC and Spike purchased from Virolabs, Inc (NJ)
- Neutralization assays were performed using pseudotyped MuLV with Spike protein of SARS-CoV (or VSV-G as negative control) as previously described (Han et al., Virology. 326: 140-149). Briefly, VERO-E6 cells were used for the pseudovirus infection and were plated at 0.5 ⁇ 10 4 cells per well in a 96-well plate one day before infection. Heat-inactivated plasma samples at indicated dilutions were incubated with 100 infectious units of pseudoviruses. The control and experimental samples of each dilution were then dispensed to the triplicate wells containing the VERO-E6 cells for 1 hr at 37° C.
- Beta-Glo assay system Promega, Madison, Wis.
- Cells were washed with PBS, and lysed with 100 ⁇ l of Report Lysis Buffer.
- 75 ⁇ l of cell lysates and 75 ⁇ l of Beta-Glo reagent were mixed in a white-walled plate. The mixtures were incubated for 30 min at RT and measured using a luminometer (Biorad, Hercules, Calif.).
- Serum samples were titrated for antibodies to viral epitopes using routine EIA analysis. Briefly, high protein binding ELISA micro plates (Fisher, Pittsburgh, Pa.) were incubated with 1 ⁇ g purified recombinant SARS Spike or SARS NC protein (Virolabs, Chantilly, Va.) overnight in standard bicarbonate coating buffer, pH 9.6 at 4° C. Following three washes with PBS/Tween 20, the plates were blocked for 1 hr at RT with PBS containing 5% normal goat serum (Sigma, St. Louis, Mo.). Serial 1:5 dilutions of the sera to be tested in PBS containing 5% normal goat serum starting at 1:500, were added to the wells for 1 hr at RT.
- the plates were incubated with an HRP-anti mouse IgG conjugate at 1:5000 (Sigma, St. Louis, Mo.), and developed using tetramethylbenzidine (TMB) substrate (Sigma, St. Louis, Mo.). Plates were read at a 405 nm wavelength using an ELISA plate reader (Molecular Devices, Sunnyvale, Calif.).
- IFN- ⁇ Mouse interferon-gamma
- ELISPOT assays were performed using splenocytes to determine the cell-mediated immune responses generated post-vaccination with delipidated SARS. Briefly, 96 well Millipore ELLIP 10SSP multiscreen plates (Millipore, Billerica, Mass.) were coated with 100 ⁇ l anti-mouse IFN- ⁇ capturing antibody (MABTECH, Cincinnati, Ohio, monoclonal Ab clone AN-18). The capturing Ab was diluted to 10 mg/ml in sterile PBS.
- RPMI 1640 containing; 10% FBS, 10 mM HEPES buffer, 2 mM glutamine, 0.5 mg/ml gentamicin, and 50 mM 2-mercaptoethanol
- the peptide pools mentioned above were added directly to wells in a volume of 50 ⁇ l and then freshly isolated splenocytes were added at a concentration of 10 5 cells/well in 50 ⁇ l of 10% RPMI media. The final concentration of the peptides in the screening assay was 10 mM. Plates were incubated for three days at 5% CO 2 at 37° C.
- ELISPOTs were developed using the Vectastain ABC Kit (Vector Laboratories, Burlingame, Calif.) according to manufacturer's protocol. The number of spots/10 5 cells/well in the ELISPOT plates were read in a plate reader in the Vanderbilt University Core Facility, Arlington, Tenn.
- FIG. 4 illustrates the total IgG antibody titers against SARS CoV Spike and NC.
- the titers obtained from all three delipidated virus vaccines were similar for both Spike and NC.
- mice vaccinated with DIPE:n-BuOH showed slightly higher NC titers, the differences were not significant.
- IgM specific titers for all samples were at an O.D. of ⁇ 1.0 indicating the presence of very low IgM antigen specific antibodies (data not shown).
- FIG. 5 illustrates the SARS neutralization titers, performed by Dr. Michael Cho. Sera from mice vaccinated with DIPE:Triton X-100 treated SARS showed slightly better titers than mice vaccinated with SARS treated with the other delipidation protocols. SARS-CoV-specific neutralizing activities were detected in the sera from all three groups above. The overall antibody levels were low, possibly because mice only received one vaccination. Of the three groups, however, mice vaccinated with SARS delipidated with the DIPE/Triton X-100 method exhibited slightly higher neutralization of >50% compared to the other two groups which averaged at about 40%.
- DIPE/Triton X-100 delipidation method was used in Experiment #2, where we performed a titration of three concentrations of DIPE:Triton X-100 delipidated SARS vaccine of 0.1 ⁇ g, 1 ⁇ g, and 10 ⁇ g of protein, as discussed below.
- mice 3 mice/group
- SARS supernatant virus was unpurified
- mice were primed with SARS supernatant (virus was unpurified) obtained from LRRI that was ⁇ -irradiated by Dr. Erdman at the CDC and had a protein concentration of 4 mg/ml.
- Mice were primed using Incomplete Freunds Adjuvant sc with 100 ⁇ g total protein in a volume of 500 ⁇ l.
- mice were boosted with the appropriate concentration of delipidated SARS, or inactivated SARS in a volume of 500 ⁇ l administered sc.
- mice were sacrificed and serum collected and sent to Dr. Cho for neutralizing antibody titers.
- Serum IgG titers to SARS NC and Spike were performed at Lipid Sciences, Inc.
- FIG. 6 illustrates the Spike Ab titers from Experiment #2, comparing the titers in mice vaccinated with delipidated SARS to those in mice vaccinated with inactivated SARS.
- FIG. 7 illustrates the NC Ab titers comparing the titers in mice vaccinated with delipidated SARS to those in mice vaccinated with inactivated SARS.
- a clear increase in Ab titers was observed for both antigens with the 10 ⁇ g booster injection.
- the Spike and NC titers in delipidated SARS boost showed a clear dose-response.
- the titers obtained from inactivated SARS boost showed a clear enhancement in titers following the 10 ⁇ g boost.
- FIG. 8 illustrates the neutralization titers from Experiment #2 comparing the titers in mice vaccinated with delipidated SARS to mice vaccinated with inactivated SARS.
- the neutralization titers in mice boosted with either delipidated or inactivated SARS FIG. 8 bottom panel
- the dose of 10 ⁇ g was chosen as the booster injection dose in Experiment #3, which evaluated the cell-mediated immune responses measured using the mouse IFN- ⁇ ELISPOT assay in vaccinated mice.
- the experiment tested the cell-mediated immune responses generated by vaccination with DIPE:Triton X-100 delipidated SARS at a concentration of 10 ⁇ g.
- the experiment was designed with four mice per group testing the following four Groups: 1) Boosting with inactivated SARS that was treated with DIPE:Triton X-100; 2) Boosting with inactivated SARS; 3) Primed only; and, 4) No prime/no boost.
- mice in groups 1, 2, and 3 were primed with the same SARS supernatant (100 ⁇ g sc in incomplete Freunds adjuvant obtained from LRRI), as per Experiment #2.
- Mice received a booster injection two weeks post priming i.v., and were sacrificed one week later since cell mediated immune responses in mice peak at about one week after a booster injection.
- Cell-mediated immune responses were measured using murine interferon-gamma (IFN- ⁇ ) ELISPOT Assay, per manufacturer's protocol (MABTech). Cells were incubated with pools of peptides covering the entire SARS CoV NC and Spike proteins ( FIG. 9 ).
- IFN- ⁇ murine interferon-gamma
- Pools of peptides were generated using SARS Overlapping Peptide Array, which was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH.
- the four digit number in each cell of each table represents a peptide whose amino acid sequence in shown in FIG. 9 .
- the numbers 1-7 at the top of each column for the top table called NC are pool components.
- pool 1 contains peptides 9539-9589 for NC peptides pool.
- the amino acid sequences for each NC peptide shown in FIG. 9 is included in Table 3.
- pool 12 contains peptides 9609-9765 for the Spike peptide pool.
- amino acid sequences for each S peptide shown in FIG. 9 is included in Table 4.
- mice vaccinated with delipidated SARS showed a significantly enhanced peptide pool response for both NC and Spike in mice vaccinated with delipidated SARS, compared to either the inactivated SARS vaccination, or primed only mice.
- mice vaccinated with inactivated SARS did not show robust ELISPOT responses, compared to mice boosted with delipidated SARS.
- mice vaccinated with DIPE:Triton X-100 had slightly higher neutralization titers (>60%).
- the overall titers were low compared to the positive control sera (data not shown), probably because mice were given one vaccination prior to serum collection.
- Experiment #2 was a prime/boost protocol, which compared boosting primed mice with 0.1 ⁇ g, 1 ⁇ g, and 10 ⁇ g inactivated SARS or DIPE:Triton X-100 delipidated SARS vaccines. Priming was performed using a SARS supernatant propagated at LRRI, which had been irradiated by Dr. Dean Erdman at the CDC. The prime/boost strategy was adopted because this protocol would enhance both cell- and humoral immune responses. Total Ab titers to SARS Spike and NC were similar in mice boosted with either inactivated or delipidated SARS ( FIG. 6-Spike , FIG. 7-NC ).
- delipidated SARS vaccination clearly enhanced cell mediated immune responses.
- delipidation may favor augmentation of cell mediated immune responses by either enhancing existing pathways of antigen processing and presentation, or by using additional and more efficient pathways of antigen processing and presentation.
- This purification method for SARS using a different SARS culture propagated by LRRI was used to yield highly purified virus that was subsequently used as the boosts for Experiment #1, 2, and 3. It was determined that SARS can be efficiently purified by layering the supernatant on a 20-55% sucrose gradient and spinning at 32,000 rpm for 4 hr at 4° C.
- NC SARS Nucleocapsid
- Peptide Sequence 9539 1 MSDNGPQSNQRSAPRI 9540 2 QSNQRSAPRITFGGPTDS 9541 3 RITFGGPTDSTDNNQNGGR 9542 4 STDNNQNGGRNGARPKQR 9543 5 GRNGARPKQRRPQGL 9544 6 RPKQRRPQGLPNNTASWF 9545 7 GLPNNTASWFTALTQHGK 9546 8 WFTALTQHGKEELRFPR 9547 9 HGKEELRFPRGQGVPI 9548 10 RFPRGQGVPINTNSGPDDQI 9549 11 NTNSGPDDQIGYYRRATR 9550 12 QIGYYRRATRRVRGGDGK 9551 13 TRRVRGGDGKMKELSPRW 9552 14 GKMKELSPRWYFYYL 9553 15 LSPRWYFYYLGTGPEASL 9554 16 YLGTGPEASLPYGANK 9555 17 EASLPYGANK
Abstract
Description
- The present application is a continuation-in-part of U.S. non-provisional patent application Ser. No. 11/401,434 filed Apr. 10, 2006 which claims the benefit of U.S. provisional patent application Ser. No. 60/670,574, filed Apr. 11, 2005, U.S. provisional patent application Ser. No. 60/669,738, filed Apr. 8, 2005, and is a continuation-in-part of U.S. non-provisional patent application Ser. No. 10/873,015, filed Jun. 21, 2004, which is a continuation in part of U.S. non-provisional patent application Ser. No. 10/601,656 filed Jun. 20, 2003, which is a continuation-in-part of U.S. non-provisional patent application Ser. No. 10/311,679 filed Dec. 18, 2002, abandoned, which is a U.S. national phase from PCT patent application number PCT/IB01/01099 filed Jun. 21, 2001, which claims the benefit of Australian patent application PQ8469 filed Jun. 29, 2000 and PCT patent application number PCT/AU00/01603 filed Dec. 28, 2000. The present application also claims the benefit of U.S. provisional patent application Ser. No. 60/925,628 filed Apr. 20, 2007. U.S. non-provisional patent application Ser. No. 10/311,679 claims the benefit of U.S. provisional patent application Ser. No. 60/390,066 filed Jun. 20, 2002. U.S. non-provisional patent application Ser. No. 10/873,015, filed Jun. 21, 2004, also claims the benefit of U.S. provisional patent application Ser. No. 60/491,928 filed Aug. 1, 2003, 60/533,542 filed Dec. 31, 2003, and 60/542,947 filed Feb. 9, 2004. All of these applications are herein incorporated by reference in their entirety.
- The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of STTR
Grant # 1 41 AI060267-01 awarded by NIAID. - The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from a virus, thereby creating a modified viral particle. In a preferred embodiment, the virus is severe acute respiratory syndrome (SARS) caused by Coronaviruses. The solvent system of the present invention is optimally designed such that upon delipidation of the virus, the viral particle remains substantially intact. By dissolving the lipid envelope surrounding the viral particle using the method of the present invention, the resultant modified viral particle has exposed antigens (or epitopes), which foster and promote cellular responses and antibody production when introduced into a human or an animal. The resulting modified viral particle of the present invention initiates a positive immunogenic response in the species into which it is re-introduced. The present invention can be applied to delipidating viruses from a specific patient for future reintroduction into the patient, to delipidating stock viruses, or non-patient specific viruses, for use as a vaccine, or to delipidating and combining both non-patient specific viruses and patient specific viruses to create a therapeutic cocktail.
- Viruses, of varied etiology, affect billions of animals and humans each year and inflict an enormous economic burden on society. Many viruses contain lipid as a major component of the membrane that surrounds them. Viruses affect animals and humans causing extreme suffering, morbidity, and mortality. These viruses travel throughout the body in biological fluids such as blood, peritoneal fluid, lymphatic fluid, pleural fluid, pericardial fluid, cerebrospinal fluid, and in various fluids of the reproductive system. Fluid contact at any site promotes transmission of disease. Other viruses reside primarily in different organ systems and in specific tissues, proliferate and then enter the circulatory system to gain access to other tissues and organs at remote sites. If the body does not exhibit a positive immune response against these pathogens, they infect many cell types within the body, inhibiting these cells from performing their normal functions.
- The human immune system is composed of various cell types that collectively protect the body from different viruses. The immune system provides multiple means for targeting and eliminating foreign elements, including humoral and cellular immune responses, participating primarily in antigen recognition and elimination. An immune response to foreign elements requires the presence of B-lymphocytes (B cells) or T-lymphocytes (T cells) in combination with antigen-presenting cells (APC), which are usually macrophage or dendrite cells. The APCs are specialized immune cells that capture antigens. Once inside an APC, antigens are broken down into smaller fragments called epitopes—the unique markers carried by the antigen surface. These epitopes are subsequently displayed on the surface of the APCs and are responsible for triggering an antibody response in defense of the infection.
- In a humoral immune response, when an APC displaying antigens (in the form of unique epitope markers) foreign to the body are recognized, B cells are activated, proliferating and producing antibodies. These antibodies specifically bind to the antigens present on the virus. After the antibody attaches, the APC engulfs the entire antigen and kills it. This type of antibody immune response is primarily involved in the prevention of viral infection.
- In a cellular immune response, T cells are activated on recognizing the antigen displayed on the APC. There are two steps in the cellular immune response. The first step involves activation of cytotoxic T cells (CTL) or CD8+ T killer cells that proliferate and kill target cells that specifically present antigens. The second involves helper T cells (HTL) or CD4+ T cells that regulate the production of antibodies and the activity of CD8+ cells. The CD4+ T cells provide growth factors to CD8+ T cells that allow them to proliferate and function efficiently.
- Certain infective pathogens are deemed “chronic” due to their structure. For example, some viruses are able to evade an immune response because of their ability to hide some of their antigens from the immune system. Viruses contain an outer envelope made up of lipids and fats derived from the host cell membrane during the budding process. Viruses are comprised of virions, non-cellular infectious agents consisting of a single type of nucleic acid (either RNA or DNA), surrounded by a protein coat. The outer protein covering of viruses is called a capsid, made up of repeating subunits called capsomeres.
- Since viruses are non-metabolic, they only reproduce within living host cells. The virus codes the proteins of the viral envelope while the host cell codes the lipids and carbohydrates. Therefore, the lipid and carbohydrate content within a given viral envelope is dependent on the particular host. The enveloped viral particles therefore partially adopt the identity of the host cell, via lipid and carbohydrate content, and are able to conceal antigens associated with them, which would normally have initiated an immune response. Instead, the viral particle confuses the host immune system by presenting it with an antigenic complex that contains components of host tissues, and is perceived by the host immune system as partly “self” and partly “foreign”. The immune system is forced to produce the “compromise”, ineffective antibodies which do not destroy the viral particles, allowing them to proliferate and slowly cause severe damage to the body, while destroying host cells.
- Recent epidemics affecting the immune system include acquired immune deficiency syndrome (AIDS), believed to be caused by the human immunodeficiency virus (HIV). Related viruses affect animal species, for example, simians and felines (SIV and FIV, respectively). Other major viral infections include, but are not limited to, severe acute respiratory syndrome (SARS) caused by Coronaviruses, meningitis, cytomegalovirus, and hepatitis in its various forms.
- One prior art method of treating viruses of varied etiology is via drug therapy. Most anti-viral drug therapies are directed toward preventing or inhibiting viral replication and appear to focus on the initial attachment of the virus to the T4 lymphocyte or macrophage, the transcription of viral RNA to viral DNA and the assembly of new virus during replication. The high mutation rate of the virus, especially in the case of HIV, is a major difficulty with existing treatments because the various strains become resistant to anti-viral drug therapy. Furthermore, anti-viral drug therapy treatment may cause the evolution of resistant strains of the virus. Other drawbacks to drug therapies are the undesirable side effects and patient compliance requirements. In addition, many individuals are afflicted with multiple viral infections such as a combination of HIV and hepatitis. Such individuals require even more aggressive and expensive drug regimens to counteract disease progression, which in turn cause greater side effects and a greater likelihood of multiple drug resistance.
- Also known in the prior art is prevention of disease via the use of vaccinations. Vaccines have been singularly responsible for conferring immune response against several human pathogens. They are designed to stimulate the immune system to protect against various viral infections. In general, a vaccine is produced from an antigen, isolated or produced from the disease-causing microorganism, which can elicit an immune response. When a vaccine is injected into the blood stream as a preventive measure to create an effective immune response, the B cells in the blood stream perceive the antigens contained by the vaccine as foreign or ‘non-self” and respond by producing antibodies, which bind to the antigens and inactivate them. Memory cells are thereby produced and remain ready to mount a quick protective immune response against subsequent infection with the same disease-causing agent. Thus when an infective pathogen containing similar antigens as the vaccine enters the body, the immune system will recognize the protein and instigate an effective defense against infection.
- The current methods of vaccination do have drawbacks, making them less than optimally desirable for immunizing individuals against particular pathogens, such as coronavirus and HIV. The existing vaccine strategies aim to expose the body to the antigens associated with infective pathogens so that the body builds an immune response against these pathogens. For example, coronavirus, hepatitis B and HIV pathogens are able to survive and proliferate in the human body despite the immune response. One explanation offered in the prior art is that the antigens of these microorganisms change constantly so the antibodies produced in response to a particular antigen are no longer effective when the antigen mutates. Although antigenic variation has been addressed via the attempted use of combination drugs or antigens, no prior art vaccine has succeeded adequately in addressing infections such as SARS.
- Another approach to treating viruses of varied etiology is to inactivate the virus. Prior art methods of inactivating viruses using chemical agents have relied on organic solvents such as chloroform or glutaraldehyde. Viral inactivation does present problems since inactivation of a virus does not provide a protective immune response against viral infection. In addition, it is largely geared towards denaturing viral proteins, thereby destroying the structure of the viral particle. In sum, prior art methods have largely focused on destroying, yet not suitably modifying, viral particles to produce an immune response.
- Described in the prior art are methods of treating viral particles with organic solvents and high temperatures thus dissolving the lipid envelopes and subsequently inactivating the virus. In those methods, blood is withdrawn from the patient and separated into two phases—the first phase including red cells and platelets and the second phase containing plasma, white cells, and cell-free virus (virion). The second phase is treated with an organic solvent, thereby killing the infected cells and virions, and subsequently reintroduced into the patient. In addition to dissolving the lipid envelope of the virus, the high organic solvent concentrations cause cell death and damage to the antigens. Essentially, this method results in a “chemical kill” of the cell.
- Glutaraldehyde is one such solvent whereby cell inactivation is achieved as known by those of ordinary skill in the art by fixation with a dilute solution of glutaraldehyde at about 1:250. Although treating the virus with glutaraldehyde effectively delipidates the virus, it also destroys the core. Destruction of the core is not desirable for producing a modified viral particle useful for inducing an immune response in a recipient.
- Chloroform is another such solvent. Chloroform, however, denatures many plasma proteins and is not suitable for use with biological fluids, which will be reintroduced into the animal or human. These plasma proteins deleteriously affected by chloroform serve important biological functions including coagulation, hormonal response, and immune response. These functions are essential to life and thus damage to these proteins may have an adverse effect on a patient's health, possibly leading to death.
- Further, many of the methods described in the prior art involve extensive exposure to elevated temperature in order to kill free virus and infected cells. Elevated temperatures have deleterious effects on the proteins contained in biological fluids, such as plasma.
- To date, several manufacturing methods have been employed in search of safe and effective vaccines for immunizing individuals against infective pathogenic agents. To protect an individual from a specific pathogenic infection, a target protein or antigen associated with the infective pathogen is administered to the individual. This includes presenting the protein as part of a non-infective (inactivated) or less infective (attenuated) agent or as a discrete protein composition. Known to one of ordinary skill in the art are the following different types of vaccines: live attenuated vaccines, whole inactivated vaccines, DNA vaccines, combination vaccines, recombinant vaccines, live recombinant vector vaccines, virus like particles and synthetic peptide vaccines.
- In live attenuated vaccines, the viruses are rendered less pathogenic to the host, either by specific genetic manipulation of the virus genome or by passage in some type of tissue culture system. In order to achieve genetic manipulation, an inessential gene is deleted or one or more essential genes in the virus are partially damaged. Upon genetic manipulation, the viral particles become less virulent yet retain antigenic features. Live attenuated vaccines can also be used as “vaccine vectors” for other genes, wherein they act as carriers of genes from a second virus (or other pathogen) against which protection is required. Attenuated vaccines (less infective and not inactivated), however, pose several problems. First, it is difficult to ascertain when the attenuated vaccine is no longer pathogenic. The risk of viral infection from the vaccine is too great to properly test for effective attenuation. In addition, attenuated vaccines carry the risk of reverting into a virulent form of the pathogen.
- Whole inactivated vaccines are known in the art for immunizing against infection by introducing killed or inactivated viruses to introduce pathogen proteins to an individual's immune system. The administration of killed or inactivated pathogens, via heat or chemical means, into an individual introduces the pathogens to the individual's immune system in a non-infective form thereby initiating an immune response defense. Wholly inactivated vaccines provide protection by directly generating cellular and humoral immune responses against the pathogenic immunogens. There is little threat of infection, because the viral pathogen is killed or otherwise inactivated.
- Subunit vaccines are yet another form of vaccination well known to one of ordinary skill in the art. These consist of one or more isolated proteins derived from the pathogen. These proteins act as target antigens against which an immune response is exhibited. The proteins selected for the subunit vaccine are displayed by the pathogen so that upon infection of an individual by the pathogen, the individual's immune system recognizes the pathogen and instigates an immune response. Subunit vaccines are not whole infective agents and are therefore incapable of becoming infective.
- DNA vaccine is another type known in the art and uses actual genetic material of pathogens. In addition, synthetic peptide vaccines are made up of parts of synthetic peptides. These synthetic peptides comprise portions of viral proteins chosen specifically to achieve an anti-viral immune response. Also mentioned in the prior art are combination vaccines that, when used in conjunction with one another, generate a broad spectrum of immune responses.
- What is needed is a therapeutic method and system for providing patients with patient-specific viral antigens capable of initiating a protective immune response. Accordingly, what is needed is a simple, effective method that does not appreciably denature or extract proteins from the biological sample being treated. What is also needed is an effective delipidation process via which a viral particle is modified, rather than destroyed, thereby both reducing and/or eliminating infectivity of the viral particle and invoking a patient specific, autologous immune response to further reduce viral infection and prevent further infection.
- What is also needed is an effective means to immunize individuals against viral pathogen infection that is unique to the individual due to viral mutations. Preferably the means would elicit a broad protective immune response with minimized risk of infecting the individual.
- The present invention solves the problems described above by providing a simple, effective and efficient method for treating and preventing viral infection. In a preferred embodiment, the present invention provides a simple, effective and efficient method for treating and preventing SARS viral infection. The method of the present invention affects the lipid envelope of a virus by utilizing an efficient solvent system, which does not denature or destroy the virus. The present invention employs an optimal solvent and energy system to create, via delipidation, a non-synthetic, host-derived or non host-derived modified viral particle that has its lipid envelope at least partially removed, generating a positive immunologic response when administered to a patient, thereby providing that patient with some degree of protection against the virus. It is believed that these modified viral particles have at least one antigen exposed that was not exposed prior to the delipidation process.
- The present invention is also effective in producing an autologous, patient-specific therapeutic vaccine against the virus, by treating a biological fluid containing the virus such that the virus is present in a modified form, with reduced infectivity, and such that an immune response is initiated upon reintroduction of the fluid with reduced lipid content into the patient. This autologous method ensures that patient specific antigens, for example patient specific viral antigens, are introduced into the same patient from which they were obtained to induce an immune response. This is an important feature since a patient's physiology may modify the antigens present in an infectious organism such as a virus. To create the vaccine, a biological fluid (for example, blood) is removed from the patient, the plasma is separated from the blood and treated to reduce the lipid content of the virus in the plasma using an optimal solvent system. A lipid-containing virus, treated in this manner in order to reduce its infectivity and create a modified viral particle with reduced lipid content is administered to a patient, such as an animal or a human, optionally together with a pharmaceutically acceptable carrier, in order to initiate an immune response in the animal or human and create antibodies that bind the exposed epitopes of the modified viral particle. Adjuvants may also be administered with the modified viral particle in the pharmaceutically acceptable carrier or separately.
- The present method is also employed to produce non-autologous vaccines, wherein biological fluids with lipid containing viruses from at least one animal or human are treated to produce a modified viral particle for administration into a different (non-autologous) animal or human. The present invention is also effective in producing an non-autologous, vaccine against the virus, by treating a biological fluid such as plasma obtained from an animal or a human with the present method to reduce lipid levels in the fluid and in the virus within the fluid. Such treated fluid with reduced lipid levels and containing modified virus with reduced lipid levels may be introduced into another animal or human which was not the source of the treated biological fluid. This non-autologous method is employed to vaccinate a recipient animal or human against one or more infectious organisms such as viruses. Biological fluids may be used from animals or humans infected with one or more infectious organisms such as viruses, and treated with the present methods to produce a vaccine for administration to a recipient animal or human. Alternatively, or in addition, various stock supplies of virus may be added to a biological fluid before treating the fluid with the method of the present invention to create a vaccine.
- The present invention encompasses vaccines made with the delipidation method of the present invention that include more than one strain of the same infectious organism, for example more than one clade of the coronavirus that causes SARS. Such vaccines provide an immune response to more than one strain of the same infectious organism. Any number of different infectious strains or clades of the same virus may be chosen and treated with the delipidation method of the present invention to form numerous vaccines. Alternatively, or in addition, various stock supplies of different strains or clades of virus may be added to a biological fluid before treating the fluid with the method of the present invention to create a vaccine capable of generating an immune response. Stocks of one or more viral preparation may be employed to make a non-autologous vaccine directed to one or more viruses. In this manner combination vaccines are produced which provide protection against multiple strains or clades of a virus or against multiple viruses.
- The present invention encompasses vaccines made with the delipidation method of the present invention that include more than one infectious organism, such as more than one virus. Such combination vaccines provide an immune response to more than one infectious organism, for example, SARS, HIV and hepatitis. Any number of different infectious organisms may be chosen and treated with the delipidation method of the present invention to form numerous combination vaccines.
- Thus an effective method is presented, by which new vaccines can be developed from lipid containing viruses by removing lipid from the lipid envelope and exposing antigens hidden within the lipid envelope or beneath the surface of the lipid envelope, in turn generating an immune response when re-introduced into the patient.
- The present invention provides a modified viral particle comprising at least a partially delipidated viral particle, wherein the partially delipidated viral particle initiates an immune response in a patient and incites protection against an infectious organism in the patient.
- The present invention provides a method for creating a modified viral particle comprising the steps of: receiving a plurality of viral particles, each having a viral envelope, in a fluid; exposing the viral particles to a delipidation process; and, partially delipidating the viral particles wherein the delipidation process at least partially removes the viral envelopes to create the modified viral particle and wherein the modified viral particle is capable of provoking a positive immune response in a patient.
- The present invention also provides an antigen delivery vehicle and a method for creating an antigen delivery vehicle comprising the steps of: receiving a plurality of viral particles, each having a viral envelope, in a fluid; exposing the viral particles to a delipidation process; and, partially delipidating the viral particles to create modified viral particles that act as antigen delivery vehicles, wherein the delipidation process at least partially removes the viral envelopes to expose at least one antigen and wherein the at least one antigen is capable of provoking a positive immune response in a patient.
- The modified viral particles of the present invention comprise at least a partially delipidated viral particle, wherein the partially delipidated viral particle is produced by exposing a non-delipidated viral particle to a delipidation process and wherein the partially delipidated viral particle comprises at least one exposed patient specific antigen that was not exposed in the non-delipidated viral particle.
- The present invention also provides a vaccine composition, comprising at least a partially delipidated viral particle having patient-specific viral antigens and optionally a pharmaceutically acceptable carrier, wherein the partially delipidated viral particle is capable of provoking a positive immune response when the composition is administered to a patient.
- The present invention also provides a method for making a vaccine comprising: contacting a lipid-containing viral particle in a fluid with a first organic solvent capable of extracting lipid from the lipid-containing viral particle; mixing the fluid and the first organic solvent for a time sufficient to extract lipid from the lipid-containing viral particle; permitting organic and aqueous phases to separate; and collecting the aqueous phase containing a modified viral particle with reduced lipid content wherein the modified viral particle is capable of provoking a positive immune response when administered to a patient. In one embodiment the vaccine protects against SARS caused by coronavirus.
- The present invention also provides a method to protect a patient against an infectious viral particle comprising administering to the patient an effective amount of a composition comprising a modified viral particle, wherein the modification comprises at least partial removal of a lipid envelope of the infectious viral particle, and optionally a pharmaceutically acceptable carrier, wherein the amount is effective to provide a protective effect against infection by the infectious viral particle in the animal or the human. In one embodiment, the infectious viral particle is coronavirus.
- The present invention also provides a method for provoking a positive immune response in a patient having a plurality of lipid-containing viral particles, comprising the steps of: obtaining a fluid containing the lipid-containing viral particles from the patient; contacting the fluid containing the lipid-containing viral particles with a first organic solvent capable of extracting lipid from the lipid-containing viral particles; mixing the fluid and the first organic solvent: permitting organic and aqueous phases to separate; collecting the aqueous phase containing modified viral particles with reduced lipid content; and introducing the aqueous phase containing the modified viral particles with reduced lipid content into the animal or the human wherein the modified viral particles with reduced lipid content provoke a positive immune response in the animal or the human. In one embodiment, the positive immune response is to the coronavirus which causes SARS.
- The present invention also provides a method for treating a viral infection in a patient comprising: removing blood containing a plurality of lipid-containing infectious viral particles from the patient; obtaining plasma from the blood, the plasma containing the lipid-containing infectious viral particles; contacting the plasma containing the lipid-containing infectious viral particles with a first organic solvent capable of extracting lipid from the lipid-containing infectious viral particles to produce modified viral particles having reduced lipid content; mixing the plasma and the first organic solvent; permitting organic and aqueous phases to separate; collecting the aqueous phase containing the modified viral particles; removing residual solvent from the aqueous phase; and, introducing the aqueous phase containing the modified viral particles into the patient wherein the modified viral particles have at least one exposed patient-specific antigen that was not exposed in the plurality of lipid-containing infectious viral particles. Introduction of these modified viral particles into the patient produces an immune response to treat or lessen the severity of the viral infection. In one embodiment the viral infection that is treated is SARS caused by coronavirus.
- The present invention also provides a method for treating a viral infection in a patient comprising: obtaining a fluid comprising plurality of lipid-containing infectious viral particles from a plurality of patients; optionally combining the lipid-containing infectious viral particles with a suitable biologically acceptable carrier; contacting the fluid containing lipid-containing infectious viral particles with a first organic solvent capable of extracting lipid from the lipid-containing infectious viral particles to produce modified viral particles having reduced lipid content; mixing the carrier and the first organic solvent; permitting organic and aqueous phases to separate; collecting the aqueous phase containing the modified viral particles; and introducing the aqueous phase containing the modified viral particles into a different patient wherein the modified viral particles have at least one exposed antigen that was not exposed in the plurality of lipid-containing infectious viral particles. In this embodiment, the lipid-containing infectious viral particles represent one or more viral strains or one or more types of virus and are not patient specific. Introduction of these modified viral particles into the patient produces an immune response to treat or lessen the severity of the viral infection. In one embodiment the viral infection that is treated is SARS caused by coronavirus.
- As shown below, the characteristics of the modified viral particle are exhibited in experimental data, showing mice having a positive immunogenic response when vaccinated as compared with a wholly inactivated vaccine. In addition, data exhibiting protein recovery indicate retention of the structural integrity of the viral particle, removing only its lipid-containing envelope.
- Fluids which may be treated with the method of the present invention include but are not limited to the following: plasma; serum; lymphatic fluid; cerebrospinal fluid; peritoneal fluid; pleural fluid; pericardial fluid; various fluids of the reproductive system including but not limited to semen, ejaculatory fluids, follicular fluid and amniotic fluid; cell culture reagents such as normal sera, fetal calf serum or serum derived from any other animal or human; and immunological reagents such as various preparations of antibodies and cytokines.
- The method of the present invention may be used to treat viruses containing lipid in the viral envelope. A preferred virus treated with the method of the present invention is the coronavirus that causes SARS, and subtypes and clades thereof. Other viruses that can be treated with the method of the present invention include the various immunodeficiency viruses including but not limited to human (HIV) and subtypes and clades such as HIV-1 and HIV-2, simian (SIV), feline (FIV), as well as any other form of immunodeficiency virus. Other preferred viruses to be treated with the method of the present invention include but are not limited to hepatitis in its various forms. Another preferred virus treated with the method of the present invention is the bovine pestivirus. It is to be understood that the present invention is not limited to the viruses provided in the list above. Additional specific viruses are described in the detailed description of this application. All viruses containing lipid, especially in their viral envelope, are included within the scope of the present invention.
- Accordingly, it is an object of the present invention to provide a method for treating lipid containing virus in order to create modified viral particles.
- It is an object of the present invention to provide a method for treating lipid containing virus in order to create modified viral particles with reduced lipid content while substantially unaffecting protein levels when compared to unmodified viral particles.
- Yet another object of the present invention is to provide a method for treating lipid containing virus in order to create modified viral particles with reduced lipid content, with substantially unaffected protein levels when compared to unmodified viral particles, and with at least one exposed antigen associated with the viral particles that was substantially unexposed in unmodified viral particles.
- It is another object of the present invention to provide a method for treating or preventing viral disease by administering to a patient modified viral particles with reduced lipid content and at least one exposed antigen associated with the viral particles that was substantially unexposed in unmodified viral particles.
- Another object of the present invention is to provide a method for treating a biological fluid in order to reduce or eliminate the infectivity of infectious viral organisms contained therein.
- Yet another object of the present invention is to provide a method for creating, in a biological fluid, a plurality of modified lipid containing viral particles having a distribution of reduced lipid content, with a substantial percentage of viral particles having substantially unaffected protein levels when compared to unmodified viral particles.
- It is further an object of the present invention to provide a method for treatment of lipid-containing viruses within a fluid, which minimizes deleterious effects on proteins contained within the fluid, thereby creating a modified viral particle with properties that are capable of initiating a positive immune response in a patient.
- It is a further object of the present invention to provide a method for treatment of lipid-containing viruses within a fluid, which minimizes deleterious effects on proteins contained within the fluid, thereby creating a modified viral particle with patient-specific viral antigens.
- It is another object of the present invention to provide a method for reducing the infectivity of viruses, wherein the method exposes antigenic determinants on the modified viral particle.
- Another object of the present invention is to completely or partially delipidate viral particles, wherein the viral particles comprise coronavirus, immunodeficiency virus, hepatitis in its various forms, or any other lipid-containing virus, thereby creating a modified viral particle.
- It is a further object of the present invention to completely or partially delipidate viral particles, wherein the viral particles comprise coronavirus, immunodeficiency virus, hepatitis in its various forms, or any other lipid-containing virus, while retaining the structural protein core of the virus.
- It is another object of the present invention to provide a method for reducing the infectivity of viruses, wherein the newly formed viral particle can be used as an antigen delivery vehicle.
- Yet another object of the present invention is to treat infectious organisms with the method of the present invention in order to reduce their infectivity and provide a vaccine comprising a modified viral particle with reduced lipid content which may be administered to an animal or a human, optionally with a pharmaceutically acceptable carrier and optionally an immunostimulant compound, to prevent or minimize clinical manifestation of disease in a patient following exposure to the virus.
- Still another object of the present invention is to treat infectious organisms with the method of the present invention in order to reduce their infectivity and provide a vaccine comprising a modified viral particle with reduced lipid content which may be administered to an animal or a human optionally with a pharmaceutically acceptable carrier and optionally an immunostimulant compound, to initiate a positive immunogenic response in the animal or human.
- It is another object of the present invention to provide a SARS anti-viral vaccine.
- Another object is to provide a method of modifying viral particles to prepare a preventative vaccine for SARS.
- Another object of the present invention is to provide an anti-viral vaccine that induces cellular responses in cells of the immune system, wherein the cellular responses include but are not limited to proliferation of cells and production of immune system molecules such as interferon gamma.
- It is a further object of the present invention to lessen the severity of a disease, particularly SARS, caused by a lipid-containing virus in an animal or human receiving a vaccine comprising a composition comprising a virus treated with the method of the present invention, optionally combined with a pharmaceutically acceptable carrier.
- It is another object of the present invention to combine viral particles with reduced lipid content having patient specific antigens with delipidated stock viral particles with reduced lipid content to create a therapeutic combination vaccine for the treatment or prevention of more than one viral disease.
- These and other features and advantages of the present invention will become apparent after review of the following drawings and detailed description of the disclosed embodiments. Various modifications to the stated embodiments will be readily apparent to those of ordinary skill in the art, and the disclosure set forth herein may be applicable to other embodiments and applications without departing from the spirit and scope of the present invention.
- The accompanying drawings, which are incorporated in and form a part of the specification, illustrate preferred embodiments of the present invention.
-
FIG. 1 is a Western blot showing MHV antigenicity following the delipidation procedure with various solvent conditions, as indicated. -
FIG. 2 shows Western Blots of SARS Spike and SARS nucleocapsid (NC) proteins post delipidation with various solvent conditions, as indicated. -
FIG. 3 representative electron micrographs of γ-irradiated SARS. -
FIG. 4 illustrates the total IgG antibody titers against SARS CoV Spike and NC post delipidation with various solvent conditions, as indicated. -
FIG. 5 illustrates the SARS neutralization titers in sera from mice vaccinated with SARS delipidated with various solvent conditions, as indicated. -
FIG. 6 illustrates the Spike Ab titers, comparing the titers in mice vaccinated with delipidated SARS to those in mice vaccinated with inactivated SARS. -
FIG. 7 illustrates the NC Ab titers comparing the titers in mice vaccinated with delipidated SARS to those in mice vaccinated with inactivated SARS. -
FIG. 8 illustrates the neutralization titers comparing the titers in mice vaccinated with delipidated SARS to mice vaccinated with inactivated SARS. -
FIG. 9 shows the SARS peptide pools generated and used for the ELISPOT assay -
FIG. 10 demonstrates IFN-γ ELISPOT responses to SARS CoV NC and Spike peptide pools (Responses from a representative mouse/group). - By the term “fluid” is meant any fluid containing an infectious organism, including but not limited to, a biological fluid obtained from an organism such as an animal or human. Preferred infectious organisms treated with the method of the present invention are viruses, particularly coronavirus. Such biological fluids obtained from an organism include but are not limited to blood, plasma, serum, cerebrospinal fluid, lymphatic fluid, peritoneal fluid, follicular fluid, amniotic fluid, pleural fluid, pericardial fluid, reproductive fluids and any other fluid contained within the organism. Other fluids may include laboratory samples containing infectious organisms suspended in any chosen fluid. Other fluids include cell culture reagents, many of which include biological compounds such as fluids obtained from living organisms, including but not limited to “normal serum” obtained from various animals and used as growth medium in cell and tissue culture applications.
- By the terms “first solvent” or “first organic solvent” “or first extraction solvent” are meant a solvent, comprising one or more solvents, used to facilitate extraction of lipid from a fluid or from a lipid-containing biological organism in the fluid. This solvent will enter the fluid and remain in the fluid until being removed. Suitable first extraction solvents include solvents that extract or dissolve lipid, including but not limited to alcohols, hydrocarbons, amines, ethers, fluoroethers (including but not limited to fluoromethyl hexafluoroisopropyl ether (Sevoflurane)), surfactants, detergents, and combinations thereof. First extraction solvents may be combinations such as the following: 1) an alcohol and an ether; 2) an alcohol and a fluoroether; 3) an alcohol and a surfactant, 4) an ether and a surfactant; or 5) an alcohol, an ether and a surfactant. First extraction solvents include, but are not limited to n-butanol, di-isopropyl ether (DIPE), fluoroether such as sevoflurane, surfactants such as Triton X-100 or
Tween 20, diethyl ether, and combinations thereof. - The term “second extraction solvent” is defined as one or more solvents that may be employed to facilitate the removal of a portion of the first extraction solvent. Suitable second extraction solvents include any solvent that facilitates removal of the first extraction solvent from the fluid. Second extraction solvents include any solvent that facilitates removal of the first extraction solvent including but not limited to ethers, alcohols, hydrocarbons, amines, and combinations thereof. Preferred second extraction solvents include diethyl ether and di-isopropyl ether, which facilitate the removal of alcohols, such as n-butanol, from the fluid. The term “de-emulsifying agent” is a second extraction solvent that assists in the removal of the first solvent which may be present in an emulsion in an aqueous layer.
- The term “delipidation” refers to the process of removing at least a portion of a total concentration of lipids in a fluid or in a lipid-containing organism. Lipid-containing organisms may be found within fluids which may or may not contain additional lipids.
- The terms “pharmaceutically acceptable carrier” or “pharmaceutically acceptable vehicle” are used herein to mean any liquid including but not limited to water or saline, a gel, salve, solvent, diluent, fluid ointment base, liposome, micelle, giant micelle, and the like, which is suitable for use in contact with living animal or human tissue without causing adverse physiological responses, and which does not interact with the other components of the composition in a deleterious manner.
- The term “patient” refers to animals and humans.
- The term “patient specific antigen” refers to an antigen that is capable of inducing a patient specific immune response when introduced into that patient. Such patient specific antigens may be viral antigens. A patient specific antigen includes any antigen, for example a viral antigen, that has been modified or influenced within the patient.
- Practice of the method of the present invention to reduce the lipid content of a virus creates a modified viral particle, particularly a coronavirus particle. These modified viral particles have lower levels of cholesterol and are immunogenic. The present methods expose epitopes that are not usually presented to the immune system by untreated virus. A structural change occurs in the modified viral particles, and proteins on, in, or near the surface of the virus are modified such that a conformational change occurs. Some of these proteins may also separate from the modified viral particle. The modified viral particle has a lower lipid content in the envelope, displays modified proteins, reduced infectivity and is immunogenic. Several embodiments of the delipidation methods provided herein do not lead to destruction of the viral envelope of the modified, partially delipidated immunogenic viral particles. A significant proportion of the viral envelopes are present following the partial delipidation. Thus, some embodiments of the partial delipidation methods provided herein result in partially delipidated particles comprising viral envelopes, including envelope proteins.
- Modified Viral Particle Resulting from Removal of Lipid from Lipid-Containing Organisms
- Methods of the present invention solve numerous problems encountered with prior art methods. By substantially removing the lipid envelope of the virus, and keeping the viral particle intact, the method of the present invention exposes additional antigens. The host immune system recognizes the viral particle as foreign. Using the method of the present invention, what is created is a modified viral particle in which the antigenic core remains intact, thereby using the epitopes of the actual viral particle to initiate a positive immunogenic response in the patient into which it is reintroduced. In addition, the method of the present invention reduces the deleterious effect on the other plasma proteins, measured by protein recovery, such that the plasma can be reintroduced into the patient.
- In creating this modified viral particle what is also created is a patient-specific antigen that induces protection against the viral particle in the species in which it is introduced. The method of the present invention creates an effective means to immunize individuals against viral pathogen infection and elicit a broad, biologically active protective immune response without risk of infecting the individual. New vaccines may be developed from certain lipid containing viruses by removing the lipid envelope and exposing antigens hidden beneath the envelope, in turn generating a positive immune response. These “autologous vaccines” can be created by the partial removal of the lipid envelope using suitable solvent systems (one which would not damage the antigens contained in the particle) exposing antigens and/or forcing a structural modification in the viral protein structures, which when introduced into the body, would provoke an effective immune response. Non-autologous vaccines are also created in the present invention which are administered to patients that are different from the source of the virus to be delipidated. Combination vaccines directed against multiple viruses are also within the scope of the present invention. Such combination vaccines may be made from various biological fluids, from stock supplies of multiple viruses (e.g., HIV, hepatitis and SARS virus) and/or from multiple strains or clades of a virus (e.g., SARS virus or HIV-1 and HIV-2).
- Modified, partially delipidated viral particles obtained with some embodiments of the methods disclosed herein represent, in some aspects, new therapeutic vaccine compositions for therapeutic immunization and induction of an immune response in animals or humans. In one aspect, modified, partially delipidated viral particles obtained with the methods disclosed herein are useful for therapeutic immunization and induction of an immune response in animals or humans infected by a coronavirus. In one embodiment of the present invention, administration of the modified, partially delipidated viral particles and compositions comprising such particles provides a new method of treatment, alleviation, or attenuation of coronavirus infections, conditions or clinical symptoms associated with these infections such as those coronaviruses leading to the condition known as SARS.
- Partially delipidated coronavirus viral particles obtained according to some of aspects of the present invention possess at least some structural characteristics that distinguish them from the conventional delipidated viruses. Such characteristics include, but are not limited to, the content of viral proteins, including viral envelope proteins or host viral membrane associated proteins, the cholesterol content of the partially delipidated viral particles, or the ratio of cholesterol content to viral protein. For example, a partially delipidated coronavirus viral particle according to some embodiments of the present invention has a lower cholesterol content than the cholesterol content of the non-delipidated coronavirus viral particle. In one embodiment, the lower cholesterol content of the partially delipidated coronavirus viral particle can be at least 20% to 30% lower than the cholesterol content of the non-delipidated coronavirus viral particle. In other embodiments, the cholesterol content in the modified, partially delipidated coronavirus viral particle is reduced, for example, no more than 80%, 60%, 55%, or 50% as compared to the unmodified viral particle. In other embodiments, the protein content in the modified, partially delipidated coronavirus viral particle is reduced, for example, no more than 5%, 10%, 15%, 20%, 30%, 40%, 50% or 55% as compared to the unmodified coronavirus viral particle. According to other embodiments, the modified, partially delipidated coronavirus viral particle has a ratio of μg of cholesterol relative to μg of total protein of at least 0.06.
- Infectious Organisms Treated with the Present Invention
- Viruses are the preferred infectious organism treated with the method of the present invention. Viral infectious organisms which may be delipidated by the present invention to form modified viral particles include, but are not limited to the lipid-containing viruses of the following genuses: Alphavirus (alphaviruses), Rubivurus (rubella virus), Flavivirus (Flaviviruses), Pestivirus (mucosal disease viruses), (unnamed, hepatitis C virus), Coronavirus, (Coronaviruses) severe acute respiratory syndrome (SARS), Torovirus, (toroviruses), Arteivirus, (arteriviruses), Paramyxovirus, (Paramyxoviruses), Rubulavirus (rubulavriuses), Morbillivirus (morbillivuruses), Pneumovirinae (the pneumoviruses), Pneumovirus (pneumoviruses), Vesiculovirus (vesiculoviruses), Lyssavirus (lyssaviruses), Ephemerovirus (ephemeroviruses), Cytorhabdovirus (plant rhabdovirus group A), Nucleorhabdovirus (plant rhabdovirus group B), Filovirus (filoviruses), Influenzavirus A, B (influenza A and B viruses), Influenza virus C (influenza C virus), (unnamed, Thogoto-like viruses), Bunyavirus (bunyaviruses), Phlebovirus (phleboviruses), Nairovirus (nairoviruses), Hantavirus (hantaviruses), Tospovirus (tospoviruses), Arenavirus (arenaviruses), unnamed mammalian type B retroviruses, unnamed, mammalian and reptilian type C retroviruses, unnamed, type D retroviruses, Lentivirus (lentiviruses), Spumavirus (spumaviruses), Orthohepadnavirus (hepadnaviruses of mammals), Avihepadnavirus (hepadnaviruses of birds), Simplexvirus (simplexviruses), Varicellovirus (varicelloviruses), Betaherpesvirinae (the cytomegaloviruses), Cytomegalovirus (cytomegaloviruses), Muromegalovirus (murine cytomegaloviruses), Roseolovirus (human herpes virus 6, 7, 8), Gammaherpesvirinae (the lymphocyte-associated herpes viruses), Lymphocryptovirus (Epstein-Barr-like viruses), Rhadinovirus (saimiri-ateles-like herpes viruses), Orthopoxvirus (orthopoxviruses), Parapoxvirus (parapoxviruses), Avipoxvirus (fowlpox viruses), Capripoxvirus (sheeppox-like viruses), Leporipoxvirus (myxomaviruses), Suipoxvirus (swine-pox viruses), Molluscipoxvirus (molluscum contagiosum viruses), Yatapoxvirus (yabapox and tanapox viruses), Unnamed, African swine fever-like viruses, Iridovirus (small iridescent insect viruses), Ranavirus (front iridoviruses), Lymphocystivirus (lymphocystis viruses of fish), Togaviridae, Flaviviridae, Coronaviridae, Enabdoviridae, Filoviridae, Paramyxoviridae, Orthomyxoviridae, Bunyaviridae, Arenaviridae, Retroviridae, Hepadnaviridae, Herpesviridae, Poxviridae, and any other lipid-containing virus.
- These viruses include the following human and animal pathogens: Ross River virus, fever virus, dengue viruses, Murray Valley encephalitis virus, tick-borne encephalitis viruses (including European and far eastern tick-borne encephalitis viruses, California encephalitis virus, St. Louis encephalitis virus, sand fly fever virus, human coronaviruses 229-E and OC43 and others causing the common cold, upper respiratory tract infection, probably pneumonia and possibly gastroenteritis),
human parainfluenza viruses human parainfluenza viruses 2, 4a and 4b, measles virus, human respiratory syncytial virus, rabies virus, Marburg virus, Ebola virus, influenza A viruses and influenza B viruses, Arenavirus: lymphocytic choriomeningitis (LCM) virus; Lassa virus,human immunodeficiency viruses human herpes viruses - One of ordinary skill in the art would appreciate that there may be multiple delipidation processes employed under the scope of this invention. In a preferred embodiment, a solvent system together with applied energy, for example a mechanical mixing system, is used to substantially delipidate the viral particle. The delipidation process is dependent upon the total amount of solvent and energy input into a system. Various solvent levels and mixing methods, as described below, may be used depending upon the overall framework of the process.
- Exemplary Solvent Systems for Use in Removal of Lipid from Viruses and Effective in Maintaining Integrity of the Viral Particle
- The solvent or combinations of solvents to be employed in the process of partially or completely delipidating lipid-containing organisms may be any solvent or combination of solvents effective in solubilizing lipids in the viral envelope while retaining the structural integrity of the modified viral particle, which can be measured, in one embodiment, via protein recovery. A delipidation process falling within the scope of the present invention uses an optimal combination of energy input and solvent to delipidate the viral particle, while still keeping it intact. Suitable solvents comprise hydrocarbons, ethers, fluoroethers, alcohols, phenols, esters, halohydrocarbons, halocarbons, amines, detergents, surfactants, and mixtures thereof. Aromatic, aliphatic, or alicyclic hydrocarbons may also be used. Other suitable solvents, which may be used with the present invention, include amines and mixtures of amines. One solvent system is DIPE, either concentrated or diluted in water or a buffer such as a physiologically acceptable buffer. One solvent combination comprises alcohols and ethers. Another solvent comprises ether or combinations of ethers and a surfactant, such as Triton X-100. Another solvent comprises ether or combinations of ethers, either in the form of symmetrical ethers, asymmetrical ethers or halogenated ethers such as fluoroethers.
- Suitable first extraction solvents include solvents that extract or dissolve lipid, including but not limited to alcohols, hydrocarbons, amines, ethers, fluoroethers (including but not limited to fluoromethyl hexafluoroisopropyl ether (sevoflurane)), surfactants, detergents, and combinations thereof. First extraction solvents may be combinations such as the following: 1) an alcohol and an ether; 2) an alcohol and a fluoroether; 3) an alcohol and a surfactant, 4) an ether and a surfactant; or 5) an alcohol, an ether and a surfactant. First extraction solvents include, but are not limited to n-butanol, di-isopropyl ether (DIPE), fluoroether such as sevoflurane, surfactants such as Triton X-100 or
Tween 20, diethyl ether, and combinations thereof. - The optimal solvent systems are those that accomplish two objectives: first, at least partially delipidating the infectious organism or viral particle and second, employing a set of conditions such that there are few or no deleterious effects on the other plasma proteins. In addition, the solvent system should maintain the integrity of the viral particle such that it can be used to initiate an immune response in the patient. It should therefore be noted that certain solvents, solvent combinations, and solvent concentrations may be too harsh to use in the present invention because they result in a chemical kill.
- It is preferred that the solvent or combination of solvents has a relatively low boiling point to facilitate removal through a vacuum and possibly heat without destroying the antigenic core of the viral particle. It is also preferred that the solvent or combination of solvents be employed at a low temperature because heat has deleterious effects on the proteins contained in biological fluids such as plasma. It is also preferred that the solvent or combination of solvents at least partially delipidate the viral particle.
- Liquid hydrocarbons dissolve compounds of low polarity such as the lipids found in the viral envelopes of the infectious organisms. Particularly effective in disrupting the lipid membrane of a viral particle are hydrocarbons which are substantially water immiscible and liquid at about 37° C. Suitable hydrocarbons include, but are not limited to the following: C5 to C20 aliphatic hydrocarbons such as petroleum ether, hexane, heptane, octane; haloaliphatic hydrocarbons such as chloroform, 1,1,2-trichloro-1,2,2-trifluoroethane, 1,1,1-trichloroethane, trichloroethylene, tetrachloroethylene, dichloromethane and carbon tetrachloride; thioaliphatic hydrocarbons each of which may be linear, branched or cyclic, saturated or unsaturated; aromatic hydrocarbons such as benzene; ketones; alkylarenes such as toluene; haloarenes; haloalkylarenes; and thioarenes. Other suitable solvents may also include saturated or unsaturated heterocyclic compounds such as pyridine and aliphatic, thio- or halo-derivatives thereof.
- Suitable esters for use in the present invention include, but are not limited to, ethyl acetate, propylacetate, butylacetate and ethylpropionate. Suitable detergents/surfactants that may be used include but are not limited to the following: sulfates, sulfonates, phosphates (including phospholipids), carboxylates, and sulfosuccinates. Some anionic amphiphilic materials useful with the present invention include but are not limited to the following: sodium dodecyl sulfate (SDS), sodium decyl sulfate, bis-(2-ethylhexyl) sodium sulfosuccinate (AOT), cholesterol sulfate and sodium laurate.
- Solvents may be removed from delipidated viral mixtures through the use of additional solvents. For example, demulsifying agents such as ethers may be used to remove a first solvent such as an alcohol from an emulsion. Removal of solvents may also be accomplished through other methods, which do not employ additional solvents, including but not limited to the use of charcoal. Charcoal may be used in a slurry or alternatively, in a column to which a mixture is applied. Charcoal is a preferred method of removing solvents. Pervaporation may also be employed to remove one or more solvents from delipidated viral mixtures.
- Examples of suitable amines for use in removal of lipid from lipid-containing organisms in the present invention are those which are substantially immiscible in water. Typical amines are aliphatic amines—those having a carbon chain of at least 6 carbon atoms. A non-limiting example of such an amine is C6H13NH2.
- Ether is a preferred solvent for use in the method of the present invention. Particularly preferred are the C4-C8 containing-ethers, including but not limited to ethyl ether, diethyl ether, and propyl ethers (including but not limited to di-isopropyl ether (DIPE)). Asymmetrical ethers may also be employed. Halogenated symmetrical and asymmetrical ethers may also be employed. Fluoroethers including but not limited to fluoromethyl hexafluoroisopropyl ether may also be employed. Halogenated symmetrical and asymmetrical ethers, such as fluoroethers may be employed alone or in combination with other solvents in different ratios such as (sevoflurane:DIPE ratios of 0.01 parts sevoflurane to 99.99 parts DIPE to 60 parts sevoflurane to 40 parts DIPE, with a specific ratio range of about 10 parts sevoflurane to 90 parts DIPE to 5 parts sevoflurane to 95 parts DIPE, with a specific ratio range of about 10 parts sevoflurane to 90 parts DIPE to 50 parts sevoflurane to 50 parts DIPE, with a specific ratio range of about 20 parts sevoflurane to 80 parts DIPE to 45 parts sevoflurane to 55 parts DIPE, with a specific range of about 25 parts sevoflurane to 75 parts DIPE.
- Low concentrations of solvents, such as ethers, may be employed to remove lipids when used alone and not in combination with other solvents. For example, a low concentration range of solvents, such as ethers includes but is not limited to 0.5% to 30%, 0.01% to 10%, 0.01% to 5%, 0.1% to 5%, 0.01% to 2%, or 0.1% to 2%, or any number within these ranges. Specific concentrations of solvents, such as ethers, that may be employed include, but are not limited to the following: 0.1%, 0.625%, 1.0% 1.25%, 2%, 2.5%, 3.0%, 3.5%, 5.0% and 10% or higher. It has been observed that dilute solutions of solvents, such as ethers, are effective. Such solutions may be aqueous solutions or solutions in aqueous buffers, such as phosphate buffered saline (PBS). Other physiological buffers may be used, including but not limited to bicarbonate, citrate, Tris, Tris/EDTA, and Trizma. Preferred ethers are di-isopropyl ether (DIPE) and diethyl ether (DEE). Low concentrations of ethers may also be used in combination with alcohols, for example, n-butanol.
- When used in the present invention, appropriate alcohols are those which are not appreciably miscible with plasma or other biological fluids. Such alcohols include, but are not limited to, straight chain and branched chain alcohols, including pentanols, hexanols, heptanols, octanols and those alcohols containing higher numbers of carbons.
- When alcohols are used in combination with another solvent, for example, an ether, a hydrocarbon, an amine, or a combination thereof, C1-C8 containing alcohols may be used. Alcohols for use in combination with another solvent include C4-C8 containing alcohols. Accordingly, alcohols that fall within the scope of the present invention are butanols, pentanols, hexanols, heptanols and octanols, and iso forms thereof, in particular, C4 alcohols or butanols (1-butanol and 2-butanol). The specific alcohol choice is dependent on the second solvent employed.
- Ethers and alcohols can be used in combination as a first solvent for treating the fluid containing the lipid-containing virus, or viral particle. Any combination of alcohol and ether may be used provided the combination is effective to at least partially remove lipid from the infectious organism, without having deleterious effects on the plasma proteins. In one embodiment, lipid is removed from the viral envelope of the infectious organism. When alcohols and ether are combined as a first solvent for treating the infectious organism contained in a fluid, ratios of alcohol to ether in this solvent range from about 0.01 parts alcohol to 99.99 parts ether to 60 parts alcohol to 40 parts ether, with a specific ratio range of about 10 parts alcohol to 90 parts ether to 5 parts alcohol to 95 parts ether, with a specific ratio range of about 10 parts alcohol to 90 parts ether to 50 parts alcohol to 50 parts ether, with a specific ratio range of about 20 parts alcohol to 80 parts ether to 45 parts alcohol to 55 parts ether, with a specific range of about 25 parts alcohol to 75 parts ether.
- One combination of alcohol and ether is the combination of butanol and di-isopropyl ether (DIPE). When butanol and DIPE are combined as a first solvent for treating the infectious organism contained in a fluid, ratios of butanol to DIPE in this solvent are about 0.01 parts butanol to 99.99 parts DIPE to 60 parts butanol to 40 parts DIPE, with a specific ratio range of about 10 parts butanol to 90 parts DIPE to 5 parts butanol to 95 parts DIPE, with a specific ratio range of about 10 parts butanol to 90 parts DIPE to 50 parts butanol to 50 parts DIPE, with a specific ratio range of about 20 parts butanol to 80 parts DIPE to 45 parts butanol to 55 parts DIPE, with a specific range of about 25 parts butanol to 75 parts DIPE.
- Another combination of alcohol and ether is the combination of butanol with diethyl ether (DEE). When butanol is used in combination with DEE as a first solvent, ratios of butanol to DEE are about 0.01 parts butanol to 99.99 parts DEE to 60 parts butanol to 40 parts DEE, with a specific ratio range of about 10 parts butanol to 90 parts DEE to 5 parts butanol to 95 parts DEE with a specific ratio range of about 10 parts butanol to 90 parts DEE to 50 parts butanol to 50 parts DEE, with a specific ratio range of about 20 parts butanol to 80 parts DEE to 45 parts butanol to 55 parts DEE, with a specific range of about 40 parts butanol to 60 parts DEE. This combination of about 40% butanol and about 60% DEE (vol:vol) has been shown to have no significant effect on a variety of biochemical and hematological blood parameters, as shown for example in U.S. Pat. No. 4,895,558.
- Surfactants such anionic and nonionic surfactants may also be employed alone or together with other solvents. Nonionic surfactants are known to one of ordinary skill in the art and may include without limitation surfactants known as Triton, for example Triton X100 (polyoxyethylene octyl phenyl ether), Tweens such as Tween 20 (PEG(20)sorbitan monolaurate), or Pluronic (block copolymers based on ethylene oxide and propylene oxide). When employed alone, or together with other solvents such as ethers or lower order alcohols, for example DIPE or n-butanol or combinations thereof, surfactants may be used in concentrations of from 0.001% to 1%, 0.07% to 0.8%, 0.05% to 0.5%, or 0.03% to 0.3%.
- As stated above, various biological fluids may be treated with the method of the present invention in order to reduce the levels of infectivity of the lipid-containing organism in the biological fluid and to create modified viral particles. In a preferred embodiment, plasma obtained from an animal or human is treated with the method of the present invention in order to reduce the concentration and/or infectivity of lipid-containing infectious organisms, such as coronavirus viral particles, within the plasma and to create modified coronavirus viral particles. In this embodiment, plasma may be obtained from an animal or human patient by withdrawing blood from the patient using well-known methods and treating the blood in order to separate the cellular components of the blood (red and white cells) from the plasma. Such methods for treating the blood are known to one of ordinary skill in the art and include but are not limited to centrifugation and filtration. One of ordinary skill in the art understands the proper centrifugation conditions for separating such lipid-containing organisms from the red and white cells. Use of the present invention permits treatment of lipid-containing organisms, for example those found within plasma, without having deleterious effects on other plasma proteins and maintaining the integrity of the viral core.
- Viruses in the plasma are affected by the treatment of the plasma with the method of the present invention. The lipid-containing viral organism may be separated from the red and white cells using techniques known to one of ordinary skill in the art.
- Biological fluids include stocks of viral preparations including various strains of viruses as well as different types of viruses. Treatment of such biological fluids with the method of the present invention produces modified viral particles that may be administered to a patient as a non-autologous vaccine. Such non-autologous vaccines provide protection in the patient against more than strain of a virus and/or against more than one type of virus. Treatment of lipid-containing organisms may occur in biological fluids other than blood and plasma. For example, peritoneal fluid may be treated with the present invention to affect the levels and infectivity of lipid-containing organisms without deleterious effects on protein components. The treated fluid may subsequently be reintroduced into the animal or human from which it was obtained. Treatment of non-blood types of fluids affects the lipid-containing organisms in the fluid, such as the virus.
- Once a biological fluid, such as plasma, is obtained either in this manner, or for example, from a storage facility housing bags of plasma, the plasma is contacted with a first organic solvent, as described above, capable of solubilizing lipid in the lipid-containing infectious organism. The first organic solvent is combined with the plasma in a ratio wherein the first solvent is present in an amount effective to substantially solubilize the lipid in the infectious organism, for example, dissolve the lipid envelope that surrounds the virus. Exemplary ratios of first solvent to plasma (expressed as a ratio of first organic solvent to plasma) are described in the following ranges: 0.5-4.0:0.5-4.0; 0.8-3.0:0.8-3.0; and 1-2:0.8-1.5. Various other ratios may be applied, depending on the nature of the biological fluid. For example, in the case of cell culture fluid, the following ranges may be employed of first organic solvent to cell culture fluid: 0.5-4.0:0.5-4.0; 0.8-3.0:0.8-3.0; and 1-2:0.8-1.5.
- After contacting the fluid containing the infectious organism with the first solvent as described above, the first solvent and fluid are mixed, using methods including but not limited to one of the following suitable mixing methods: gentle stirring; vigorous stirring; vortexing; swirling; homogenization; and, end-over-end rotation.
- The amount of time required for adequate mixing of the first solvent with the fluid is related to the mixing method employed. Fluids are mixed for a period of time sufficient to permit intimate contact between the organic and aqueous phases, and for the first solvent to at least partially or completely solubilize the lipid contained in the infectious organism. Typically, mixing will occur for a period of about 10 seconds to about 24 hours, possibly about 10 seconds to about 2 hours, possibly approximately 10 seconds to approximately 10 or 20 minutes, or possibly about 30 seconds to about 1 hour, depending on the mixing method employed. Non-limiting examples of mixing durations associated with different methods include 1) gentle stirring and end-over-end rotation for a period of about 10 seconds to about 24 hours, 2) vigorous stirring and vortexing for a period of about 10 seconds to about 30 minutes, 3) swirling for a period of about 10 seconds to about 2 hours, or 4) homogenization for a period of about 10 seconds to about 10 minutes.
- After mixing of the first solvent with the fluid, the solvent is separated from the fluid being treated. The organic and aqueous phases may be separated by any suitable manner known to one of ordinary skill in the art. Since the first solvent is typically immiscible in the aqueous fluid, the two layers are permitted to separate and the undesired layer is removed. The undesired layer is the solvent layer containing dissolved lipids and its identification, as known to one of ordinary skill in the art, depends on whether the solvent is more or less dense than the aqueous phase. An advantage of separation in this manner is that dissolved lipids in the solvent layer may be removed.
- In addition, separation may be achieved through means, including but not limited to the following: removing the undesired layer via pipetting; centrifugation followed by removal of the layer to be separated; creating a path or hole in the bottom of the tube containing the layers and permitting the lower layer to pass through; utilization of a container with valves or ports located at specific lengths along the long axis of the container to facilitate access to and removal of specific layers; and any other means known to one of ordinary skill in the art. Another method of separating the layers, especially when the solvent layer is volatile, is through distillation under reduced pressure or evaporation at room temperature, optionally combined with mild heating. In one embodiment employing centrifugation, relatively low g forces are employed, such as 900×g for about 5 to 15 minutes to separate the phases.
- A preferred method of removing solvent is through the use of charcoal, preferably activated charcoal. This charcoal is optionally contained in a column. Alternatively the charcoal may be used in slurry form. Various biocompatible forms of charcoal may be used in these columns. Pervaporation methods and use of charcoal to remove solvents are preferred methods for removing solvent.
- Following separation of the first solvent from the treated fluid, some of the first solvent may remain entrapped in the aqueous layer as an emulsion. A preferred method of removing a first solvent or a demulsifying agent is through the use of adsorbants, such as charcoal. The charcoal is preferably activated charcoal. This charcoal is optionally contained in a column, as described above. Still another method of removing solvent is the use of hollow fiber contactors. Pervaporation methods and charcoal adsorbant methods of removing solvents are preferred. In yet another embodiment, a de-emulsifying agent is employed to facilitate removal of the trapped first solvent. The de-emulsifying agent may be any agent effective to facilitate removal of the first solvent. A preferred de-emulsifying agent is ether and a more preferred de-emulsifying agent is diethyl ether. The de-emulsifying agent may be added to the fluid or in the alternative the fluid may be dispersed in the de-emulsifying agent. In vaccine preparation, alkanes in a ratio of about 0.5 to 4.0 to about 1 part of emulsion (vol:vol) may be employed as a de-emulsifying agent, followed by washing to remove the residual alkane from the remaining delipidated organism used for preparing the vaccine. Preferred alkanes include, but are not limited to, pentane, hexane and higher order straight and branched chain alkanes.
- The de-emulsifying agent, such as ether, may be removed through means known to one of skill in the art, including such means as described in the previous paragraph. One convenient method to remove the de-emulsifying agent, such as ether, from the system, is to permit the ether to evaporate from the system in a running fume hood or other suitable device for collecting and removing the de-emulsifying agent from the environment. In addition, de-emulsifying agents may be removed through application of higher temperatures, for example from about 24 to 37° C. with or without pressures of about 10 to 20 mbar. Another method to remove the de-emulsifying agent involves separation by centrifugation, followed by removal of organic solvent through aspiration, further followed by evaporation under reduced pressure (for example 50 mbar) or further supply of an inert gas, such as nitrogen, over the meniscus to aid in evaporation.
- It is to be understood that the method of the present invention may be employed in either a continuous or discontinuous manner. That is, in a continuous manner, a fluid may be fed to a system employing a first solvent which is then mixed with the fluid, separated, and optionally further removed through application of a de-emulsifying agent. The continuous method also facilitates subsequent return of the fluid containing delipidated infectious organism to a desired location. Such locations may be containers for receipt and/or storage of such treated fluid, and may also include the vascular system of a human or animal or some other body compartment of a human or animal, such as the pleural, pericardial, peritoneal, and abdominopelvic spaces.
- In one embodiment of the continuous method of the present invention, a biological fluid, for example, blood, is removed from an animal or a human through means known to one of ordinary skill in the art, such as a catheter. Appropriate anti-clotting factors as known to one of ordinary skill in the art are employed, such as heparin, ethylenediaminetetraacetic acid (EDTA) or citrate. This blood is then separated into its cellular and plasma components through the use of a centrifuge. The plasma is then contacted with the first solvent and mixed with the first solvent to effectuate lipid removal from the infectious organism contained within the plasma. Following separation of the first solvent from the treated plasma, charcoal, pervaporation or a de-emulsifying agent is optionally employed to remove entrapped first solvent. After ensuring that acceptable levels (non-toxic) of first solvent or de-emulsifying agent, if employed, are found within the plasma containing the delipidated infectious organism, the plasma is then optionally combined with the cells previously separated from the blood to form a new blood sample containing at least partially delipidated viral particles, also called modified viral particles herein.
- Through the practice of this method, the infectivity of the infectious organism is greatly reduced or eliminated. Following recombination with the cells originally separated from the blood, the fluid with reduced lipid levels and containing virus with reduced lipid levels may be reintroduced into either the vascular system or some other system of the human or animal. The effect of such treatment of plasma removed from the human or animal and return of the sample containing the partially or completely delipidated infectious organism, or modified viral particle, to the human or animal causes a net decrease in the infectivity of the infectious organism contained within the vascular system of the human or animal. The modified viral particle also serves to initiate an autologous immune response in the patient when administered to the patient. In this mode of operation, the method of the present invention is employed to treat body fluids in a continuous manner—while the human or animal is connected to an extracorporeal device for such treatment.
- In yet another embodiment, the discontinuous or batch mode, the human or animal is not connected to an extracorporeal device for processing bodily fluids with the method of the present invention. In a discontinuous mode of operation, the present invention employs a fluid previously obtained from a human or animal, which may include, but is not limited to plasma, lymphatic fluid, or follicular fluid. The fluid may be contained within a blood bank or in the alternative, drawn from a human or animal prior to application of the method. The fluid may be a reproductive fluid or any fluid used in the process of artificial insemination or in vitro fertilization. The fluid may also be one not directly obtained from a human or animal but rather any fluid containing a potentially infectious organism, such as cell culture fluid. Stocks of various strains or clades of a virus and also stocks of multiple viruses may be used in the present method to produce vaccines. In this mode of operation, this fluid is treated with the method of the present invention to produce a new fluid with reduced lipid levels which contains at least partially or completely delipidated infectious organisms, or modified viral particles. One embodiment of this mode of the present invention is to treat plasma samples previously obtained from other animals or humans and stored in a blood bank for subsequent transfusion. This is a non-autologous method of providing vaccine protection. These samples may be treated with the method of the present invention to treat or prevent one or more infectious disease, such as SARS, HIV, hepatitis, and/or cytomegalovirus, from the biological sample.
- Delipidation of an infectious organism can be achieved by various means. A batch method can be used for fresh or stored biological fluids, for example, fresh frozen plasma. In this case a variety of the described organic solvents or mixtures thereof can be used for viral inactivation. Extraction time depends on the solvent or mixture thereof and the mixing procedure employed.
- Through the use of the methods of the present invention, levels of lipid in lipid-containing viruses in a fluid are reduced, and the fluid, for example, delipidated plasma containing the modified viral particles may be administered to the patient. Such fluid contains modified viral particles with reduced infectivity, act as a vaccine and provide protection in the patient against the virus or provide a treatment in an infected patient by generating an immune response and decreasing the severity of the disease. These modified viral particles induce an immune response in the recipient to exposed epitopes on the modified viral particles. Alternatively the modified viral particles may be combined with a pharmaceutically acceptable carrier, and optionally an adjuvant, and administered as a vaccine composition to a human or an animal to induce an immune response in the recipient.
- In one embodiment, the modified viral particle, which is at least partially or substantially delipidated and has immunogenic properties, is optionally combined with a pharmaceutically acceptable carrier to make a composition comprising a vaccine. In a preferred embodiment, the modified viral particle is retained in the biological fluid, such as plasma, with reduced lipid levels and is administered to a patient as a vaccine. This vaccine composition is optionally combined with an adjuvant or an immunostimulant and administered to an animal or a human. Both autologous and non-autologous vaccines, including combination vaccines, are within the scope of the present invention. It is to be understood that vaccine compositions may contain more than one type of modified viral particle or component thereof, in order to provide protection against more than one strain of a virus or more than one viral disease after vaccination. Such combinations may be selected according to the desired immunity. For example, preferred combinations include, but are not limited to SARS and HIV, SARS and influenza, and SARS and hepatitis. More specifically, the vaccine can comprise a plurality of modified viral particles having patient-specific antigens and modified viral particles having non-patient specific antigens or stock viral particles that have undergone the delipidation process of the present invention. The remaining modified viral particles of the organism are retained in the delipidated biological fluid, and when reintroduced into the animal or human, are presumably ingested by phagocytes and generate an immune response.
- Administration of Vaccine Produced with the Method of the Present Invention
- When a delipidated infectious organism, for example one in the form of a modified viral particle with exposed antigenic determinants, is administered to an animal or a human, it is optionally combined with a pharmaceutically acceptable carrier to produce a vaccine, and optionally combined with an adjuvant or an immunostimulant as known to one of ordinary skill in the art. The vaccine formulations may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques known to one of ordinary skill in the art. Such techniques include uniformly and intimately bringing into association the active ingredient and the liquid carriers (pharmaceutical carrier(s) or excipient(s)). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- The formulations may be presented in unit-dose or multi-dose containers—for example, sealed ampules and vials—and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. The vaccine may be stored at temperatures of from about 4° C. to −100° C. The vaccine may also be stored in a lyophilized state at different temperatures including room temperature. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets commonly used by one of ordinary skill in the art. The vaccine may be sterilized through conventional means known to one of ordinary skill in the art. Such means include, but are not limited to filtration, radiation and heat. The vaccine of the present invention may also be combined with bacteriostatic agents, such as thimerosal, to inhibit bacterial growth.
- Preferred unit dosage formulations are those containing a dose or unit, or an appropriate fraction thereof, of the administered ingredient. It should be understood that in addition to the ingredients, particularly mentioned above, the formulations of the present invention may include other agents commonly used by one of ordinary skill in the art.
- The vaccine may be administered through different routes, such as oral, including buccal and sublingual, rectal, parenteral, aerosol, nasal, intramuscular, subcutaneous, intradermal, intravenous, intraperitoneal, and topical. The vaccine may also be administered in the vicinity of lymphatic tissue, for example through administration to the lymph nodes such as axillary, inguinal or cervical lymph nodes.
- The vaccine of the present invention may be administered in different forms, including but not limited to solutions, emulsions and suspensions, microspheres, particles, microparticles, nanoparticles, and liposomes. It is expected that from about 1 to 5 dosages may be required per immunization regimen. One of ordinary skill in the medical or veterinary arts of administering vaccines will be familiar with the amount of vaccine to be administered in an initial injection and in booster injections, if required, taking into consideration, for example, the age and size of a patient. Initial injections may range from about less than 1 ng to 1 gram based on total viral protein. A non-limiting range may be 1 ml to 10 ml. The volume of administration may vary depending on the administration route.
- The vaccines of the present invention may be administered before, during or after an infection. The vaccine of the present invention may be administered to either humans or animals. In one embodiment, the viral load (one or more viruses) of a human or an animal may be reduced by delipidation treatment of the plasma. The same individual may receive a vaccine directed to the one or more viruses, thereby stimulating the immune system to combat against the virus that remains in the individual. The time for administration of the vaccine before initial infection is known to one of ordinary skill in the art. However, the vaccine may also be administered after initial infection to ameliorate disease progression or to treat the disease.
- A variety of adjuvants known to one of ordinary skill in the art may be administered in conjunction with the modified viral particles in the vaccine composition. Such adjuvants include, but are not limited to the following: polymers, co-polymers such as polyoxyethylene-polyoxypropylene co-polymers, including block co-polymers; polymer P1005; monotide ISA72; Freund's complete adjuvant (for animals); Freund's incomplete adjuvant; sorbitan monooleate; squalene; CRL-8300 adjuvant; alum;
QS 21, muramyl dipeptide; trehalose; bacterial extracts, including mycobacterial extracts; detoxified endotoxins; membrane lipids; water-in-oil mixtures, water-in-oil-in-water mixtures or combinations thereof. - A variety of suspending fluids or carriers known to one of ordinary skill in the art may be employed to suspend the vaccine composition. Such fluids include without limitation: sterile water, saline, buffer, or complex fluids derived from growth medium or other biological fluids. Preservatives, stabilizers and antibiotics known to one of ordinary skill in the art may be employed in the vaccine composition.
- The following experimental examples are illustrative in showing that a delipidation process of the viral particle occurred and in particular, that the viral particle was modified and noted to exhibit a positive immunogenic response in the species from which it was derived. It will be appreciated that other embodiments and uses will be apparent to those skilled in the art and that the invention is not limited to these specific illustrative examples or preferred embodiments.
- Solvent treatment technology was used to develop a modified coronavirus viral particle to use as a prophylactic vaccine against the SARS virus. In addition, solvent-treated virus that was subsequently subjected to chemical inactivation was tested for the ability to raise neutralizing antibodies and produce a cellular immune response in mice. In the following text and elsewhere in the application, the coronavirus that produces SARS is also referred to as SARS.
- The SARS stocks used in the experiments were propagated at the Lovelace Respiratory Research Institute (LRRI), Albuquerque, N. Mex., in the laboratory of Dr. Kevin Harrod, Director of the Infectious Disease Program. The initial SARS seed stock was provided by the Centers for Disease Control (CDC). Supernatants from SARS infected VERO cells were then sent to Dr. Erdman at the CDC for inactivation by gamma irradiation.
- The delipidation process was optimized using Mouse Hepatitis Virus (MHV), provided by Dr. Katherine Holmes at the University of Colorado-Health Sciences Center. Dr. Holmes provided a seed stock of MHV as well as the permissive cell line MHV-A59.
- Seven different delipidation methods were developed using MHV. The methods were characterized based on the amount of cholesterol removed (measured by the Amplex Red Cholesterol Assay), and protein recovery. Three of these methods were selected for use in in vivo mouse immunization studies using gamma irradiated SARS. Dr. Erdman at the Center for Disease Control gamma irradiated a stock of SARS with 5×106 rads, and certified its inactivation. 1) 3% diisopropyl ether (DIPE) with end-over-end mixing 20 min at room temperature resulted in 80% cholesterol removal, and 85% SARS nucleocapsid (NC) recovery, 2) DIPE/Butanol (n-BuOH) (75:25) at a ratio of 99:1 SARS to solvent (vol:vol) with end-over-end mixing for 20 min at room temperature resulted in 44% cholesterol removal and 80% NC recovery, 3) DIPE/Triton X-100 (3%/0.05%) end-over-end mixing for 20 min at room temperature resulted in 60% cholesterol removal and 85% NC recovery.
- Western blot analysis of the delipidated SARS from each of the three procedures confirmed the presence of SARS NC and SARS envelope specific protein (Spike-S). S protein mediates the receptor binding and membrane fusion process mediated by S protein, indicating that major viral proteins are present after the delipidation procedure. (Gallagher, T. M. & Buchmeier, M. J. (2001) Virology 279: 371-374). This data was similar to the initial optimization data obtained from delipidating MHV.
- In summary, three unique delipidation processes optimized for inactivated SARS were developed. Gamma-irradiated SARS was used for safety reasons and because gamma irradiation was known not to damage the viral structure of SARS or its antigenicity. Inactivated SARS was structurally similar to live SARS as visualized by ultrastructural analysis (kindly preformed by Dr. Humphrey at the CDC), and by previous findings that gamma irradiation did not affect the structural integrity or antigenicity of SARS, since gamma irradiated VERO-E6 cells that were infected with SARS could be used for immunofluorescence assays (Ksiazek T G et al., 2003 N. Engl. J. Med. 348:1953-1966). Thus, inactivated SARS was used to test the utililty of delipidation in enhancing immunogenicity of SARS vaccine. To determine the immunogenicity of the delipidated SARS in vivo, a series of in vivo mouse experiments were performed.
- The experiments tested the effects of different delipidation methods on the ability of the delipidated and inactivated SARS to generate an immune response. The experiment was designed with four mice per group. Three groups were tested:
- a) Inactivated purified SARS treated with 3% DIPE;
- b) Inactivated purified SARS treated with DIPE/n-BuOH;
- c) Inactivated purified SARS treated with DIPE/Triton X-100.
- Mice were vaccinated subcutaneously (sc) with 50 ug of inactivated purified delipidated SARS in incomplete Freund's Adjuvant in a 50 ul volume in one footpad. SARS was propagated at Lovelace Respiratory Research Institute (LRRI) by Dr. Kevin Harrod, and virions were purified by Lipid Sciences, Inc.). At three weeks post vaccination, mice were sacrificed, and serum was harvested.
- Serum aliquots were analyzed by Dr. Michael W. Cho at Case Western Reserve University, where SARS neutralization titers were established. Dr. Cho's laboratory has established a novel and very reliable neutralization assay for SARS using pseudotyped murine leukemia virus (MuLV) with the Spike protein of SARS-coronavirus (CoV) (or vesicular stomatitis virus-G protein (VSV-G) as a negative control) as previously described (Han et al., 2004 Virology. 326:140-149). SARS NC and Spike antibody titers were performed at Lipid Sciences, Inc. using recombinant SARS NC and Spike purchased from Virolabs, Inc (NJ).
- Results: SARS-CoV-specific neutralizing activities were detected in all three groups above, although the antibody levels were low, possibly because mice only received one vaccination. Of the three groups, however, mice vaccinated with SARS delipidated with the DIPE/Triton X-100 method exhibited slightly higher neutralization of >50% compared to the other two groups which averaged about 40%. Antibody titers for SARS Spike Protein were similar in all three groups, while the SARS NC titers were higher in mice vaccinated with SARS delipidated with 3% DIPE. Therefore, the “optimal” delipidation was chosen to be the DIPE/Triton X-100 method.
- This experiment tested three different concentrations of delipidated inactivated purified SARS in comparison to inactivated purified SARS only, at 0.1 ug, 1 ug, and 10 ug boosts, in a prime-boost vaccine model, with the aim of enhancing the humoral immune response observed in
Experiment # 1. Mice were primed with SARS supernatant obtained from LRRI in Incomplete Freunds Adjuvant sc with 100 ug total protein. Two weeks later, mice were boosted with the appropriate concentration of DIPE:Triton X-100 delipidated SARS, or inactivated SARS. Four weeks after the boost, mice were sacrificed and serum collected and sent to Dr. Cho for determination of neutralizing antibody titers. Serum IgG titers to SARS NC and Spike were performed at Lipid Sciences, Inc. - Results: Both the inactivated virus and the delipidated inactivated virus were able to boost neutralizing activity. There were no significant differences in either the neutralizing antibody titers or anti-Spike/NC antibody titers, between mice boosted with DIPE:Triton X-100 delipidated, inactivated SARS virus and mice boosted with inactivated SARS virus.
- These two studies established that the delipidation process did not result in major structural damage to the virus. Immunogenicity was maintained in the delipidated inactivated virions, since the neutralizing antibody titers were not affected by the delipidation. Based upon these results, a 10 ug dose was tested as the boost concentration in
Experiment # 3. - Experiment #3: Determining the Cell-Mediated Immune Responses in Mice Boosted with Optimally Delipidated Vaccines
- The experiment tested the cell-mediated immune responses generated by vaccination with delipidated, inactivated SARS at a concentration of 10.0 ug. The experiment was designed with four mice per group in the following four groups:
- 1) Boost with inactivated SARS that was treated with DIPE/Triton X-100;
- 2) Boost with inactivated SARS;
- 3) Primed only; and
- 4) No prime/no boost.
- All mice in
groups Experiment # 2. Mice were injected two weeks post priming, and sacrificed one week after the booster injection since cell mediated immune responses in mice peak at about one week after the booster injection. Cell-mediated immune responses were measured using murine interferon-gamma (IFN-γ) ELISPOT Assay, per manufacturer's protocol (MABTech). Cells were incubated with pools of peptides covering the entire SARS CoV NC and Spike proteins. - The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: SARS Overlapping Peptide Array, NR-143. Pools of peptides (eight peptides per pool, 13- to 20-mers with approximately 10 amino acid overlaps) were generated and used in the enzyme-linked immunosorbent spot (ELISPOT Assay: Czerkinsky C, et al., (1983) “A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells”. J Immunol Methods 65 (1-2): 109-21.).
- Results: Mice boosted with delipidated, inactivated SARS had enhanced immune responses to Spike and NC peptide pools compared to booster injection with inactivated SARS. There was a boosting effect observed, compared to the no-boost Group. Booster injections with delipidated, inactivated SARS enhanced cell-mediated immune response, but did not change the antibody titers of Spike and NC.
Conclusion: The above findings indicate that delipidated/inactivated SARS generated better cell mediated immune responses than a preparation of inactivated SARS alone. The enhanced cell-mediated immune responses may greatly assist in preventing establishment of infection due to the broad epitope recognition in recipients primed with our vaccine. - Production of mouse neutralizing antibodies was measured with a neutralization assay for SARS using pseudotyped murine leukemia virus (MuLV) expressing the Spike protein of SARS-CoV (or VSV-G as a negative control) as previously described (Han et al., 2004 Virology. 326:140-149). Cell mediated immune responses were measured using ELISPOT Assays for IFN-γ. ELISPOT Assays have been used extensively for measuring cell mediated immune responses in several different disease models.
- The experiments demonstrated the utility of the delipidation process in creating a SARS vaccine: 1) capable of triggering a strong cell-mediated immune response; 2) of increased efficacy; and 3) usable separately or as a part of a component vaccine. In addition, this delipidation process is easy to perform and easily scaled for commercial production.
- MHV-A59, the MHV permissive cell line 17CL.1, and A04 (a polyclonal goat anti-MHV antibody), were kindly provided by Dr. Kathryn Holmes, University of Colorado Health Sciences. MHV was propagated in 17CL.1 and purified according to Sturman, et al. (J. Virol 1980 33:449-462). Briefly, viral supernatant was precipitated using polyethylene glycol (PEG, Sigma, St. Louis, Mo.) at a final concentration of 10%, incubated for 15 min at room temperature (RT), and pelleted at 10,000×g for 1 hr at 4° C. The pellet was resuspended in 4 ml of tris-maleate buffer (TME, Sigma, St. Louis, Mo.), pH 6.0, and layered on top of the 20%-55% sucrose gradient layer. Virus was pelleted by spinning at 32,000 rpm for 4 hr at 4° C. in a 80 Ti rotor (Beckman Coulter, Fullerton, Calif.). Aliquots (0.4 ml) were collected from the bottom of the tube, and quantitated using the Biorad Total Protein Assay (Biorad, Hercules, Calif.).
- SARS CoV-Utah strain was obtained from the Centers for Disease Control (CDC). SARS permissive cell line VERO-E6 stock was obtained from ATCC Inc. SARS was propagated in VERO-E6 cells in the laboratory of Dr. Kevin Harrod, Lovelace Respiratory Research Institute (LRRI), Albuquerque, N. Mex., and purified using a modified MHV purification protocol, in which SARS supernatant was not PEG precipitated. SARS supernatant was directly layered on top of a 20%-55% sucrose gradient layer, and pelleted at 32,000 rpm for 4 hr at 4° C. in a 80 Ti rotor (Beckman Coulter, Fullerton, Calif.). Aliquots (0.4 ml) were collected from the bottom of the tube, and analyzed using both the SARS Ag ELISA kit (MedQuick Testing, SimiValley, Calif.) and the Biorad Total Protein Assay kit (Biorad, Hercules, Calif.).
- To quantify the amount of SARS antigen, a SARS-CoV-Ag ELISA kit (MedQuick Testing, SimiValley, Calif.) targeting SARS NC protein, was used according to the manufacturer's instructions.
- Cholesterol in the viral fractions was analyzed by the Amplex Red Total Cholesterol Assay according to manufacturer's protocol (Molecular Probes, Eugene, Oreg.).
- MHV Western Blot:
- For both Western blot and Coomasie staining, 10% SDS-PAGE gels (Biorad, Hercules, Calif.) were used. Samples were loaded at 7 ul (concentration of 2 mg/ml) and 7 ul of 2× loading dye with 2-mercaptoethanol (2-ME, Sigma, St. Louis, Calif.). The gels were run at 220 V constant voltage for 1 hr. The Western blot gel was transferred to a nitrocellulose membrane (Biorad, Hercules, Calif.), and blocked with 5% milk and 0.1% Tween-20 (Sigma, St. Louis, Mo.) in a tris-glycine buffer (Biorad, Hercules, Calif.). The primary antibody AO4 (goat anti-MHV Ab) was used at 1:2000 dilution. The secondary antibody was a rabbit anti-goat horseradish peroxidase (HRP) (Sigma, St. Louis, Mo.) used at 1:5000 dilution. A colorimetric substrate diaminobenzidine (DAB) Enhanced Liquid Substrate System for Membrane ELISA, Sigma, St. Louis, Mo.) for HRP was used for Western blot development.
- SARS Western Blot:
- For both Western blot and Coomasie staining, 10% SDS-PAGE gels (Biorad, Hercules, Calif.) were used. Samples were loaded at 7 ul (concentration of 2 mg/ml) and 7 ul of 2× loading dye with 2-mercaptoethanol (2-ME, Sigma, St. Louis, Mo.). The gels were run at 220 V constant voltage for 1 hr. The Western blot gel was transferred to a nitrocellulose membrane (Biorad, Hercules, Calif.), and blocked with 5% milk and 0.1% Tween-20 (Sigma, St. Louis, Mo.) in a tris-glycine buffer (Biorad, Hercules, Calif.). The primary antibody solution was a cocktail of mouse monoclonal antibodies against SARS Spike and NC (Imgenex, San Diego, Calif.). Positive controls for Spike and NC (Virolabs, Chantilly, Va.) were run at 3.5 ug each. The secondary antibody, a goat anti-mouse-HRP polyclonal antibody (Sigma, St. Louis, Mo.) was used at a dilution of 1:5000. A chemiluminescent substrate (ECL+, Amersham BioSciences, Piscataway, N.J.) for HRP was used for Western blot development. The membrane was developed on a Kodak MS Film (Eastman Kodak, Rochester, N.Y.).
- A total of seven different delipidation matrices were developed, using MHV as a surrogate for SARS, due to SARS material constraints:
- 1. Diisopropylether (DIPE, VWR, West Chester, Pa.) 17 ul/ml, end-over-end (EOE) mixing for 20 min at room temperature (RT). Solvent was removed by passing the mixture through an activated charcoal column.
2. DIPE and n-butanol (n-BuOH, VWR, West Chester, Pa.) at a 95:5 mixture and at a 99:1 virus:solvent ratio (vol:vol), 20 min EOE mixing at RT. Solvent was removed by passing the mixture through an activated charcoal column.
3. DIPE and n-butanol (n-BuOH) at a 95:5 mixture and at a 99:1 virus:solvent ratio (vol:vol), vortexed at high speed for 15 sec at RT. Solvent was removed by passing the mixture through an activated charcoal column.
4. BuOH and sevoflurane (Abbott Labs, Abbott Park, Ill.) at a 75:25 mixture and at a 1:2 virus:solvent ratio (vol:vol), vortexed high speed for 15 sec, with gravity separation at RT. The aqueous layer was removed. Solvent was removed by passing the mixture through an activated charcoal column.
5. A final concentration of 3% DIPE and 0.05% Triton X-100, EOE mixing for 20 min at RT. Solvent was removed by passing the mixture through an activated charcoal column.
6. A final concentration of 3% DIPE, EOE mixing for 20 min at RT. Solvent was removed by passing the mixture through an activated charcoal column.
7. A final concentration of 0.05% Triton X-100 (Sigma, St. Louis, Mo.), EOE mixing for 20 min at RT. Solvent was removed by passing the mixture through an activated charcoal column. - The three delipidation procedures selected for SARS delipidation experiments were:
- 1. DIPE and n-butanol (n-BuOH) at a 95:5 mixture and at a 99:1 virus:solvent ratio (vol:vol), 20 min EOE with mixing at RT. Solvent was removed by passing the mixture through an activated charcoal column.
2. A final concentration of 3% DIPE and 0.05% Triton X-100, EOE mixing for 20 min at RT. Solvent was removed by passing the mixture through an activated charcoal column.
3. A final concentration of 3% DIPE, EOE mixing for 20 min at RT. Solvent was removed by passing the mixture through an activated charcoal column. - Electron micrographs (EMs) of γ-irradiated SARS were made by Dr. Dean Erdman and Dr. Charles Humphrey at the CDC. SARS supernatants containing about 1×106 PFU/ml were gamma irradiated with 5×106 rads, and certified inactivated by Dr. Dean Erdman.
-
-
TABLE 1 Optimization of delipidation protocol using MHV as a surrogate for SARS Percent Percent Protein Cholesterol Solvent Recovered Removed 1 DIPE 80.26 39.20 2 DIPE:n-Butanol, EOE 91.43 43 3 DIPE:n-Butanol, vortex 85.1 31 4 n-Butanol:Sevoflurane 48.32 ND* below detection level 5 DIPE:Triton X-100 70.95 70.35 6 DIPE (3%) 75.45 70 7 Triton X-100 78.02 25.5 (0.05%) - Table 1 summarizes the data obtained from the seven delipidations performed on MHV, a surrogate for SARS. Protein recoveries post-delipidation were >70%, except for n-BuOH:Sevoflurane delipidated virus, where the recovery was 48%.
- The following three delipidation protocols were used on purified SARS virus:
- 1. DIPE and n-butanol (n-BuOH) at a 95:5 mixture and at a 99:1 virus:solvent ratio (vol:vol), 20 min EOE, RT. Solvent was removed by passing the mixture through an activated charcoal column. This is
protocol # 2 in Table 1.
2. A final concentration of 3% DIPE and 0.05% Triton X-100,EOE 20 min at RT. Solvent was removed by passing the mixture through an activated charcoal column. This isprotocol # 5 in Table 1.
3. A final concentration of 3% DIPE,EOE 20 min at RT. Solvent was removed by passing the mixture through an activated charcoal column. This isprotocol # 6 in Table 1. -
TABLE 2 Protein and Cholesterol Results: SARS delipidation methods Percent Nucleocapsid Percent Cholesterol Solvent Recovered Removed 1 DIPE (3%) 85 80 2 DIPE:Triton X-100 85 60 3 DIPE:n-Butanol (95:5) 80 44 - Table 2 summarizes the data obtained from the three chosen delipidation methods performed on SARS. The protein recoveries as measured by the SARS ELISA detecting SARS NC were all ≧80%. The cholesterol removal was similar to those observed in MHV, as seen in Table 1.
-
FIG. 1 illustrates a Western Blot performed on delipidated MHV as discussed in Table 1. The polyclonal anti-MHV antibody A04 was kindly provided by Dr. Kathryn Holmes. All lanes show positive reactivity with the anti-MHV Ab. The Western Blot for samples delipidated bymethod # 1, and #3 of the delipidation matrix in Table 1 also showed the same patterns of staining as the DIPE: triton delipidated SARS (data not shown). -
FIG. 2 shows Western Blots of SARS Spike and SARS NC proteins post delipidation. Lanes 1-3 correspond to samples 1-3 in the SARS delipidation methods listed in Table 2 above.Lane 4 is purified SARS Spike and NC proteins from Virolabs. Spike reactivity is seen in 3% DIPE delipidated SARS, while very strong reactivity to NC was observed in all three delipidation protocols. The primary antibodies used in SARS Western blots were monoclonal antibodies. -
FIG. 3 shows representative electron micrographs of γ-irradiated SARS The EMs of virus pre- and post-irradiation were not significantly different. The picture on the right, a magnification of 23000×, has a typical SARS CoV appearance. The Spike proteins are clearly seen on the membrane, and the morphology is consistent with those of SARS CoV. - By using MHV as a surrogate for SARS, seven different delipidation protocols were evaluated, as listed in Table 1. The n-BuOH/sevoflurane method clearly elicited major structural damage, as inferred by the protein recovery. Western blot analysis of the various delipidated MHV (
FIG. 1 ) showed that viral proteins were intact and immunogenic. No significant loss of viral proteins was seen in any of the delipidation methods, except the sevoflurane:n-BuOH delipidated samples.Protocols - Three delipidation protocols were tested on purified SARS CoV as listed in Table 2. Western blot analysis of the various delipidated SARS samples showed that reactivity to SARS NC was very strong in all delipidated samples. Viruses delipidated with 3% DIPE showed readily detectable reactivity to SARS Spike protein, while the other two samples did not.
- Ultrastructural analyses were performed on irradiated SARS supernatant to determine the effects of irradiation on the viral structure. It was confirmed that the cultures were SARS CoV and that irradiation did not significantly alter the virion structure. The results indicated development of three unique delipidation methods for SARS CoV, which were tested for their in vivo immunogenicity.
- The ability of solvent and chemically treated SARS virions to produce an immune response was examined by:
- A. Vaccinating mice with solvent and chemically treated SARS virions;
B. Testing for production of mouse neutralizing antibodies in serum using Vero E6 cell cytopathic assay; and,
C. Evaluating mouse cellular response to vaccination with solvent-treated SARS virions. - The immunogenicity of delipidated SARS in vivo, in a murine model was tested. Three experimental protocols were used:
- 1) Evaluation of three Different Delipidation Methods for SARS;
2) Dose Escalation Study of Optimally Delipidated SARS Vaccine; and,
3) Determining The Cell-Mediated Immune Responses in Mice Boosted with Optimally Delipidated Vaccines. - The particles obtained by three delipidation processes were tested with respect to generating an immune response. The experiment was designed with three mice per group testing the following three groups:
- A. Inactivated SARS treated with 3% DIPE;
B. Inactivated SARS treated with DIPE/n-BuOH (95:5); and,
C. Inactivated SARS treated with 3% DIPE/0.05% Triton X-100. - Mice were vaccinated sc with 50 μg of inactivated delipidated SARS in 50 μl in one footpad. At three weeks post vaccination, mice were sacrificed, and serum was harvested.
- Serum aliquots were sent to the laboratory of Dr. Michael W. Cho (Case Western Reserve University), where SARS neutralization titers were evaluated using a neutralization assay for SARS using pseudotyped murine leukemia virus (MuLV) with the Spike protein of SARS-CoV (or VSV-G as a negative control) as previously described (Han et al., 2004 Virology. 326:140-149). SARS NC and Spike antibody titers were performed at Lipid Sciences, Inc. using recombinant SARS NC and Spike purchased from Virolabs, Inc (NJ)
- Pseudotyped SARS Neutralization Assay:
- Neutralization assays were performed using pseudotyped MuLV with Spike protein of SARS-CoV (or VSV-G as negative control) as previously described (Han et al., Virology. 326: 140-149). Briefly, VERO-E6 cells were used for the pseudovirus infection and were plated at 0.5×104 cells per well in a 96-well plate one day before infection. Heat-inactivated plasma samples at indicated dilutions were incubated with 100 infectious units of pseudoviruses. The control and experimental samples of each dilution were then dispensed to the triplicate wells containing the VERO-E6 cells for 1 hr at 37° C. After removing the serum:virus mix, cells were further incubated in DMEM with 5% FBS at 37° C. in a 5% CO2 incubator for 1.5 days. To determine the neutralization activity, the Beta-Glo assay system (Promega, Madison, Wis.) was used according to manufacturer's protocol. Cells were washed with PBS, and lysed with 100 μl of Report Lysis Buffer. 75 μl of cell lysates and 75 μl of Beta-Glo reagent were mixed in a white-walled plate. The mixtures were incubated for 30 min at RT and measured using a luminometer (Biorad, Hercules, Calif.).
- SARS Spike and NC Antibody Titers:
- Serum samples were titrated for antibodies to viral epitopes using routine EIA analysis. Briefly, high protein binding ELISA micro plates (Fisher, Pittsburgh, Pa.) were incubated with 1 μg purified recombinant SARS Spike or SARS NC protein (Virolabs, Chantilly, Va.) overnight in standard bicarbonate coating buffer, pH 9.6 at 4° C. Following three washes with PBS/
Tween 20, the plates were blocked for 1 hr at RT with PBS containing 5% normal goat serum (Sigma, St. Louis, Mo.). Serial 1:5 dilutions of the sera to be tested in PBS containing 5% normal goat serum starting at 1:500, were added to the wells for 1 hr at RT. After washing the unbound antibodies, the plates were incubated with an HRP-anti mouse IgG conjugate at 1:5000 (Sigma, St. Louis, Mo.), and developed using tetramethylbenzidine (TMB) substrate (Sigma, St. Louis, Mo.). Plates were read at a 405 nm wavelength using an ELISA plate reader (Molecular Devices, Sunnyvale, Calif.). - ELISPOT Assay:
- Mouse interferon-gamma (IFN-γ) ELISPOT assays were performed using splenocytes to determine the cell-mediated immune responses generated post-vaccination with delipidated SARS. Briefly, 96 well Millipore ELLIP 10SSP multiscreen plates (Millipore, Billerica, Mass.) were coated with 100 μl anti-mouse IFN-γ capturing antibody (MABTECH, Cincinnati, Ohio, monoclonal Ab clone AN-18). The capturing Ab was diluted to 10 mg/ml in sterile PBS. Plates were blocked with 150 μl/well of 10% RPMI (RPMI 1640 containing; 10% FBS, 10 mM HEPES buffer, 2 mM glutamine, 0.5 mg/ml gentamicin, and 50 mM 2-mercaptoethanol) and the plates incubated at room temperature for at least 2 hours. The peptide pools mentioned above were added directly to wells in a volume of 50 μl and then freshly isolated splenocytes were added at a concentration of 105 cells/well in 50 μl of 10% RPMI media. The final concentration of the peptides in the screening assay was 10 mM. Plates were incubated for three days at 5% CO2 at 37° C. washed and 100 l/well of 2 mg/ml biotinylated anti-IFN-γ mAb (clone R4-6A2, MABTECH, Cincinnati, Ohio) in PBS were added and incubated at room temperature for 3 h, followed by 100 μl/well avidin peroxidase conjugate (APC) for 1 hr. After washing, ELISPOTs were developed using the Vectastain ABC Kit (Vector Laboratories, Burlingame, Calif.) according to manufacturer's protocol. The number of spots/105 cells/well in the ELISPOT plates were read in a plate reader in the Vanderbilt University Core Facility, Nashville, Tenn.
-
FIG. 4 illustrates the total IgG antibody titers against SARS CoV Spike and NC. The titers obtained from all three delipidated virus vaccines were similar for both Spike and NC. Although mice vaccinated with DIPE:n-BuOH showed slightly higher NC titers, the differences were not significant. Data reflect mean O.D. (standard deviation of <10%). IgM specific titers for all samples were at an O.D. of <1.0 indicating the presence of very low IgM antigen specific antibodies (data not shown). -
FIG. 5 illustrates the SARS neutralization titers, performed by Dr. Michael Cho. Sera from mice vaccinated with DIPE:Triton X-100 treated SARS showed slightly better titers than mice vaccinated with SARS treated with the other delipidation protocols. SARS-CoV-specific neutralizing activities were detected in the sera from all three groups above. The overall antibody levels were low, possibly because mice only received one vaccination. Of the three groups, however, mice vaccinated with SARS delipidated with the DIPE/Triton X-100 method exhibited slightly higher neutralization of >50% compared to the other two groups which averaged at about 40%. - The DIPE/Triton X-100 delipidation method was used in
Experiment # 2, where we performed a titration of three concentrations of DIPE:Triton X-100 delipidated SARS vaccine of 0.1 μg, 1 μg, and 10 μg of protein, as discussed below. - The objective of this study was to test three different concentrations of delipidated inactivated purified SARS with inactivated purified SARS only, at 0.1 μg, 1 μg, and 10 μg boosts. Mice (3 mice/group) were primed with SARS supernatant (virus was unpurified) obtained from LRRI that was γ-irradiated by Dr. Erdman at the CDC and had a protein concentration of 4 mg/ml. Mice were primed using Incomplete Freunds Adjuvant sc with 100 μg total protein in a volume of 500 μl. Two weeks later, mice were boosted with the appropriate concentration of delipidated SARS, or inactivated SARS in a volume of 500 μl administered sc. Four weeks after the booster injection, mice were sacrificed and serum collected and sent to Dr. Cho for neutralizing antibody titers. Serum IgG titers to SARS NC and Spike were performed at Lipid Sciences, Inc.
-
FIG. 6 illustrates the Spike Ab titers fromExperiment # 2, comparing the titers in mice vaccinated with delipidated SARS to those in mice vaccinated with inactivated SARS.FIG. 7 illustrates the NC Ab titers comparing the titers in mice vaccinated with delipidated SARS to those in mice vaccinated with inactivated SARS. A clear increase in Ab titers was observed for both antigens with the 10 μg booster injection. The Spike and NC titers in delipidated SARS boost showed a clear dose-response. The titers obtained from inactivated SARS boost showed a clear enhancement in titers following the 10 μg boost. However, the overall patterns of Ab titers in both groups were surprisingly similar. When comparing the overall Ab titers to mice primed only, the patterns were similar as well. IgM specific titers for all samples were at an O.D. of <1.0 indicating the presence of very low IgM antigen specific antibodies (data not shown). -
FIG. 8 illustrates the neutralization titers fromExperiment # 2 comparing the titers in mice vaccinated with delipidated SARS to mice vaccinated with inactivated SARS. Titers obtained from mice vaccinated with 10 μg delipidated SARS had the highest neutralization titers, followed by mice vaccinated with 1 μg, then 0.1 μg delipidated SARS (FIG. 8 top panel). The neutralization titers in mice boosted with either delipidated or inactivated SARS (FIG. 8 bottom panel) were not significantly different, although a clear boosting response was observed when compared to the primed only group. These results were surprising, since the Ab titers to Spike and NC were similar in all groups primed and boosted. - From these results, the dose of 10 μg was chosen as the booster injection dose in
Experiment # 3, which evaluated the cell-mediated immune responses measured using the mouse IFN-γ ELISPOT assay in vaccinated mice. -
Experiment # 3 SARS-Determining the Cell-Mediated Immune Responses in Mice Boosted with Optimally Delipidated Vaccines - The experiment tested the cell-mediated immune responses generated by vaccination with DIPE:Triton X-100 delipidated SARS at a concentration of 10 μg. The experiment was designed with four mice per group testing the following four Groups: 1) Boosting with inactivated SARS that was treated with DIPE:Triton X-100; 2) Boosting with inactivated SARS; 3) Primed only; and, 4) No prime/no boost.
- All mice in
groups Experiment # 2. Mice received a booster injection two weeks post priming i.v., and were sacrificed one week later since cell mediated immune responses in mice peak at about one week after a booster injection. Cell-mediated immune responses were measured using murine interferon-gamma (IFN-γ) ELISPOT Assay, per manufacturer's protocol (MABTech). Cells were incubated with pools of peptides covering the entire SARS CoV NC and Spike proteins (FIG. 9 ). - Pools of peptides (eight peptides per pool for NC, 12 peptides per pool for Spike, 13- to 20-mers with approximately 10 amino acid overlaps) were generated using SARS Overlapping Peptide Array, which was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH. The four digit number in each cell of each table represents a peptide whose amino acid sequence in shown in
FIG. 9 . The numbers 1-7 at the top of each column for the top table called NC are pool components. For example,pool 1 contains peptides 9539-9589 for NC peptides pool. The amino acid sequences for each NC peptide shown inFIG. 9 is included in Table 3. - The numbers 1-12 at the top of each column for the bottom table called Spike are pool components. For example,
pool 12 contains peptides 9609-9765 for the Spike peptide pool. The amino acid sequences for each S peptide shown inFIG. 9 is included in Table 4. - The ELISPOT data showed a significantly enhanced peptide pool response for both NC and Spike in mice vaccinated with delipidated SARS, compared to either the inactivated SARS vaccination, or primed only mice. Surprisingly, mice vaccinated with inactivated SARS did not show robust ELISPOT responses, compared to mice boosted with delipidated SARS.
- The experiments measured the immune responses in vivo in mice vaccinated with delipidated or inactivated SARS.
Experiment # 1 tested delipidation methods for use in the dose-escalation study inExperiment # 2. We focused on a single immunization with SARS delipidated by 3% DIPE, DIPE:n-BuOH, or DIPE:Triton X-100. Total IgG Ab titers to SARS Spike and NC antigens were measured, as well as the neutralization Ab titers.FIG. 4 illustrates the Ab titers to SARS Spike and NC. The Ab titers from SARS delipidated with the three different methods were similar. The neutralization Ab titers (FIG. 5 ) showed that mice vaccinated with DIPE:Triton X-100 had slightly higher neutralization titers (>60%). The overall titers were low compared to the positive control sera (data not shown), probably because mice were given one vaccination prior to serum collection. -
Experiment # 2 was a prime/boost protocol, which compared boosting primed mice with 0.1 μg, 1 μg, and 10 μg inactivated SARS or DIPE:Triton X-100 delipidated SARS vaccines. Priming was performed using a SARS supernatant propagated at LRRI, which had been irradiated by Dr. Dean Erdman at the CDC. The prime/boost strategy was adopted because this protocol would enhance both cell- and humoral immune responses. Total Ab titers to SARS Spike and NC were similar in mice boosted with either inactivated or delipidated SARS (FIG. 6-Spike ,FIG. 7-NC ). These titers were higher than in mice that were primed only and did not receive a booster injection, indicating a clear enhancement of humoral immune responses by adding a booster injection. A dose-dependant increase in Ab titers was observed in delipidated SARS boosted mice; overall, the 10 μg booster injections gave higher titers than other doses used for booster injections. The neutralizing Ab titers (FIG. 8 ) also showed a dose-dependant response: 10 μg>1 μg>0.1 μg booster injections. - It was decided that a booster injection of 10 μg DIPE:Triton X-100 delipidated SARS, and the resulting cell-mediated immune responses (measured by IFN-γ ELISPOT) would be compared to a 10 μg inactivated SARS boost. The ELISPOT plates were read using an ELISPOT plate reader. The ELISPOT data (
FIG. 10 ) was surprising. Mice boosted with delipidated SARS had greatly enhanced responses to both Spike and NC peptide pools, compared to mice boosted with inactivated SARS. These data were surprising, since the neutralizing Ab titers in the two groups were similar, and the total Ab titers for both Spike and NC were similar in the two groups. - The data indicate that delipidated SARS vaccination clearly enhanced cell mediated immune responses. The current data indicated that delipidation may favor augmentation of cell mediated immune responses by either enhancing existing pathways of antigen processing and presentation, or by using additional and more efficient pathways of antigen processing and presentation.
- Gamma-irradiated SARS supernatant was used for priming mice in the prime/
boost Experiment # - This purification method for SARS using a different SARS culture propagated by LRRI, was used to yield highly purified virus that was subsequently used as the boosts for
Experiment # -
TABLE 3 SARS Nucleocapsid (NC) Peptides SEQ ID Cat # NO: Peptide Sequence 9539 1 MSDNGPQSNQRSAPRI 9540 2 QSNQRSAPRITFGGPTDS 9541 3 RITFGGPTDSTDNNQNGGR 9542 4 STDNNQNGGRNGARPKQR 9543 5 GRNGARPKQRRPQGL 9544 6 RPKQRRPQGLPNNTASWF 9545 7 GLPNNTASWFTALTQHGK 9546 8 WFTALTQHGKEELRFPR 9547 9 HGKEELRFPRGQGVPI 9548 10 RFPRGQGVPINTNSGPDDQI 9549 11 NTNSGPDDQIGYYRRATR 9550 12 QIGYYRRATRRVRGGDGK 9551 13 TRRVRGGDGKMKELSPRW 9552 14 GKMKELSPRWYFYYL 9553 15 LSPRWYFYYLGTGPEASL 9554 16 YLGTGPEASLPYGANK 9555 17 EASLPYGANKEGIVWVA 9556 18 ANKEGIVWVATEGAL 9557 19 IVWVATEGALNTPKDHI 9558 20 GALNTPKDHIGTRNPNNNA 9559 21 IGTRNPNNNAATVLQL 9560 22 NNNAATVLQLPQGTTLPK 9561 23 QLPQGTTLPKGFYAEGSR 9562 24 PKGFYAEGSRGGSQASSR 9563 25 SRGGSQASSRSSSRSR 9564 26 ASSRSSSRSRGNSRNST 9565 27 RSRGNSRNSTPGSSR 9566 28 SRNSTPGSSRGNSPARMA 9567 29 SRGNSPARMASGGGETAL 9569 30 ALALLLLDRLNQLESKV 9570 31 DRLNQLESKVSGKGQQQQ 9571 32 KVSGKGQQQQGQTVTKK 9572 33 QQQGQTVTKKSAAEASKK 9573 34 KKSAAEASKKPRQKRTA 9574 35 SKKPRQKRTATKQYNV 9575 36 KRTATKQYNVTQAFGRR 9576 37 YNVTQAFGRRGPEQTQGNF 9577 38 RGPEQTQGNFGDQDLIR 9578 39 GNFGDQDLIRQGTDYKHW 9579 40 IRQGTDYKHWPQIAQFA 9580 41 KHWPQIAQFAPSASAFF 9581 42 QFAPSASAFFGMSRIGM 9582 43 AFFGMSRIGMEVTPSGTW 9583 44 GMEVTPSGTWLTYHGAIK 9584 45 TWLTYHGAIKLDDKDPQF 9585 46 IKLDDKDPQFKDNVILL 9586 47 PQFKDNVILLNKHIDAYK 9587 48 LLNKHIDAYKTFPPTEPK 9588 49 YKTFPPTEPKKDKKKK 9589 50 TEPKKDKKKKTDEAQPL 9590 51 KKKTDEAQPLPQRQKK 9591 52 AQPLPQRQKKQPTVTLL 9592 53 QKKQPTVTLLPAADMDDF 9594 54 LLPAADMDDFSRQLQNSM 9595 55 DFSRQLQNSMSGASA -
TABLE 4 SARS Spike (5) Peptides SEQ ID Cat # NO: Peptide Sequence 9597 56 MFIFLLFLTLTSGSDLDR 9598 57 TLTSGSDLDRCTTFDDV 9599 58 LDRCTTFDDVQAPNYTQH 9601 59 QHTSSMRGVYYPDEIFR 9602 60 GVYYPDEIFRSDTLYL 9603 61 EIFRSDTLYLTQDLFLPF 9604 62 YLTQDLFLPFYSNVTGFH 9605 63 PFYSNVTGFHTINHTF 9606 64 TGFHTINHTFGNPVIPFK 9607 65 TFGNPVIPFKDGIYFAA 9608 66 PFKDGIYFAATEKSNVVR 9609 67 AATEKSNVVRGWVFGSTM 9610 68 VRGWVFGSTMNNKSQSVI 9611 69 TMNNKSQSVIIINNSTNV 9612 70 VIIINNSTNVVIRACNF 9614 71 NFELCDNPFFAVSKPM 9615 72 NPFFAVSKPMGTQTHTMI 9616 73 PMGTQTHTMIFDNAF 9619 74 YISDAFSLDVSEKSGNFK 9620 75 DVSEKSGNFKHLREFVFK 9621 76 FKHLREFVFKNKDGFLYV 9622 77 FKNKDGFLYVYKGYQPI 9623 78 LYVYKGYQPIDVVRDL 9624 79 YQPIDVVRDLPSGFNTLK 9625 80 DLPSGFNTLKPIFKLPL 9626 81 TLKPIFKLPLGINITNFR 9627 82 PLGINITNFRAILTAF 9628 83 TNFRAILTAFSPAQDIW 9629 84 TAFSPAQDIWGTSAAAYF 9631 85 AAAYFVGYLKPTTFMLKY 9632 86 LKPTTFMLKYDENGTI 9633 87 MLKYDENGTITDAVDCSQ 9634 88 TITDAVDCSQNPLAELK 9636 89 LKCSVKSFEIDKG1Y 9637 90 KSFEIDKGIYQTSNFRVV 9638 91 IYQTSNFRVVPSGDVVRF 9639 92 VVPSGDVVRFPNITNL 9640 93 VVRFPNITNLCPFGEVF 9641 94 TNLCPFGEVFNATKFPSV 9642 95 VFNATKFPSVYAWERKKI 9643 96 SVYAWERKKISNCVADY 9644 97 KKISNCVADYSVLYNSTF 9645 98 DYSVLYNSTFFSTFKCY 9646 99 STFFSTFKCYGVSATKL 9647 100 KCYGVSATKLNDLCFSNV 9648 101 KLNDLCFSNVYADSFVVK 9649 102 NVYADSFVVKGDDVRQIA 9650 103 VKGDDVRQIAPGQTGVIA 9651 104 IAPGQTGVIADYNYKL 9652 105 GVIADYNYKLPDDFMGCV 9653 106 KLPDDFMGCVLAWNTRNI 9655 107 NIDATSTGNYNYKYRYLR 9656 108 NYNYKYRYLRHGKLRPF 9657 109 YLRHGKLRPFERDISNV 9658 110 RPFERDISNVPFSPDGK 9659 111 SNVPFSPDGKPCTPPAL 9660 112 DGKPCTPPALNCYWPL 9661 113 PPALNCYWPLNDYGFY 9663 114 GFYTTTGIGYQPYRVVVL 9665 115 VVLSFELLNAPATVCGPK 9666 116 NAPATVCGPKLSTDLIK 9667 117 GPKLSTDLIKNQCVNFNF 9668 118 IKNQCVNFNFNGLTGTGV 9669 119 NFNGLTGTGVLTPSSKRF 9670 120 GVLTPSSKRFQPFQQFGR 9671 121 RFQPFQQFGRDVSDF 9672 122 QQFGRDVSDFTDSVRDPK 9673 123 DFTDSVRDPKTSEILDI 9674 124 DPKTSEILDISPCSFGGV 9675 125 DISPCSFGGVSVITPGTNA 9676 126 VSVITPGTNASSEVAVLY 9678 127 LYQDVNCTDVSTAIHA 9679 128 CTDVSTAIHADQLTPAWR 9680 129 HADQLTPAWRIYSTGNNV 9681 130 WRIYSTGNNVFQTQAGCL 9682 131 NVFQTQAGCLIGAEHV 9684 132 HVDTSYECDIPIGAGICA 9685 133 DIPIGAGICASYHTVSLL 9686 134 CASYHTVSLLRSTSQKSI 9687 135 LLRSTSQKSTVAYTMSL 9688 136 KSIVAYTMSLGADSSIAY 9689 137 SLGADSSIAYSNNTIAI 9690 138 IAYSNNTIAIPTNFSISI 9691 139 AIPTNFSISITTEVMPV 9692 140 ISITTEVMPVSMAKTSV 9694 141 KTSVDCNMYICGDSTECA 9697 142 LQYGSFCTQLNRALSGIA 9698 143 QLNRALSGIAAEQDRNTR 9699 144 IAAEQDRNTREVFAQVK 9700 145 NTREVFAQVKQMYKTPTL 9701 146 VKQMYKTPTLKYFGGFNF 9702 147 TLKYFGGFNFSQILPDPL 9703 148 NFSQILPDPLKPTKRSFI 9704 149 PLKPTKRSFIEDLLFNKV 9705 150 FIEDLLFNKVTLADAGFM 9706 151 KVTLADAGFMKQYGECL 9707 152 GFMKQYGECLGDTNARDL 9708 153 CLGDTNARDLICAQKF 9709 154 ARDLICAQKFNGLTVL 9710 155 AQKFNGLTVLPPLLTDDM 9711 156 VLPPLLTDDMIAAYTAAL 9713 157 AALVSGTATAGWTFGAGA 9715 158 GAALQIPFAMQMAYRF 9716 159 PFAMQMAYRFNGIGV 9718 160 GIGVTQNVLYENQKQIA 9719 161 VLYENQKQIANQFNKAI 9721 162 KAISQIQESLTTTSTAL 9723 163 TALGKLQDVVNQNAQAL 9725 164 QALNTLVKQLSSNFGAI 9727 165 AISSVLNDILSRLDKVEA 9728 166 ILSRLDKVEAEVQIDRLI 9731 167 SLQTYVTQQLIRAAEIRA 9732 168 QLIRAAEIRASANLAATK 9733 169 RASANLAATKMSECVL 9734 170 AATKMSECVLGQSKRVDF 9735 171 VLGQSKRVDFCGKGYHLM 9736 172 DFCGKGYHLMSFPQAAPH 9737 173 LMSFPQAAPHGVVFLHV 9738 174 APHGVVFLHVTYVPSQER 9739 175 HVTYVPSQERNFTTAPAI 9740 176 ERNFTTAPAICHEGKAYF 9741 177 AICHEGKAYFPREGVFVF 9742 178 YFPREGVFVFNGTSWFI 9743 179 FVFNGTSWFITQRNFF 9744 180 SWFITQRNFFSPQII 9745 181 QRNFFSPQIITTDNTFV 9748 182 VIGIINNTVYDPLQPEL 9749 183 TVYDPLQPELDSFKEEL 9750 184 PELDSFKEELDKYFKNH 9751 185 EELDKYFKNHTSPDVDL 9752 186 KNHTSPDVDLGDISGINA 9753 187 DLGDISGTNASVVNIQK 9754 188 INASVVNIQKEIDRLNEV 9755 189 QKEIDRLNEVAKNLNESL 9756 190 EVAKNLNESLIDLQELGK 9757 191 SLIDLQELGKYEQYIKW 9758 192 LGKYEQYIKWPWYVWLGF 9759 193 KWPWYVWLGFIAGLIAIV 9760 194 GFIAGLIAIVMVTILL 9761 195 IAIVMVTILLCCMTSCCSCL 9762 196 CCMTSCCSCLKGACSCGS 9763 197 CLKGACSCGSCCKFDEDD 9764 198 GSCCKFDEDDSEPVLKGV 9765 199 DDSEPVLKGVKLHYT - All patents, publications and abstracts cited above are incorporated herein by reference in their entirety. It should be understood, of course, that the foregoing relates only to preferred embodiments of the present invention and that numerous modifications or alterations may be made therein without departing from the spirit and the scope of the invention as set forth in the appended claims.
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/106,021 US20090017069A1 (en) | 2000-06-29 | 2008-04-18 | SARS Vaccine Compositions and Methods of Making and Using Them |
US12/655,299 US8506968B2 (en) | 2000-06-29 | 2009-12-28 | SARS vaccine compositions and methods of making and using them |
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ8469A AUPQ846900A0 (en) | 2000-06-29 | 2000-06-29 | A vaccine |
AUPQ8469 | 2000-06-29 | ||
AUPCT/AU00/01603 | 2000-12-28 | ||
PCT/AU2000/001603 WO2001045718A1 (en) | 1999-12-23 | 2000-12-28 | A method of treating infectious diseases |
US10/311,679 US20030119782A1 (en) | 2000-06-29 | 2001-06-21 | Method of treating and preventing infectious diesases |
PCT/IB2001/001099 WO2002000266A2 (en) | 2000-06-29 | 2001-06-21 | A method of treating and preventing infectious diseases |
US39006602P | 2002-06-20 | 2002-06-20 | |
US10/601,656 US7407663B2 (en) | 2000-06-29 | 2003-06-20 | Modified immunodeficiency virus particles |
US49192803P | 2003-08-01 | 2003-08-01 | |
US53354203P | 2003-12-31 | 2003-12-31 | |
US54294704P | 2004-02-09 | 2004-02-09 | |
US10/873,015 US7407662B2 (en) | 2000-06-29 | 2004-06-21 | Modified viral particles with immunogenic properties and reduced lipid content |
US66973805P | 2005-04-08 | 2005-04-08 | |
US67057405P | 2005-04-11 | 2005-04-11 | |
US11/401,434 US7439052B2 (en) | 2000-06-29 | 2006-04-10 | Method of making modified immunodeficiency virus particles |
US92562807P | 2007-04-20 | 2007-04-20 | |
US12/106,021 US20090017069A1 (en) | 2000-06-29 | 2008-04-18 | SARS Vaccine Compositions and Methods of Making and Using Them |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/401,434 Continuation-In-Part US7439052B2 (en) | 2000-06-29 | 2006-04-10 | Method of making modified immunodeficiency virus particles |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/655,299 Continuation US8506968B2 (en) | 2000-06-29 | 2009-12-28 | SARS vaccine compositions and methods of making and using them |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090017069A1 true US20090017069A1 (en) | 2009-01-15 |
Family
ID=56291050
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/106,021 Abandoned US20090017069A1 (en) | 2000-06-29 | 2008-04-18 | SARS Vaccine Compositions and Methods of Making and Using Them |
US12/655,299 Expired - Fee Related US8506968B2 (en) | 2000-06-29 | 2009-12-28 | SARS vaccine compositions and methods of making and using them |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/655,299 Expired - Fee Related US8506968B2 (en) | 2000-06-29 | 2009-12-28 | SARS vaccine compositions and methods of making and using them |
Country Status (1)
Country | Link |
---|---|
US (2) | US20090017069A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070212376A1 (en) * | 2000-06-29 | 2007-09-13 | Cham Bill E | Method of treating and preventing infectious diseases |
US20080220016A1 (en) * | 2000-06-29 | 2008-09-11 | Lipid Sciences, Inc. | Method of Treating and Preventing Infectious Diseases via Creation of a Modified Viral Particle with Immunogenic Properties |
US7740872B2 (en) | 2005-07-27 | 2010-06-22 | Eli Lilly And Company | Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
US20110150929A1 (en) * | 2000-06-29 | 2011-06-23 | Eli Lilly And Company | SARS vaccine compositions and methods of making and using them |
WO2017132059A1 (en) * | 2016-01-27 | 2017-08-03 | Eli Lilly And Company | Inactivation of viruses by delipidation |
CN112341526A (en) * | 2020-09-24 | 2021-02-09 | 杭州医学院 | Novel coronavirus nucleocapsid protein specific antigen polypeptide and application thereof |
US20210283201A1 (en) * | 2020-03-06 | 2021-09-16 | Hdl Therapeutics, Inc. | Systems and Methods for Treating Patients Infected with SARS-COV-2 |
WO2021235553A1 (en) * | 2020-05-22 | 2021-11-25 | 国立研究開発法人理化学研究所 | Multiple antigenic peptide against coronavirus, and immunostimulating composition containing same |
WO2022023727A1 (en) * | 2020-07-28 | 2022-02-03 | Oxford University Innovation Limited | Polypeptide panels and uses thereof |
US11684669B2 (en) * | 2020-03-01 | 2023-06-27 | Valneva Austria Gmbh | CpG-adjuvanted SARS-CoV-2 virus vaccine |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017033188A1 (en) | 2015-08-24 | 2017-03-02 | Yeda Research And Development Co. Ltd. | Algal oil and biofuel and methods of producing same |
AU2020437632A1 (en) * | 2020-03-24 | 2022-10-13 | Byung Chul Ahn | Method for producing serum composition for preventing or treating mucosa-related infectious disease in young mammals, serum composition produced thereby, and use thereof |
WO2021236614A1 (en) * | 2020-05-18 | 2021-11-25 | Northwestern University | Targeted antiviral drugs |
CN111978378B (en) * | 2020-08-10 | 2022-02-01 | 武汉大学 | SARS-CoV-2 antigen polypeptide and its application |
US20220040291A1 (en) * | 2020-08-10 | 2022-02-10 | Timothy S. Moore | HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTION |
TR202013279A2 (en) * | 2020-08-21 | 2020-10-21 | Acibadem Labmed Saglik Hizmetleri A S | A FAST, INCLUSIVE AND HIGH-DOSE INACTIVE VACCINE PRODUCTION FOR USE AGAINST SARS-CoV-2 VIRUS |
WO2023287324A1 (en) * | 2021-07-16 | 2023-01-19 | Joint Stock Company "Biocad" | Influenza virus-based isolated recombinant virus |
Citations (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3647624A (en) * | 1969-07-24 | 1972-03-07 | Wisconsin Alumni Res Found | Treatment of blood with oleaginous substance |
US3958939A (en) * | 1975-01-08 | 1976-05-25 | Coulter Electronics, Inc. | Method for clarification of lipemic serum |
US3983008A (en) * | 1974-05-27 | 1976-09-28 | Idemitsu Kosan Co., Ltd. | Method of extracting useful components from microbial cells |
US4025423A (en) * | 1975-01-15 | 1977-05-24 | Metallgesellschaft Aktiengesellschaft | Process for removing monohydric and polyhydric phenols from waste water |
US4103685A (en) * | 1976-01-05 | 1978-08-01 | Lupien Paul J | Method and apparatus for extravascular treatment of blood |
US4258010A (en) * | 1975-11-19 | 1981-03-24 | Eszakmagyarorszagi Vegyimu_ vek | Solvent extraction apparatus |
US4391711A (en) * | 1980-03-19 | 1983-07-05 | Davy Mckee (Minerals & Metals) Limited | Method of, and apparatus for, effecting liquid-liquid contact |
US4399217A (en) * | 1979-05-02 | 1983-08-16 | Laboratoires Goella | Process and a device for the determination of serum lipoproteins |
US4431633A (en) * | 1982-04-27 | 1984-02-14 | Merck & Co., Inc. | Influenza vaccine |
US4435289A (en) * | 1981-12-23 | 1984-03-06 | Romicon, Inc. | Series ultrafiltration with pressurized permeate |
US4463988A (en) * | 1982-09-07 | 1984-08-07 | Cities Service Co. | Horizontal heated plane process |
US4522809A (en) * | 1980-02-11 | 1985-06-11 | Institut Pasteur | Process for obtaining lipid envelope virus sub-units, notably antigens for use as vaccines, the products obtained and their applications |
US4581231A (en) * | 1982-06-10 | 1986-04-08 | The United States Of America As Represented By The Secretary Of Health And Human Services | Inactivation of viruses containing essential lipids |
US4591505A (en) * | 1982-04-14 | 1986-05-27 | New York Blood Center, Inc. | Process for inactivating hepatitis B virus |
US4643718A (en) * | 1983-02-22 | 1987-02-17 | Applied Immunesciences, Inc. | Therapeutic apheresis |
US4645512A (en) * | 1985-05-06 | 1987-02-24 | The Dow Chemical Company | Continuous process for removing water-soluble particles from organic liquids |
US4647280A (en) * | 1984-06-27 | 1987-03-03 | Akzo Nv | Binder for low density lipoproteins |
US4648974A (en) * | 1983-03-24 | 1987-03-10 | Intermedicat Gmbh | Process for the selective extracorporeal separation of blood constituents |
US4668398A (en) * | 1983-07-21 | 1987-05-26 | Colgate-Palmolive Company | Continuous extraction apparatus and process |
US4671909A (en) * | 1978-09-21 | 1987-06-09 | Torobin Leonard B | Method for making hollow porous microspheres |
US4677057A (en) * | 1985-03-11 | 1987-06-30 | Scripps Clinic And Research Foundation | Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins |
US4676905A (en) * | 1975-12-15 | 1987-06-30 | Toray Industries, Inc. | Fluid separation method and apparatus |
US4680320A (en) * | 1984-12-06 | 1987-07-14 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Method for preparation of droplets |
US4832034A (en) * | 1987-04-09 | 1989-05-23 | Pizziconi Vincent B | Method and apparatus for withdrawing, collecting and biosensing chemical constituents from complex fluids |
US4836928A (en) * | 1984-04-28 | 1989-06-06 | Terumo Kabushiki Kaisha | Separation method, separation device and separation apparatus for separating body fluid into respective components |
US4895558A (en) * | 1985-07-15 | 1990-01-23 | University Of Queensland | Autologous plasma delipidation using a continuous flow system |
US4908354A (en) * | 1984-06-16 | 1990-03-13 | B. Braun-Ssg Ag | Process for the selective extracorporeal precipitation of low-density lipoproteins |
US4909942A (en) * | 1987-10-16 | 1990-03-20 | Tanabe Seiyaku Co., Ltd. | Process for removing pyrogens |
US4909940A (en) * | 1987-12-30 | 1990-03-20 | New York Blood Center, Inc. | Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons |
US4923439A (en) * | 1981-09-10 | 1990-05-08 | B. Braun-Ssc Ag | Process for the selective extracorporeal precipitation of low-density lipoproteins from whole serum or plasma |
US4935204A (en) * | 1984-06-16 | 1990-06-19 | B. Braun-Ssc Ag | Process and device for the specific adsorption of heparin |
US5026479A (en) * | 1990-02-13 | 1991-06-25 | Union Carbide Industrial Gases Technology Corporation | Fluid separation device |
US5080796A (en) * | 1985-12-19 | 1992-01-14 | The Cleveland Clinic Foundation | Thermofiltration of plasma |
US5089602A (en) * | 1988-02-08 | 1992-02-18 | Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk | Process for the manufacture of apolipoproteins from human blood plasma or serum |
US5112956A (en) * | 1987-12-02 | 1992-05-12 | The Nutrasweet Company | Method for extraction of lipids and cholesterol |
US5116307A (en) * | 1990-07-09 | 1992-05-26 | Collins Harvey T | Method and system for treatment of AIDS |
US5126240A (en) * | 1986-09-29 | 1992-06-30 | Curtiss Linda K | Hybridomas and monoclonal paratopic molecules to apolipoprotein a-i |
US5128318A (en) * | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
US5187010A (en) * | 1990-11-27 | 1993-02-16 | W. R. Grace & Co.-Conn. | Membrane having high affinity for low density lipoprotein-cholesterol from whole blood |
US5203778A (en) * | 1986-02-18 | 1993-04-20 | Boehringer Laboratories | Process and apparatus for removal of insoluble fat from blood of a patient |
US5211850A (en) * | 1991-07-26 | 1993-05-18 | Research Medical, Inc. | Plasma filter sorbent system for removal of components from blood |
US5236644A (en) * | 1990-11-27 | 1993-08-17 | W. R. Grace & Co.-Conn. | Process of making membrane for removal of low density lipoprotein-cholesterol from whole blood |
US5279540A (en) * | 1992-09-24 | 1994-01-18 | Davidson Michael H | Method for reducing the risk of atherosclerosis |
US5301694A (en) * | 1991-11-12 | 1994-04-12 | Philip Morris Incorporated | Process for isolating plant extract fractions |
US5391143A (en) * | 1993-03-12 | 1995-02-21 | Kensey Nash Corporation | Method and system for effecting weight reduction of living beings |
US5393429A (en) * | 1991-11-05 | 1995-02-28 | Jgc Corporation | Liquid-liquid contactor |
US5401466A (en) * | 1993-06-01 | 1995-03-28 | Miles Inc. | Device for the direct measurement of low density lipoprotein cholesterol |
US5401415A (en) * | 1990-06-12 | 1995-03-28 | B. Braun Melsungen Ag | Adsorption material for the selective removal of LDL and/or vLDL and method of using therefor |
US5418061A (en) * | 1990-11-27 | 1995-05-23 | W. R. Grace & Co.-Conn. | Microporous polysulfone supports suitable for removal of low density lipoprotein-cholesterol |
US5419759A (en) * | 1988-11-17 | 1995-05-30 | Naficy; Sadeque S. | Apparatus and methods for treatment of HIV infections and AIDS |
US5424068A (en) * | 1992-12-07 | 1995-06-13 | P. Doina International Ltd. | Method for immunization of mammals against atherosclerosis and pharmaceutical compositions for obtaining said immunization |
US5484396A (en) * | 1988-11-17 | 1996-01-16 | Naficy; Sadeque S. | Method and device for treatment of HIV infections and AIDS |
US5496637A (en) * | 1990-11-27 | 1996-03-05 | W. R. Grace & Co.-Conn. | High efficiency removal of low density lipoprotein-cholesterol from whole blood |
US5523096A (en) * | 1993-03-16 | 1996-06-04 | Applied Immune Sciences, Inc. | Removal of selected factors from whole blood or its components |
US5634893A (en) * | 1995-04-24 | 1997-06-03 | Haemonetics Corporation | Autotransfusion apparatus |
US5637224A (en) * | 1994-09-14 | 1997-06-10 | New Jersey Institute Of Technology | Hollow fiber contained liquid membrane pervaporation for removal of volatile organic compounds from aqueous solutions |
US5652339A (en) * | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
US5707673A (en) * | 1996-10-04 | 1998-01-13 | Prewell Industries, L.L.C. | Process for extracting lipids and organics from animal and plant matter or organics-containing waste streams |
US5719194A (en) * | 1995-08-22 | 1998-02-17 | Ausimont S.P.A. | Prevention and treatment of topical viral infections with perfluoropolyethers or compositions thereof |
US5744038A (en) * | 1993-07-30 | 1998-04-28 | Aruba International Pty Ltd. | Solvent extraction methods for delipidating plasma |
US5753227A (en) * | 1993-07-23 | 1998-05-19 | Strahilevitz; Meir | Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases |
US5855782A (en) * | 1993-08-10 | 1999-01-05 | Falkenhagen; Dieter | Arrangement for removing substances from liquids, in particular blood |
US5858238A (en) * | 1996-03-08 | 1999-01-12 | Baxter Research Medical, Inc. | Salvage of autologous blood via selective membrane/sorption technologies |
US5877005A (en) * | 1992-03-02 | 1999-03-02 | Aphios Corporation | Viral inactivation method using near critical, supercritical or critical fluids |
US5879685A (en) * | 1991-05-08 | 1999-03-09 | Schweiz, Serum- & Impfinstitut Bern | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
US5885578A (en) * | 1987-06-10 | 1999-03-23 | The Immune Response Corporation | Prevention and treatment of retroviral disease |
US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
US5911698A (en) * | 1995-12-22 | 1999-06-15 | Aruba International Pty. Ltd. | Treatment for cardiovascular and related diseases |
US5919369A (en) * | 1992-02-06 | 1999-07-06 | Hemocleanse, Inc. | Hemofiltration and plasmafiltration devices and methods |
US5932468A (en) * | 1995-11-03 | 1999-08-03 | Grupo Grifols, S.A. | Method of inactivating viruses in proteins |
US6022333A (en) * | 1997-05-01 | 2000-02-08 | S.L.I.M. Tech, Ltd. | Method and system for removing materials from lymphatic and other fluids |
US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6037458A (en) * | 1987-11-20 | 2000-03-14 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for serum amyloid protein |
US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
US6171373B1 (en) * | 1996-04-23 | 2001-01-09 | Applied Ceramics, Inc. | Adsorptive monolith including activated carbon, method for making said monolith, and method for adsorbing chemical agents from fluid streams |
US6193891B1 (en) * | 1996-07-10 | 2001-02-27 | American National Red Cross | Methods for the selective separation of organic components from biological fluids |
US6337066B1 (en) * | 1997-12-15 | 2002-01-08 | L'oreal | Cosmetic and/or dermatological composition based on ascorbic acid in powder form |
US6337368B1 (en) * | 1997-06-03 | 2002-01-08 | Kaneka Corporation | Lipoprotein adsorbent and lipoprotein adsorber made with the use of the same |
US6369048B1 (en) * | 1998-01-12 | 2002-04-09 | V.I. Technologies, Inc. | Methods and compositions for inactivating viruses |
US20020055529A1 (en) * | 1998-12-02 | 2002-05-09 | Bisgaier Charles Larry | Method for treating alzheimer's disease |
US20020107173A1 (en) * | 1999-11-04 | 2002-08-08 | Lawrence Friedhoff | Method of treating amyloid beta precursor disorders |
US20030018013A1 (en) * | 2000-10-11 | 2003-01-23 | Dasseux Jean-Louis Henri | Ether compounds and compositions for cholesterol management and related uses |
US20030044428A1 (en) * | 2001-01-26 | 2003-03-06 | Moss Ronald B. | Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment |
US20030119782A1 (en) * | 2000-06-29 | 2003-06-26 | Cham Bill E. | Method of treating and preventing infectious diesases |
US6605588B1 (en) * | 1996-11-27 | 2003-08-12 | Boston Heart Foundation, Inc. | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
US6706008B2 (en) * | 2001-03-06 | 2004-03-16 | Baxter International Inc. | Automated system and method for withdrawing compounds from blood |
US20070031923A1 (en) * | 2000-06-29 | 2007-02-08 | Cham Bill E | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases |
US7407663B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified immunodeficiency virus particles |
US7407662B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1538322A (en) | 1966-11-21 | 1968-09-06 | Rhone Poulenc Sa | Process for preparing an inactivated viral suspension |
US3989466A (en) | 1973-08-13 | 1976-11-02 | Pan Samuel C | Liquid-liquid extraction apparatus including fibrous strand packing |
DE2710241A1 (en) | 1976-03-11 | 1977-09-22 | Krebs & Co Ag | PROCESS FOR MIXING AND SEPARATING TWO IMMISCABLE LIQUIDS |
JPS5549791Y2 (en) | 1976-04-21 | 1980-11-20 | ||
US4424131A (en) | 1978-12-18 | 1984-01-03 | Artisan Industries Inc. | Liquid-liquid extraction method and apparatus |
US4234317A (en) | 1979-05-24 | 1980-11-18 | Analytical Products, Inc. | Apparatus and method for fractionation of lipoproteins |
DE2944138A1 (en) | 1979-11-02 | 1981-06-11 | Technicon Gmbh, 6368 Bad Vilbel | Automatic analysis of separation of deposits from liquids - is by extracting fraction of flowing segmented sample following sedimentation |
US4350156A (en) | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
DE3118072A1 (en) | 1981-05-07 | 1982-11-25 | Claus-Christian Dr.Rer.Nat. Dr.Med. 6901 Wilhelmsfeld Heuck | Process for separating lipophilic constituents from aqueous colloid solutions for preparative purposes and/or for detecting an analyte in the aqueous phase |
JPS58155865A (en) | 1982-03-12 | 1983-09-16 | 株式会社クラレ | Hollow yarn membrane for treating serum |
DE3213390A1 (en) | 1982-04-10 | 1983-10-20 | Dieter 3000 Hannover Biela | DEVICE FOR ACCOUNTING FOR LIQUID EXCHANGE IN HAEMOFILTRATIONS |
US4481189A (en) | 1982-04-14 | 1984-11-06 | New York Blood Center Inc. | Process for preparing sterilized plasma and plasma derivatives |
EP0101066B1 (en) | 1982-08-14 | 1988-12-21 | Gustav E. Dr. Phil. Utzinger | Liquid-spraying system |
US4540401A (en) | 1983-02-22 | 1985-09-10 | Applied Immune Sciences, Inc. | In vivo therapeutic apheresis using lipid vesicles |
DE3310263A1 (en) | 1983-03-22 | 1984-09-27 | Fresenius AG, 6380 Bad Homburg | Process for eliminating lipophilic substances from aqueous solutions and apparatus for carrying out the process |
US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
US4615886A (en) | 1983-08-31 | 1986-10-07 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus |
FR2571971B1 (en) | 1984-10-23 | 1988-12-02 | Haas Thierry | DEVICE USING ELASTINE TO LOWER THE CONCENTRATION OF LIPID CONSTITUENTS OF A LIQUID. |
JPS61119271A (en) | 1984-11-13 | 1986-06-06 | 鐘淵化学工業株式会社 | Blood component treatment circuit and method |
US4613501A (en) | 1984-12-21 | 1986-09-23 | New York Blood Center, Inc. | Inactivation of viruses in labile blood derivatives |
US4970144A (en) | 1984-12-31 | 1990-11-13 | International Genetic Engineering | Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use |
US4605648A (en) | 1985-08-15 | 1986-08-12 | Price E Pendleton | Treatment of Herpes Simplex viruses |
CA1259915A (en) | 1985-10-09 | 1989-09-26 | Sailen S. Mookerjea | Means to reduce plasma cholesterol |
ATE69383T1 (en) | 1985-11-22 | 1991-11-15 | Schweiz Serum & Impfinst | PROCESS FOR THE PREPARATION OF A RABIES VACCINE AND VACCINE OBTAINED BY SUCH PROCESS. |
US4966709A (en) | 1985-12-19 | 1990-10-30 | The Cleveland Clinic Foundation | Thermofiltration of plasma |
US5354262A (en) | 1986-02-18 | 1994-10-11 | Boehringer Laboratories | Apparatus for removal of insoluble fat from blood of a patient |
US4841023A (en) | 1986-06-25 | 1989-06-20 | New York Blood Center, Inc. | Inactivation of viruses in labile protein-containing compositions using fatty acids |
US4855113A (en) | 1986-10-27 | 1989-08-08 | Pennwalt Corporation | Apparatus for removing sulfur from organic polysulfides |
US5948441A (en) | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
JPH085804B2 (en) | 1988-04-28 | 1996-01-24 | 財団法人化学及血清療法研究所 | Hepatitis A and B mixed adjuvant vaccine |
US6291228B1 (en) | 1988-08-03 | 2001-09-18 | Vericore Limited | Vaccine |
US5152743A (en) | 1988-08-05 | 1992-10-06 | Healthdyne, Inc. | Apparatus and method for selective separation of blood cholesterol |
US5476715A (en) | 1989-10-03 | 1995-12-19 | Fresenius Ag | Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits |
US5418130A (en) | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
JPH06500128A (en) | 1991-05-08 | 1994-01-06 | シュバイツ・ゼルム―・ウント・インプフィンスティテュート・ベルン | Immune stimulating and immunoenhancing reconstituted influenza virosomes and vaccines containing the same |
GB9110808D0 (en) | 1991-05-17 | 1991-07-10 | Retroscreen Ltd | Aids vaccine and method for its production |
US7223410B1 (en) | 1994-08-05 | 2007-05-29 | Sanofi Pasteur Limited | Inactivated respiratory syncytial viral vaccines |
EP0882493A3 (en) | 1994-06-22 | 1999-06-30 | Fls Miljo A/S | Mass transfer method |
US5962322A (en) | 1996-11-15 | 1999-10-05 | Massachusetts Institute Of Technology | Methods for modulation of cholesterol transport |
DE4435612A1 (en) | 1994-10-05 | 1996-04-11 | Braun Melsungen Ag | Process for the simultaneous removal of tumor necrosis factor alpha and bacterial lipopolysaccharides from an aqueous liquid |
AU6059898A (en) | 1996-09-05 | 1998-03-26 | Uab Research Foundation, The | Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis |
US5834015A (en) | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
US6008221A (en) | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
AT405939B (en) | 1997-02-24 | 1999-12-27 | Immuno Ag | METHOD FOR INACTIVATING LIPID-ENVIRONED VIRUSES |
US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6093564A (en) * | 1997-10-03 | 2000-07-25 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of nucleic acids |
US5980478A (en) | 1997-10-10 | 1999-11-09 | Transvivo, Inc. | Apparatus and method for the treatment of acute and chronic renal disease by continuous passive plasma ultrafiltration |
US20020188012A1 (en) | 1998-01-28 | 2002-12-12 | Bisgaier Charles Larry | Method for treating Alzheimer's disease |
US6472421B1 (en) | 1998-11-13 | 2002-10-29 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor |
US6214221B1 (en) | 1999-02-22 | 2001-04-10 | Henry B. Kopf | Method and apparatus for purification of biological substances |
US6737066B1 (en) | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
JP2001171936A (en) | 1999-12-17 | 2001-06-26 | Mitsubishi Electric Building Techno Service Co Ltd | Braking torque adjusting device for elevator |
WO2001056579A1 (en) | 2000-02-04 | 2001-08-09 | Esperion Therapeutics Inc. | Methods for treating alzheimer's disease |
US6835717B2 (en) | 2000-03-08 | 2004-12-28 | The Johns Hopkins University School Of Medicine | β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases |
US20090017069A1 (en) | 2000-06-29 | 2009-01-15 | Lipid Sciences, Inc. | SARS Vaccine Compositions and Methods of Making and Using Them |
EP1409108A4 (en) | 2001-06-25 | 2007-11-14 | Lipid Sciences Inc | Hollow fiber contactor systems for removal of lipids from fluids |
AU2002322284A1 (en) | 2001-06-25 | 2003-01-08 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
US20030104350A1 (en) | 2001-06-25 | 2003-06-05 | Bomberger David C. | Systems and methods using a solvent for the removal of lipids from fluids |
US20060060520A1 (en) | 2001-06-25 | 2006-03-23 | Bomberger David C | Systems and methods using a solvent for the removal of lipids from fluids |
US6991727B2 (en) | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
WO2004017946A1 (en) | 2002-08-26 | 2004-03-04 | Lipid Sciences, Inc. | Treating alzheimers using delipidated protein particles |
PT1917029E (en) | 2005-07-27 | 2013-03-13 | Lilly Co Eli | A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
-
2008
- 2008-04-18 US US12/106,021 patent/US20090017069A1/en not_active Abandoned
-
2009
- 2009-12-28 US US12/655,299 patent/US8506968B2/en not_active Expired - Fee Related
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3647624A (en) * | 1969-07-24 | 1972-03-07 | Wisconsin Alumni Res Found | Treatment of blood with oleaginous substance |
US3983008A (en) * | 1974-05-27 | 1976-09-28 | Idemitsu Kosan Co., Ltd. | Method of extracting useful components from microbial cells |
US3958939A (en) * | 1975-01-08 | 1976-05-25 | Coulter Electronics, Inc. | Method for clarification of lipemic serum |
US4025423A (en) * | 1975-01-15 | 1977-05-24 | Metallgesellschaft Aktiengesellschaft | Process for removing monohydric and polyhydric phenols from waste water |
US4258010A (en) * | 1975-11-19 | 1981-03-24 | Eszakmagyarorszagi Vegyimu_ vek | Solvent extraction apparatus |
US4676905A (en) * | 1975-12-15 | 1987-06-30 | Toray Industries, Inc. | Fluid separation method and apparatus |
US4103685A (en) * | 1976-01-05 | 1978-08-01 | Lupien Paul J | Method and apparatus for extravascular treatment of blood |
US4671909A (en) * | 1978-09-21 | 1987-06-09 | Torobin Leonard B | Method for making hollow porous microspheres |
US4399217A (en) * | 1979-05-02 | 1983-08-16 | Laboratoires Goella | Process and a device for the determination of serum lipoproteins |
US4522809A (en) * | 1980-02-11 | 1985-06-11 | Institut Pasteur | Process for obtaining lipid envelope virus sub-units, notably antigens for use as vaccines, the products obtained and their applications |
US4391711A (en) * | 1980-03-19 | 1983-07-05 | Davy Mckee (Minerals & Metals) Limited | Method of, and apparatus for, effecting liquid-liquid contact |
US4923439A (en) * | 1981-09-10 | 1990-05-08 | B. Braun-Ssc Ag | Process for the selective extracorporeal precipitation of low-density lipoproteins from whole serum or plasma |
US4435289A (en) * | 1981-12-23 | 1984-03-06 | Romicon, Inc. | Series ultrafiltration with pressurized permeate |
US4591505A (en) * | 1982-04-14 | 1986-05-27 | New York Blood Center, Inc. | Process for inactivating hepatitis B virus |
US4431633A (en) * | 1982-04-27 | 1984-02-14 | Merck & Co., Inc. | Influenza vaccine |
US4581231A (en) * | 1982-06-10 | 1986-04-08 | The United States Of America As Represented By The Secretary Of Health And Human Services | Inactivation of viruses containing essential lipids |
US4463988A (en) * | 1982-09-07 | 1984-08-07 | Cities Service Co. | Horizontal heated plane process |
US4643718A (en) * | 1983-02-22 | 1987-02-17 | Applied Immunesciences, Inc. | Therapeutic apheresis |
US4648974A (en) * | 1983-03-24 | 1987-03-10 | Intermedicat Gmbh | Process for the selective extracorporeal separation of blood constituents |
US4668398A (en) * | 1983-07-21 | 1987-05-26 | Colgate-Palmolive Company | Continuous extraction apparatus and process |
US4836928A (en) * | 1984-04-28 | 1989-06-06 | Terumo Kabushiki Kaisha | Separation method, separation device and separation apparatus for separating body fluid into respective components |
US4908354A (en) * | 1984-06-16 | 1990-03-13 | B. Braun-Ssg Ag | Process for the selective extracorporeal precipitation of low-density lipoproteins |
US4935204A (en) * | 1984-06-16 | 1990-06-19 | B. Braun-Ssc Ag | Process and device for the specific adsorption of heparin |
US4647280A (en) * | 1984-06-27 | 1987-03-03 | Akzo Nv | Binder for low density lipoproteins |
US4680320A (en) * | 1984-12-06 | 1987-07-14 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Method for preparation of droplets |
US4677057A (en) * | 1985-03-11 | 1987-06-30 | Scripps Clinic And Research Foundation | Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins |
US4645512A (en) * | 1985-05-06 | 1987-02-24 | The Dow Chemical Company | Continuous process for removing water-soluble particles from organic liquids |
US4895558A (en) * | 1985-07-15 | 1990-01-23 | University Of Queensland | Autologous plasma delipidation using a continuous flow system |
US5080796A (en) * | 1985-12-19 | 1992-01-14 | The Cleveland Clinic Foundation | Thermofiltration of plasma |
US5203778A (en) * | 1986-02-18 | 1993-04-20 | Boehringer Laboratories | Process and apparatus for removal of insoluble fat from blood of a patient |
US5126240A (en) * | 1986-09-29 | 1992-06-30 | Curtiss Linda K | Hybridomas and monoclonal paratopic molecules to apolipoprotein a-i |
US4832034A (en) * | 1987-04-09 | 1989-05-23 | Pizziconi Vincent B | Method and apparatus for withdrawing, collecting and biosensing chemical constituents from complex fluids |
US5128318A (en) * | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
US6017543A (en) * | 1987-06-10 | 2000-01-25 | The Immune Response Corporation | Prevention and treatment of retroviral disease |
US5928930A (en) * | 1987-06-10 | 1999-07-27 | Immune Response Corporation | Prevention and treatment of retroviral disease |
US5916806A (en) * | 1987-06-10 | 1999-06-29 | The Immune Response Corporation | Prevention and treatment of retroviral disease |
US5895650A (en) * | 1987-06-10 | 1999-04-20 | The Immune Response Corporation | Prevention and treatment of retroviral disease |
US5885578A (en) * | 1987-06-10 | 1999-03-23 | The Immune Response Corporation | Prevention and treatment of retroviral disease |
US4909942A (en) * | 1987-10-16 | 1990-03-20 | Tanabe Seiyaku Co., Ltd. | Process for removing pyrogens |
US6037458A (en) * | 1987-11-20 | 2000-03-14 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for serum amyloid protein |
US5112956A (en) * | 1987-12-02 | 1992-05-12 | The Nutrasweet Company | Method for extraction of lipids and cholesterol |
US4909940A (en) * | 1987-12-30 | 1990-03-20 | New York Blood Center, Inc. | Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons |
US5089602A (en) * | 1988-02-08 | 1992-02-18 | Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk | Process for the manufacture of apolipoproteins from human blood plasma or serum |
US5484396A (en) * | 1988-11-17 | 1996-01-16 | Naficy; Sadeque S. | Method and device for treatment of HIV infections and AIDS |
US5419759A (en) * | 1988-11-17 | 1995-05-30 | Naficy; Sadeque S. | Apparatus and methods for treatment of HIV infections and AIDS |
US5026479A (en) * | 1990-02-13 | 1991-06-25 | Union Carbide Industrial Gases Technology Corporation | Fluid separation device |
US5401415A (en) * | 1990-06-12 | 1995-03-28 | B. Braun Melsungen Ag | Adsorption material for the selective removal of LDL and/or vLDL and method of using therefor |
US5116307A (en) * | 1990-07-09 | 1992-05-26 | Collins Harvey T | Method and system for treatment of AIDS |
US5418061A (en) * | 1990-11-27 | 1995-05-23 | W. R. Grace & Co.-Conn. | Microporous polysulfone supports suitable for removal of low density lipoprotein-cholesterol |
US5236644A (en) * | 1990-11-27 | 1993-08-17 | W. R. Grace & Co.-Conn. | Process of making membrane for removal of low density lipoprotein-cholesterol from whole blood |
US5187010A (en) * | 1990-11-27 | 1993-02-16 | W. R. Grace & Co.-Conn. | Membrane having high affinity for low density lipoprotein-cholesterol from whole blood |
US5496637A (en) * | 1990-11-27 | 1996-03-05 | W. R. Grace & Co.-Conn. | High efficiency removal of low density lipoprotein-cholesterol from whole blood |
US5879685A (en) * | 1991-05-08 | 1999-03-09 | Schweiz, Serum- & Impfinstitut Bern | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
US5211850A (en) * | 1991-07-26 | 1993-05-18 | Research Medical, Inc. | Plasma filter sorbent system for removal of components from blood |
US5393429A (en) * | 1991-11-05 | 1995-02-28 | Jgc Corporation | Liquid-liquid contactor |
US5301694A (en) * | 1991-11-12 | 1994-04-12 | Philip Morris Incorporated | Process for isolating plant extract fractions |
US5919369A (en) * | 1992-02-06 | 1999-07-06 | Hemocleanse, Inc. | Hemofiltration and plasmafiltration devices and methods |
US5877005A (en) * | 1992-03-02 | 1999-03-02 | Aphios Corporation | Viral inactivation method using near critical, supercritical or critical fluids |
US5279540A (en) * | 1992-09-24 | 1994-01-18 | Davidson Michael H | Method for reducing the risk of atherosclerosis |
US5424068A (en) * | 1992-12-07 | 1995-06-13 | P. Doina International Ltd. | Method for immunization of mammals against atherosclerosis and pharmaceutical compositions for obtaining said immunization |
US5391143A (en) * | 1993-03-12 | 1995-02-21 | Kensey Nash Corporation | Method and system for effecting weight reduction of living beings |
US5523096A (en) * | 1993-03-16 | 1996-06-04 | Applied Immune Sciences, Inc. | Removal of selected factors from whole blood or its components |
US5401466A (en) * | 1993-06-01 | 1995-03-28 | Miles Inc. | Device for the direct measurement of low density lipoprotein cholesterol |
US6039946A (en) * | 1993-07-23 | 2000-03-21 | Strahilevitz; Meir | Extracorporeal affinity adsorption devices |
US5753227A (en) * | 1993-07-23 | 1998-05-19 | Strahilevitz; Meir | Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases |
US6264623B1 (en) * | 1993-07-23 | 2001-07-24 | Meir Strahilevitz | Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune disease |
US5744038A (en) * | 1993-07-30 | 1998-04-28 | Aruba International Pty Ltd. | Solvent extraction methods for delipidating plasma |
US5855782A (en) * | 1993-08-10 | 1999-01-05 | Falkenhagen; Dieter | Arrangement for removing substances from liquids, in particular blood |
US5652339A (en) * | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
US5637224A (en) * | 1994-09-14 | 1997-06-10 | New Jersey Institute Of Technology | Hollow fiber contained liquid membrane pervaporation for removal of volatile organic compounds from aqueous solutions |
US5634893A (en) * | 1995-04-24 | 1997-06-03 | Haemonetics Corporation | Autotransfusion apparatus |
US5719194A (en) * | 1995-08-22 | 1998-02-17 | Ausimont S.P.A. | Prevention and treatment of topical viral infections with perfluoropolyethers or compositions thereof |
US5932468A (en) * | 1995-11-03 | 1999-08-03 | Grupo Grifols, S.A. | Method of inactivating viruses in proteins |
US5911698A (en) * | 1995-12-22 | 1999-06-15 | Aruba International Pty. Ltd. | Treatment for cardiovascular and related diseases |
US5858238A (en) * | 1996-03-08 | 1999-01-12 | Baxter Research Medical, Inc. | Salvage of autologous blood via selective membrane/sorption technologies |
US6171373B1 (en) * | 1996-04-23 | 2001-01-09 | Applied Ceramics, Inc. | Adsorptive monolith including activated carbon, method for making said monolith, and method for adsorbing chemical agents from fluid streams |
US6193891B1 (en) * | 1996-07-10 | 2001-02-27 | American National Red Cross | Methods for the selective separation of organic components from biological fluids |
US5707673A (en) * | 1996-10-04 | 1998-01-13 | Prewell Industries, L.L.C. | Process for extracting lipids and organics from animal and plant matter or organics-containing waste streams |
US6605588B1 (en) * | 1996-11-27 | 2003-08-12 | Boston Heart Foundation, Inc. | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
US6022333A (en) * | 1997-05-01 | 2000-02-08 | S.L.I.M. Tech, Ltd. | Method and system for removing materials from lymphatic and other fluids |
US6337368B1 (en) * | 1997-06-03 | 2002-01-08 | Kaneka Corporation | Lipoprotein adsorbent and lipoprotein adsorber made with the use of the same |
US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6337066B1 (en) * | 1997-12-15 | 2002-01-08 | L'oreal | Cosmetic and/or dermatological composition based on ascorbic acid in powder form |
US6369048B1 (en) * | 1998-01-12 | 2002-04-09 | V.I. Technologies, Inc. | Methods and compositions for inactivating viruses |
US6440387B1 (en) * | 1998-03-23 | 2002-08-27 | Children's Medical Center Corporation | Methods for determining risk of Alzheimer's disease |
US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
US20020081263A1 (en) * | 1998-03-23 | 2002-06-27 | Bruce A. Yankner | Methods for decreasing beta amyloid protein |
US20020055529A1 (en) * | 1998-12-02 | 2002-05-09 | Bisgaier Charles Larry | Method for treating alzheimer's disease |
US20020107173A1 (en) * | 1999-11-04 | 2002-08-08 | Lawrence Friedhoff | Method of treating amyloid beta precursor disorders |
US20030119782A1 (en) * | 2000-06-29 | 2003-06-26 | Cham Bill E. | Method of treating and preventing infectious diesases |
US20030133929A1 (en) * | 2000-06-29 | 2003-07-17 | Cham Bill E | Method of treating infectious diseases |
US7407663B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified immunodeficiency virus particles |
US7407662B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
US20070031923A1 (en) * | 2000-06-29 | 2007-02-08 | Cham Bill E | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases |
US20030018013A1 (en) * | 2000-10-11 | 2003-01-23 | Dasseux Jean-Louis Henri | Ether compounds and compositions for cholesterol management and related uses |
US20030044428A1 (en) * | 2001-01-26 | 2003-03-06 | Moss Ronald B. | Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment |
US6706008B2 (en) * | 2001-03-06 | 2004-03-16 | Baxter International Inc. | Automated system and method for withdrawing compounds from blood |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070212376A1 (en) * | 2000-06-29 | 2007-09-13 | Cham Bill E | Method of treating and preventing infectious diseases |
US20080220016A1 (en) * | 2000-06-29 | 2008-09-11 | Lipid Sciences, Inc. | Method of Treating and Preventing Infectious Diseases via Creation of a Modified Viral Particle with Immunogenic Properties |
US20110150929A1 (en) * | 2000-06-29 | 2011-06-23 | Eli Lilly And Company | SARS vaccine compositions and methods of making and using them |
US8506968B2 (en) | 2000-06-29 | 2013-08-13 | Eli Lilly And Company | SARS vaccine compositions and methods of making and using them |
US7740872B2 (en) | 2005-07-27 | 2010-06-22 | Eli Lilly And Company | Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
US20100215698A1 (en) * | 2005-07-27 | 2010-08-26 | Eli Lilly And Company | Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
US8435531B2 (en) | 2005-07-27 | 2013-05-07 | Eli Lilly And Company | Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
KR20180096775A (en) * | 2016-01-27 | 2018-08-29 | 엘랑코 유에스 인코포레이티드 | Deactivation of virus by degreasing nitrification |
WO2017132059A1 (en) * | 2016-01-27 | 2017-08-03 | Eli Lilly And Company | Inactivation of viruses by delipidation |
CN108602860A (en) * | 2016-01-27 | 2018-09-28 | 伊兰科美国公司 | Pass through delipidation inactivation of viruses |
KR102202475B1 (en) | 2016-01-27 | 2021-01-12 | 엘랑코 유에스 인코포레이티드 | Virus inactivation by delipidation |
EA038712B1 (en) * | 2016-01-27 | 2021-10-08 | Эланко Юэс Инк. | Inactivation of viruses by delipidation |
US11684669B2 (en) * | 2020-03-01 | 2023-06-27 | Valneva Austria Gmbh | CpG-adjuvanted SARS-CoV-2 virus vaccine |
US20210283201A1 (en) * | 2020-03-06 | 2021-09-16 | Hdl Therapeutics, Inc. | Systems and Methods for Treating Patients Infected with SARS-COV-2 |
WO2021235553A1 (en) * | 2020-05-22 | 2021-11-25 | 国立研究開発法人理化学研究所 | Multiple antigenic peptide against coronavirus, and immunostimulating composition containing same |
WO2022023727A1 (en) * | 2020-07-28 | 2022-02-03 | Oxford University Innovation Limited | Polypeptide panels and uses thereof |
CN112341526A (en) * | 2020-09-24 | 2021-02-09 | 杭州医学院 | Novel coronavirus nucleocapsid protein specific antigen polypeptide and application thereof |
Also Published As
Publication number | Publication date |
---|---|
US8506968B2 (en) | 2013-08-13 |
US20110150929A1 (en) | 2011-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8506968B2 (en) | SARS vaccine compositions and methods of making and using them | |
US20080267997A1 (en) | Modified Viral Particles with Immunogenic Properties and Reduced Lipid Content Useful for Treating and Preventing Infectious Diseases | |
JP5231379B2 (en) | Infectious disease treatment and protection method | |
US20080220016A1 (en) | Method of Treating and Preventing Infectious Diseases via Creation of a Modified Viral Particle with Immunogenic Properties | |
US10143740B2 (en) | Inactivating pathogens with oxidizing agents for vaccine production | |
EP0514199B1 (en) | Vaccines and methods for their production | |
AU2001274382A1 (en) | A method of treating and preventing infectious diseases | |
US7439052B2 (en) | Method of making modified immunodeficiency virus particles | |
EP1567188B1 (en) | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases | |
AU2008201523B2 (en) | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases | |
AU2004264842B2 (en) | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases | |
KR20020084079A (en) | A method of treating infectious diseases | |
ES2387276T3 (en) | Modified viral particles with immunogenic properties and reduced lipid content, useful for the treatment and prevention of infectious diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LIPID SCIENCES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AKEEFE, HASSIBULLAH;KITABWALLA, MOIZ;REEL/FRAME:021463/0812;SIGNING DATES FROM 20080827 TO 20080828 |
|
AS | Assignment |
Owner name: ELI LILLY AND COMPANY, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRADY, LOIS I.;REEL/FRAME:023065/0430 Effective date: 20090713 Owner name: ELI LILLY AND COMPANY,INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRADY, LOIS I.;REEL/FRAME:023065/0430 Effective date: 20090713 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |